METHODS AND PRODUCTS FOR PRODUCING ENGINEERED MAMMALIAN CELL LINES WITH AMPLIFIED TRANSGENES

Description

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 14/806,175, filed Jul. 22, 2015, which is a continuation of U.S. patent application Ser. No. 14/091,572, filed Nov. 27, 2013, which is a continuation of International Application No. PCT/US2012/040599, filed Jun. 1, 2012, which claims priority to U.S. Provisional application No. 61/492,174 filed Jun. 1, 2011, the disclosures of all of which are hereby incorporated by reference in their entireties for all purposes.

FIELD OF THE INVENTION

The invention relates to the field of molecular biology and recombinant nucleic acid technology. In particular, the invention relates to methods of inserting genes into defined locations in the chromosomal DNA of cultured mammalian cell lines which are subject to gene amplification. The invention also relates to meganucleases, vectors and engineered cell lines necessary for performing the methods, cell lines resulting from the application of the methods, and use of the cell lines to produce protein products of interest.

BACKGROUND OF THE INVENTION

Therapeutic proteins are the primary growth driver in the global pharmaceutical market (Kresse, Eur J Pharm Biopharm 72, 479 (2009)). In 2001, biopharmaceuticals accounted for $24.3 billion in sales. By 2007, this number had more than doubled to $54.5 billion. The market is currently estimated to reach $78 billion by 2012 (Pickering, Spectrum Pharmaceutical Industry Dynamics Report, Decision Resources, Inc., 5 (2008)). This includes sales of “blockbuster” drugs such as erythropoietin, tissue plasminogen activator, and interferon, as well as numerous “niche” drugs such as enzyme replacement therapies for lysosomal storage disorders. The unparalleled growth in market size, however, is driven primarily by skyrocketing demand for fully human and humanized monoclonal antibodies (Reichert, Curr Pharm Biotechnol 9, 423 (2008)). Because they have the ability to confer a virtually unlimited spectrum of biological activities, monoclonal antibodies are quickly becoming the most powerful class of therapeutics available to physicians. Not surprisingly, more than 25% of the molecules currently undergoing clinical trials in the United States and Europe are monoclonal antibodies (Reichert, Curr Pharm Biotechnol 9, 423 (2008)).

Unlike more traditional pharmaceuticals, therapeutic proteins are produced in living cells. This greatly complicates the manufacturing process and introduces significant heterogeneity into product formulations (Field, Recombinant Human IgG Production from Myeloma and Chinese Hamster Ovary Cells, in Cell Culture and Upstream Processing, Butler, ed., (Taylor and Francis Group, New York, 2007)). In addition, protein drugs are typically required at unusually high doses, which necessitates highly scalable manufacturing processes and makes manufacturing input costs a major price determinant. For these reasons, treatment with a typical therapeutic antibody (e.g., the anti-HER2-neu monoclonal Herceptin®) costs $60,000-$80,000 for a full course of treatment (Fleck, Hastings Center Report 36, 12 (2006)). Further complicating the economics of biopharmaceutical production is the fact that many of the early blockbuster biopharmaceuticals are off-patent (or will be off-patent soon) and the US and EU governments are expected to greatly streamline the regulatory approval process for “biogeneric” and “biosimilar” therapeutics (Kresse, Eur J Pharm Biopharm 72, 479 (2009)). These factors should lead to a significant increase in competition for sales of many prominent biopharmaceuticals (Pickering, Spectrum Pharmaceutical Industry Dynamics Report, Decision Resources, Inc., 5 (2008)). Therefore, there is enormous interest in technologies which reduce manufacturing costs of protein therapeutics (Seth et al., Curr Opin Biotechnol 18, 557 (2007)).

Many of the protein pharmaceuticals on the market are glycoproteins that cannot readily be produced in easy-to-manipulate biological systems such as bacteria or yeast. For this reason, recombinant therapeutic proteins are produced almost exclusively in mammalian cell lines, primarily Chinese hamster ovary (e.g., CHO-K1), mouse myeloma (e.g., NSO), baby hamster kidney (BHK), murine C127, human embryonic kidney (e.g., HEK-293), or human retina-derived (e.g., PER-C6) cells (Andersen and Krummen, Curr Opin Biotechnol 13, 117 (2002)). Of these, CHO cells are, by far, the most common platform for bioproduction because they offer the best combination of high protein expression levels, short doubling time, tolerance to a wide range of media conditions, established transfection and amplification protocols, an inability to propagate most human pathogens, a paucity of blocking intellectual property, and the longest track record of FDA approval (Field, Recombinant Human IgG Production from Myeloma and Chinese Hamster Ovary Cells, in Cell Culture and Upstream Processing, Butler, ed. (Taylor and Francis Group, New York, 2007)).

Large-market biopharmaceuticals are typically produced in enormous stirred-tank bioreactors containing hundreds of liters of CHO cells stably expressing the protein product of interest (Chu and Robinson, Curr Opin Biotechnol 12, 180 (2001), Coco-Martin and Harmsen, Bioprocess International 6, 28 (2008)). Under optimized industrial conditions, such manufacturing processes can yield in excess of 5g of protein per liter of cells per day (Coco-Martin and Harmsen, Bioprocess International 6, 28 (2008)). Because of the large number of cells involved (˜50 billion cells per liter), the level of protein expression per cell has a very dramatic effect on yield. For this reason, all of the cells involved in the production of a particular biopharmaceutical must be derived from a single “high-producer” clone, the production of which constitutes one of the most time- and resource-intensive steps in the manufacturing process (Clarke and Compton, Bioprocess International 6, 24 (2008)).

The first step in the large-scale manufacture of a biopharmaceutical is the transfection of mammalian cells with plasmid DNA encoding the protein product of interest under the control of a strong constitutive promoter. Stable transfectants are selected by using a selectable marker gene also carried on the plasmid. Most frequently, this marker is a dihydrofolate reductase (DHFR) gene which, when transfected into a DHFR deficient cell line such as DG44, allows for the selection of stable transfectants using media deficient in hypoxanthine. The primary reason for using DHFR as a selectable marker is that it enables a process called “gene amplification”. By growing stable transfectants in gradually increasing concentrations of methotrexate (MTX), a DHFR inhibitor, it is possible to amplify the number of copies of the DHFR gene present in the genome. Because the gene encoding the protein product of interest is physically coupled to the DHFR gene, this results in amplification of both genes with a concomitant increase in the expression level of the therapeutic protein (Butler, Cell Line Development for Culture Strategies: Future Prospects to Improve Yields, in Cell Culture and Upstream Processing, Butler, ed., (Taylor and Francis Group, New York, 2007)). Related systems for the creation of stable bioproduction lines use the glutamine synthetase (GS) or hypoxanthine phosphoribosyltransferase (HPRT) genes as selectable markers and require the use of GS- or HPRT- deficient cell lines as hosts for transfection (Clarke and Compton, Bioprocess International 6, 24 (2008)). In the case of the GS system, gene amplification is accomplished by growing cells in the presence of methionine sulphoximine (MSX) (Clarke and Compton, Bioprocess International 6, 24 (2008)). In the case of the HPRT system, gene amplification is accomplished by growing cells in HAT medium, which contains aminopterin, hypoxanthine, and thymidine (Kellems, ed. Gene amplification in mammalian cells: a comprehensive guide, Marcel Dekker, New York, 1993).

In all of these systems, the initial plasmid DNA comprising a biotherapeutic gene expression cassette and a selectable marker integrates into a random location in the genome, resulting in extreme variability in therapeutic protein expression from one stable transfectant to another (Collingwood and Urnov, Targeted Gene Insertion to Enhance Protein Production from Cell Lines, in Cell Culture and Upstream Processing, Butler, ed. (Taylor and Francis Group, New York, 2007)). For this reason, it is necessary to screen hundreds to thousands of initial transfectants to identify cells which express acceptably high levels of gene product both before and after gene amplification (Butler, Cell Line Development for Culture Strategies: Future Prospects to Improve Yields, in Cell Culture and Upstream Processing, Butler, ed. (Taylor and Francis Group, New York, 2007)). A second and more problematic consequence of random gene integration is the phenomenon of transgene silencing, in which recombinant protein expression slows or ceases entirely over time (Collingwood and Urnov, Targeted Gene Insertion to Enhance Protein Production from Cell Lines, in Cell Culture and Upstream Processing, Butler, ed. (Taylor and Francis Group, New York, 2007)). Because these effects often do not manifest themselves for weeks to months following the initial transfection and screening process, it is generally necessary to carry and expand dozens of independent clonal lines to identify one that expresses the protein of interest consistently over time (Butler, Cell Line Development for Culture Strategies: Future Prospects to Improve Yields, in Cell Culture and Upstream Processing, Butler, ed. (Taylor and Francis Group, New York, 2007)).

This large number of screening and expansion steps results in a very lengthy and expensive process to simply generate the cell line that will, ultimately, produce the therapeutic of interest. Indeed, using conventional methods, a minimum of 10 months (with an average of 18 months) and an upfront investment of tens of millions of dollars in labor and material is required to produce an initial pool of protein-expressing cells suitable for industrial manufacturing (Butler, Cell Line Development for Culture Strategies: Future Prospects to Improve Yields, in Cell Culture and Upstream Processing, Butler, ed. (Taylor and Francis Group, New York, 2007)). If one takes into account lost time on market for a blockbuster protein therapeutic, inefficiencies in cell line production can cost biopharmaceutical manufacturers hundreds of millions of dollars (Seth et al., Curr Opin Biotechnol 18, 557 (2007)).

Much of the time and expense of bioproduction cell line creation can be attributed to random genomic integration of the bioproduct gene resulting in clone-to-clone variability in genotype and, hence, variability in gene expression. One way to overcome this is to target gene integration to a defined location that is known to support a high level of gene expression. To this end, a number of systems have been described which use the Cre, Flp, or ΦC31 recombinases to target the insertion of a bioproduct gene (reviewed in Collingwood and Urnov, Targeted Gene Insertion to Enhance Protein Production from Cell Lines, in Cell Culture and Upstream Processing, Butler, ed. (Taylor and Francis Group, New York, 2007)). Recent embodiments of these systems, most notably the Flp-In® system marketed by Invitrogen Corp. (Carlsbad, Calif.), couple bioproduct gene integration with the reconstitution of a split selectable marker so that cells with correctly targeted genes can be selected. As expected, these systems result in greatly reduced heterogeneity in gene expression and, in some cases, individual stable transfectants can be pooled, obviating the time and expense associated with expanding a single clone.

The principal drawback to recombinase-based gene targeting systems is that the recombinase recognition sites (loxP, FRT, or attB/attP sites) do not naturally occur in mammalian genomes. Therefore, cells must be pre-engineered to incorporate a recognition site for the recombinase before that site can be subsequently targeted for gene insertion. Because the recombinase site itself integrates randomly into the genome, it is still necessary to undertake extensive screening and evaluation to identify clones which carry the site at a location that is suitable for high level, long-term gene expression (Collingwood and Urnov, Targeted Gene Insertion to Enhance Protein Production from Cell Lines, in Cell Culture and Upstream Processing, Butler, ed. (Taylor and Francis Group, New York, 2007)). In addition, the biomanufacturing industry is notoriously hesitant to adopt “new” cell lines, such as those that have been engineered to carry a recombinase site, that do not have a track record of FDA approval. For these reasons, recombinase-based cell engineering systems may not readily be adopted by the industry and an approach that allows biomanufacturers to utilize their existing cell lines is preferable.

SUMMARY OF THE INVENTION

The present invention depends, in part, upon the development of mammalian cell lines in which sequences of interest (e.g., exogenous, actively transcribed transgenes) are inserted proximal to an endogenous selectable gene in an amplifiable locus, and the discovery that (a) the insertion of such exogenous sequences of interest does not inhibit amplification of the endogenous selectable gene, (b) the exogenous sequence of interest can be co-amplified with the endogenous selectable gene, and (c) the resultant cell lines, with an amplified region comprising multiple copies of the endogenous selectable gene and the exogenous sequence of interest, are stable for extended periods even in the absence of the selection regime which was employed to induce amplification. Thus, in one aspect, the invention provides a method for producing cell lines which can be used for biomanufacturing of a protein product of interest by specifically targeting the insertion of an exogenous sequence of interest capable of actively expressing the protein product of interest proximal to an endogenous selectable gene.

In another aspect, the invention provides engineered cell lines that can be used to produce protein products of interest (e.g., therapeutic proteins such as monoclonal antibodies) at high levels.

It is understood that any of the embodiments described below can be combined in any desired way, and any embodiment or combination of embodiments can be applied to each of the aspects described below, unless the context indicates otherwise.

In one aspect, the invention provides a recombinant mammalian cell comprising an engineered target site stably integrated within selectable gene within an amplifiable locus, wherein the engineered target site disrupts the function of the selectable gene and wherein the engineered target site comprises a recognition sequence for a site specific endonuclease.

In some embodiments, the selectable gene is glutamine synthetase (GS) and the locus is methionine sulphoximine (MSX) amplifiable. In some embodiments, the selectable gene is dihydrofolate reductase (DHFR) and the locus is Methotrexate (MTX) amplifiable.

In some embodiments, the selectable gene is selected from the group consisting of Dihydrofolate Reductase, Glutamine Synthetase, Hypoxanthine Phosphoribosyltransferase, Threonyl tRNA Synthetase, Na,K-ATPase, Asparagine Synthetase, Ornithine Decarboxylase, Inosine-5′-monophosphate dehydrogenase, Adenosine Deaminase, Thymidylate Synthetase, Aspartate Transcarbamylase, Metallothionein, Adenylate Deaminase (1,2), UMP-Synthetase and Ribonucleotide Reductase.

In some embodiments, the selectable gene is amplifiable by selection with a selection agent selected from the group consisting of Methotrexate (MTX), Methionine sulphoximine (MSX), Aminopterin, hypoxanthine, thymidine, Borrelidin, Ouabain, Albizziin, Beta-aspartyl hydroxamate, alpha-difluoromethylornithine (DFMO), Mycophenolic Acid, Adenosine, Alanosine, 2′ deoxycoformycin, Fluorouracil, N-Phosphonacetyl-L-Aspartate (PALA), Cadmium, Adenine, Azaserine, Coformycin, 6-azauridine, pyrazofuran, hydroxyurea, motexafin gadolinium, fludarabine, cladribine, gemcitabine, tezacitabine and triapine.

In some embodiments, the engineered target site is inserted into an exon of the selectable gene. In some embodiments, the site specific endonuclease is a meganuclease, a zinc finger nuclease or TAL effector nuclease. In some embodiment, the recombinant cell further comprises the site specific endonuclease.

In one aspect, the invention provides a recombinant mammalian cell comprising an engineered target site stably integrated proximal to a selectable gene within an amplifiable locus, wherein the engineered target site comprises a recognition sequence for a site specific endonuclease.

In some embodiments, the engineered target site is downstream from the 3′ regulatory region of the selectable gene. In some embodiments, the engineered target site is 0 to 100,000 base pairs downstream from the 3′ regulatory region of the selectable gene. In other embodiments, the engineered target site is upstream from the 5′ regulatory region of the selectable gene. In some embodiments, the engineered target site is 0 to 100,000 base pairs upstream from the 5′ regulatory region of the selectable gene.

In another aspect, the invention provides a method for inserting an exogenous sequence into an amplifiable locus of a mammalian cell comprising: (a) providing a mammalian cell having an endogenous target site proximal to a selectable gene within the amplifiable locus, wherein the endogenous target site comprises: (i) a recognition sequence for an engineered meganuclease; (ii) a 5′ flanking region 5′ to the recognition sequence; and

(iii) a 3′ flanking region 3′ to the recognition sequence; and (b) introducing a double-stranded break between the 5′ and 3′ flanking regions of the endogenous target site; (c) contacting the cell with a donor vector comprising from 5′ to 3′: (i) a donor 5′ flanking region homologous to the 5′ flanking region of the endogenous target site; (ii) an exogenous sequence; and (iii) a donor 3′ flanking region homologous to the 3′ flanking region of the endogenous target site; whereby the donor 5′ flanking region, the exogenous sequence and the donor 3′ flanking region are inserted between the 5′ and 3′ flanking regions of the endogenous target site by homologous recombination to provide a modified cell.

In some embodiments, the method futhter comprises growing the modified cell in the presence of a compound that inhibits the function of the selectable gene to amplify the copy number of the selectable gene. In some embodiments, the exogenous sequence comprises a gene of interest.

In some embodiments endogenous target site is downstream from the 3′ regulatory region of the selectable gene. In some embodiments, the endogenous target site is 0 to 100,000 base pairs downstream from the 3′ regulatory region of the selectable gene. In other embodiments, the endogenous target site is upstream from the 5′ regulatory region of the selectable gene. In some embodiments, the endogenous target site is 0 to 100,000 base pairs upstream from the 5′ regulatory region of the selectable gene.

In one aspect, the invention provides a method for inserting an exogenous sequence into an amplifiable locus of a mammalian cell comprising: (a) providing a mammalian cell having an endogenous target site proximal to a selectable gene within the amplifiable locus, wherein the endogenous target site comprises: (i) a recognition sequence for an engineered meganuclease; (ii) a 5′ flanking region 5′ to the recognition sequence; and (iii) a 3′ flanking region 3′ to the recognition sequence; and (b) introducing a double-stranded break between the 5′ and 3′ flanking regions of the endogenous target site; (c) contacting the cell with an engineered target site donor vector comprising from 5′ to 3′: (i) a donor 5′ flanking region homologous to the 5′ flanking region of the endogenous target site; (ii) an exogenous sequence comprising an engineered target site; and (iii) a donor 3′ flanking region homologous to the 3′ flanking region of the endogenous target site; whereby the donor 5′ flanking region, the exogenous sequence and the donor 3′ flanking region are inserted between the 5′ and 3′ flanking regions of the endogenous target site by homologous recombination to provide a mammalian cell comprising the engineered target site; (d) introducing a double-stranded break between the 5′ and 3′ flanking regions of the engineered target site; (e) contacting the cell comprising the engineered target site with a sequence of interest donor vector comprising from 5′ to 3′: (i) a donor 5′ flanking region homologous to the 5′ flanking region of the engineered target site; (ii) an exogenous sequence comprising a sequence of interest; and (iii) a donor 3′ flanking region homologous to the 3′ flanking region of the engineered target site; whereby the donor 5′ flanking region, the exogenous sequence comprising the sequence of interest and the donor 3′ flanking region are inserted between the 5′ and 3′ flanking regions of the engineered target site by homologous recombination to provide an engineered mammalian cell comprising the sequence of interest.

In some embodiments, the methof further comprises growing the engineered mammalian cell in the presence of a compound that inhibits the function of the selectable gene to amplify the copy number of the selectable gene. In some embodiments, the sequence of interest comprises a gene.

In another aspect, the invention provides a method for inserting an exogenous sequence into an amplifiable locus of a mammalian cell comprising: (a) providing a mammalian cell having an endogenous target site within a selectable gene within the amplifiable locus, wherein the endogenous target site comprises: (i) a recognition sequence for an engineered meganuclease; (ii) a 5′ flanking region 5′ to the recognition sequence; and

(iii) a 3′ flanking region 3′ to the recognition sequence; and (b) introducing a double-stranded break between the 5′ and 3′ flanking regions of the endogenous target site; (c) contacting the cell with an engineered target site donor vector comprising from 5′ to 3′: (i) a donor 5′ flanking region homologous to the 5′ flanking region of the endogenous target site; (ii) an exogenous sequence comprising an engineered target site; and (iii) a donor 3′ flanking region homologous to the 3′ flanking region of the endogenous target site; whereby the donor 5′ flanking region, the exogenous sequence and the donor 3′ flanking region are inserted between the 5′ and 3′ flanking regions of the endogenous target site by homologous recombination to provide a mammalian cell comprising the engineered target site; (d) introducing a double-stranded break between the 5′ and 3′ flanking regions of the engineered target site; (e) contacting the cell comprising the engineered target site with a sequence of interest donor vector comprising from 5′ to 3′: (i) a donor 5′ flanking region homologous to the 5′ flanking region of the engineered target site; (ii) an exogenous sequence comprising a sequence of interest; and (iii) a donor 3′ flanking region homologous to the 3′ flanking region of the engineered target site; whereby the donor 5′ flanking region, the exogenous sequence comprising the sequence of interest and the donor 3′ flanking region are inserted between the 5′ and 3′ flanking regions of the engineered target site by homologous recombination to provide a engineered mammalian cell comprising the sequence of interest.

In some emboduments, the method further comprises growing the engineered mammalian cell in the presence of a compound that inhibits the function of the selectable gene to amplify the copy number of the selectable gene.

In some embodiments, the sequence of interest comprises a gene.

In some embodiments, the endogenous target site is within an intron of the selectable gene. In other embodiments, the endogenous target site is within an exon of the selectable gene.

In one aspect, the invention provides a recombinant meganuclease comprising a polypeptide having at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% sequence identity to SEQ ID NO: 15.

In another aspect, the invention provides a recombinant meganuclease comprising the amino acid sequence of SEQ ID NO: 15.

In another aspect, the invention provides a recombinant meganuclease which recognizes and cleaves a recognition site having 75%, 85%, 90%, 95%, 97%, 98% or 99% sequence identity to SEQ ID NO: 14. In one embodiment, the meganuclease recognizes and cleaves a recognition site of SEQ ID NO: 14.

In another aspect, the invention provides a recombinant meganuclease comprising a polypeptide having at least 75%, 85%, 90%, 95%, 97%, 98% or 99% sequence identity to SEQ ID NO: 9. In one embodiment, the recombinant meganuclease has the sequence of the meganuclease of SEQ ID NO: 9.

In another aspect, the invention provides a recombinant meganuclease which recognizes and cleaves a recognition site having at least 75%, 85%, 90%, 95%, 97%, 98% or 99% sequence identity to SEQ ID NO: 7. In one embodiment, the meganuclease recognizes and cleaves a recognition site of SEQ ID NO: 7.

In another aspect, the invention provides a recombinant meganuclease comprising a polypeptide having at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% sequence identity to SEQ ID NO: 10. In one embodiment, the recombinant meganuclease comprises the polypeptide of SEQ ID NO: 10.

In another aspect, the invention provides a recombinant meganuclease which recognizes and cleaves a recognition site having at least 75%, 85%, 90%, 95%, 97%, 98% or 99% sequence identity to SEQ ID NO: 8. In one embodiment, the meganuclease recognizes and cleaves a recognition site of SEQ ID NO: 8.

In another aspect, the invention provides a recombinant meganuclease comprising a polypeptide having at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% sequence identity to SEQ ID NO: 13. In one embodiment, rhe recombinant meganuclease comprises the polypeptide of SEQ ID NO: 13.

In another aspect, the invention provides a recombinant meganuclease which recognizes and cleaves a recognition site having at least 75%, 85%, 90%, 95%, 97%, 98% or 99% sequence identity to SEQ ID NO: 12. In one embodiment, the meganuclease recognizes and cleaves a recognition site of SEQ ID NO: 12.

In another aspect, the invention provides a recombinant meganuclease comprising a polypeptide having at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% sequence identity to SEQ ID NO: 29. In one embodiment, the recombinant meganuclease comprises the polypeptide of SEQ ID NO: 29.

In another aspect, the invention provides a recombinant meganuclease which recognizes and cleaves a recognition site having at least 75%, 85%, 90%, 95%, 97%, 98% or 99% sequence identity to SEQ ID NO: 30. In one embodiment, the meganuclease recognizes and cleaves a recognition site of SEQ ID NO: 30.

In another aspect, the invention provides recombinant mammalian cell lines which continue to express a protein product of interest from an exogenous sequence of interest present in an amplified region of the genome (i.e., present in 2-1,000 copies, co-amplified with a selectable gene in an amplifiable locus) for a period of at least 8, 9, 10, 11, 12, 13, or 14 weeks after removal of the amplification selection agent, and with a reduction of expression levels and/or copy number of less than 20, 25, 30, 35 or 40%.

In another aspect, the invention provides methods of producing recombinant cells with amplified regions including a sequence of interest and a selectable gene by subjecting the above-described recombinant cells to selection with a selection agent which causes co-amplification of the sequence of interest and the selectable gene.

In another aspect, the invention provides methods of producing a protein product of interest by culturing the above-described recombinant cells, or the above-described recombinant cells with amplified regions, and obtaining the protein product of interest from the culture medium or a cell lysate.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1. A general strategy for targeting a sequence of interest to an amplifiable locus.

FIGS. 2A and 2B. (A) Schematic of the CHO DHFR locus showing a preferred region for targeting a sequence of interest 5,000-60,000 base pairs downstream of the DHFR gene. (B) Schematic of the CHO GS locus showing a preferred region for targeting a sequence of interest 5,000-55,000 base pairs downstream of the GS gene.

FIG. 3. Strategy for inserting a sequence of interest into an amplifiable locus in a two-step process involving a pre-integrated engineered target sequence.

FIG. 4. Strategy for inserting an engineered target sequence into an amplifiable locus with concomitant removal of a portion of the selectable gene, followed by insertion of a sequence of interest and reconstitution of the selectable gene.

FIG. 5. Strategy for inserting an engineered target sequence into an amplifiable locus with concomitant disruption of the coding sequence of a selectable gene, followed by insertion of a sequence of interest and reconstitution of the selectable gene.

FIG. 6. Strategy for inserting an engineered target sequence into an amplifiable locus with concomitant disruption of the mRNA processing, followed by insertion of a sequence of interest and reconstitution of the selectable gene.

FIGS. 7A through 7D. (A) A direct-repeat recombination assay for site-specific endonuclease activity. (B) Results of the assay in (A) applied to the CHO-23/24 and CHO-51/52 meganucleases.(C) Alignment of sequences obtained from CHO cells transfected with mRNA encoding the CHO-23/24 meganuclease (SEQ ID NOS 37-39, 38, 40, 38, and 38, respectively, in order of appearance). (D) Alignment of sequences obtained from CHO cells transfected with mRNA encoding the CHO-51/52 meganuclease (SEQ ID NOS 41-51, respectively, in order of appearance).

FIGS. 8A and 8B. (A) Strategy for inserting an exogenous DNA sequence into the CHO DHFR locus using the CHO-51/52 meganuclease.(B) PCR products demonstrating insertion of an engineered target sequence.

FIGS. 9A through 9C. (A) Strategy for inserting an engineered target sequence into the CHO DHFR locus using the CHO-23/24 meganuclease, followed by Flp recombinase-mediated insertion of a sequence of interest. (B) PCR products from hygromycin-resistant clones produced in (A). (C) GFP expression by the 24 clones produced in (B).

FIGS. 10A through 10C. Results of experiments with a GFP-expressing CHO line produced by integrating a GFP gene expression cassette into the DHFR locus using a target sequence strategy as shown in FIG. 9.

FIGS. 11A through 11C. (A) A direct-repeat recombination assay, as in FIG. 5A. (B) The assay in (A) applied to the CHO-13/14 and CGS-5/6 meganucleases. (C) Alignment of sequences obtained from CHO cells transfected with mRNA encoding the CGS-5/6 meganuclease (SEQ ID NOS 52-56, 56, 56-63, 63, 63, and 63-64, respectively, in order of appearance).

DETAILED DESCRIPTION OF THE INVENTION

1.1 Introduction

The present invention depends, in part, upon the development of mammalian cell lines in which exogenous actively transcribed transgenes have been inserted proximal to an endogenous amplifiable locus, and the discovery that (a) the insertion of such exogenous actively transcribed transgenes does not prevent or substantially inhibit amplification of the endogenous amplifiable locus, (b) the exogenous actively transcribed transgene can be co-amplified with the endogenous amplifiable locus, and (c) the resultant cell line, with an amplified region comprising multiple copies of the endogenous amplifiable locus and the exogenous actively transcribed transgene is stable for extended periods even in the absence of the selection regime which was employed to induce amplification. Thus, in one aspect, the invention provides a method for producing cell lines which can be used for biomanufacturing of a protein product of interest by specifically targeting the insertion of an exogenous gene capable of actively expressing the protein product of interest proximal to an endogenous amplifiable locus. In another aspect, the invention provides engineered cell lines that can be used to produce protein products of interest (e.g., therapeutic proteins such as monoclonal antibodies) at high levels.

1.2 References and Definitions

The patent and scientific literature referred to herein establishes knowledge that is available to those of skill in the art. The entire disclosures of the issued U.S. patents, pending applications, published foreign applications, and scientific and technical references cited herein, including protein and nucleic acid database sequences, are hereby incorporated by reference to the same extent as if each was specifically and individually indicated to be incorporated by reference.

As used herein, the term “meganuclease” refers to naturally-occurring homing endonucleases (also referred to as Group I intron encoded endonucleases) or non-naturally-occurring (e.g., rationally designed or engineered) endonucleases based upon the amino acid sequence of a naturally-occurring homing endonuclease. Examples of naturally-occurring meganucleases include I-SceI, I-CreI, I-Ceul, I-Dmol, I-Msol, I-AniI, etc. Rationally designed meganucleases are disclosed in, for example, WO 2007/047859 and WO 2009/059195, and can be engineered to have modified DNA-binding specificity, DNA cleavage activity, DNA-binding affinity, or dimerization properties relative to a naturally occurring meganuclease. A meganuclease may bind to double-stranded DNA as a homodimer (e.g., wild-type I-CreI), or it may bind to DNA as a heterodimer (e.g., engineered meganucleases disclosed in WO 2007/047859). An engineered meganuclease may also be a “single-chain meganuclease” in which a pair of DNA-binding domains derived from a natural meganuclease are joined into a single polypeptide using a peptide linker (e.g., single-chain meganucleases disclosed in WO 2009/059195).

As used herein, the term “single-chain meganuclease” refers to a polypeptide comprising a pair of meganuclease subunits joined by a linker. A single-chain meganuclease has the organization: N-terminal subunit—Linker—C-terminal subunit. The two meganuclease subunits will generally be non-identical in amino acid sequence and will recognize non-identical DNA sequences. Thus, single-chain meganucleases typically cleave pseudo-palindromic or non-palindromic recognition sequences. Methods of producing single-chain meganucleases are disclosed in WO 2009/059195.

As used herein, the term “site specific endonuclease” means a meganuclease, zinc-finger nuclease or TAL effector nuclease.

As used herein, with respect to a protein, the term “recombinant” means having an altered amino acid sequence as a result of the application of genetic engineering techniques to nucleic acids which encode the protein, and cells or organisms which express the protein. With respect to a nucleic acid, the term “recombinant” means having an altered nucleic acid sequence as a result of the application of genetic engineering techniques. Genetic engineering techniques include, but are not limited to, PCR and DNA cloning technologies; transfection, transformation and other gene transfer technologies; homologous recombination; site-directed mutagenesis; and gene fusion. In accordance with this definition, a protein having an amino acid sequence identical to a naturally-occurring protein, but produced by cloning and expression in a heterologous host, is not considered recombinant. As used herein, the term “engineered” is synonymous with the term “recombinant.”

As used herein, with respect to a meganuclease, the term “wild-type” refers to any naturally-occurring form of a meganuclease. The term “wild-type” is not intended to mean the most common allelic variant of the enzyme in nature but, rather, any allelic variant found in nature. Wild-type homing endonucleases are distinguished from recombinant or non-naturally-occurring meganucleases.

As used herein, the term “recognition sequence” refers to a DNA sequence that is bound and cleaved by a meganuclease. A recognition sequence comprises a pair of inverted, 9 base pair “half sites” which are separated by four base pairs. In the case of a homo- or heterodimeric meganucleases, each of the two monomers makes base-specific contacts with one half-site. In the case of a single-chain heterodimer meganuclease, the N-terminal domain of the protein contacts a first half-site and the C-terminal domain of the protein contacts a second half-site. In the case if I-CreI, for example, the recognition sequence is 22 base pairs and comprises a pair of inverted, 9 base pair “half sites” which are separated by four base pairs.

As used herein, the term “target site” refers to a region of the chromosomal DNA of a cell comprising a target sequence into which a sequence of interest can be inserted. As used herein, the term “engineered target site” refers to an exogenous sequence of DNA integrated into the chromosomal DNA of a cell comprising an engineered target sequence into which a sequence of interest can be inserted.

As used herein, the term “target sequence” means a DNA sequence within a target site which includes one or more recognition sequences for a nuclease, integrase, transposase, and/or recombinase. For example, a target sequence can include a recognition sequence for a meganuclease. As used herein, an “engineered target sequence” means an exogenous target sequence which is introduced into a chromosome to serve as the insertion point for another sequence.

As used herein, the term “flanking region” or “flanking sequence” refers to a sequence of >3 or, preferably, >50 or, more preferably, >200 or, most preferably, >400 base pairs of DNA which is immediately 5′ or 3′ to a reference sequence (e.g., a target sequence or sequence of interest).

As used herein, the terms “amplifiable locus” refers to a region of the chromosomal DNA of a cell which can be amplified by selection with one or more compounds (e.g., drugs) in the growth media. An amplifiable locus will typically comprise a gene encoding a protein which, under the appropriate conditions, is necessary for cell survival. By inhibiting the function of such an essential protein, for example with a small molecule drug, the amplifiable locus is duplicated many times over as a means of increasing the copy number of the essential gene. A gene of interest, if integrated into an amplifiable locus, will also become duplicated with the essential gene. Examples of amplifiable loci include the chromosomal regions comprising the DHFR, GS, and HPRT genes.

As used herein, the term “amplified locus” or “amplified gene” or “amplified sequence” refers to a locus, gene or sequence which is present in 2-1,000 copies as a result of gene amplification in response to selection of a selectable gene. An amplified gene or sequence can be a gene or sequence which is co-amplified due to selection of a selectable gene in the same amplifiable locus. In preferred embodiments, a sequence of interest is amplified to at least 3, 4, 5, 6, 7, 8, 9 or 10 copies.

As used herein, the term “selectable gene” refers to an endogenous gene that is essential for cell survival under some specific culture conditions (e.g., presence or absence of a nutrient, toxin or drug). Selectable genes are endogenous to the cell and are distinguished from exogenous “selectable markers” such as antibiotic resistance genes. Selectable genes exist in their natural context in the chromosomal DNA of the cell. For example, DHFR is a selectable gene which is necessary for cell survival in the presence of MTX in the culture medium. The gene is essential for growth in the absence of hypoxanthine and thymidine. If the endogenous DHFR selectable gene is eliminated, cells are able to grow in the absence of hypoxanthine and thymidine if they are given an exogenous copy of the DHFR gene. This exogenous copy of the DHFR gene is a selectable marker but is not a selectable gene. An amplifiable locus comprises a selectable gene and a target site. A target site is found outside of a selectable gene such that a selectable gene does not comprise a target site. Examples of selectable genes are given in Table 1.

As used herein, when used in connection with the position of a target site, recognition sequence, or inserted sequence of interest relative to the position of a selectable gene, the term “proximal” means that the target site, recognition sequence, or inserted sequence of interest is within the same amplifiable locus as the selectable gene, either upstream (5′) or downstream (3′) of the selectable gene, and preferably between the selectable gene and the next gene in the region (whether upstream (5′) or downstream (3′)). Typically, a “proximal” target site, recognition sequence, or inserted sequence of interest will be within <100,000 base pairs of the selectable gene, as measured from the first or last nucleotide of the first or last regulatory element of the selectable gene.

As used herein, the term “homologous recombination” refers to the natural, cellular process in which a double-stranded DNA-break is repaired using a homologous DNA sequence as the repair template (see, e.g. Cahill et al. (2006), Front. Biosci. 11:1958-1976). The homologous DNA sequence may be an endogenous chromosomal sequence or an exogenous nucleic acid that was delivered to the cell. Thus, for some applications of engineered meganucleases, a meganuclease is used to cleave a recognition sequence within a target sequence in a genome and an exogenous nucleic acid with homology to or substantial sequence similarity with the target sequence is delivered into the cell and used as a template for repair by homologous recombination. The DNA sequence of the exogenous nucleic acid, which may differ significantly from the target sequence, is thereby inserted or incorporated into the chromosomal sequence. The process of homologous recombination occurs primarily in eukaryotic organisms. The term “homology” is used herein as equivalent to “sequence similarity” and is not intended to require identity by descent or phylogenetic relatedness.

As used herein, the term “stably integrated” means that an exogenous or heterologous DNA sequence has been covlently inserted into a chromosome (e.g., by homologous recombination, non-homologous end joining, transposition, etc.) and has remained in the chromosome for a period of at least 8 weeks.&&

As used herein, the term “non-homologous end-joining” or “NHEJ” refers to the natural, cellular process in which a double-stranded DNA-break is repaired by the direct joining of two non-homologous DNA segments (see, e.g. Cahill et al. (2006), Front. Biosci. 11:1958-1976). DNA repair by non-homologous end-joining is error-prone and frequently results in the untemplated addition or deletion of DNA sequences at the site of repair. Thus, for certain applications, an engineered meganuclease can be used to produce a double-stranded break at a meganuclease recognition sequence within an amplifiable locus and an exogenous nucleic acid molecule, such as a PCR product, can be captured at the site of the DNA break by NHEJ (see, e.g. Salomon et al. (1998), EMBO J. 17:6086-6095). In such cases, the exogenous nucleic acid may or may not have homology to the target sequence. The process of non-homologous end-joining occurs in both eukaryotes and prokaryotes such as bacteria.

As used herein, the term “sequence of interest” means any nucleic acid sequence, whether it codes for a protein, RNA, or regulatory element (e.g., an enhancer, silencer, or promoter sequence), that can be inserted into a genome or used to replace a genomic DNA sequence. Sequences of interest can have heterologous DNA sequences that allow for tagging a protein or RNA that is expressed from the sequence of interest. For instance, a protein can be tagged with tags including, but not limited to, an epitope (e.g., c-myc, FLAG) or other ligand (e.g., poly-His). Furthermore, a sequence of interest can encode a fusion protein, according to techniques known in the art (see, e.g., Ausubel et al., Current Protocols in Molecular Biology, Wiley 1999). In preferred embodiments, a sequence of interest comprises a promoter operably linked to a gene encoding a protein of medicinal value such as an antibody, antibody fragment, cytokine, growth factor, hormone, or enzyme. For some applications, the sequence of interest is flanked by a DNA sequence that is recognized by the engineered meganuclease for cleavage. Thus, the flanking sequences are cleaved allowing for proper insertion of the sequence of interest into genomic recognition sequences cleaved by an engineered meganuclease. For some applications, the sequence of interest is flanked by DNA sequences with homology to or substantial sequence similarity with the target site such that homologous recombination inserts the sequence of interest within the genome at the locus of the target sequence.

As used herein, the term “donor DNA” refers to a DNA molecule comprising a sequence of interest flanked by DNA sequences homologous to a target site. Donor DNA can serve as a template for DNA repair by homologous recombination if it is delivered to a cell with a site-specific nuclease such as a meganuclease, zinc-finger nuclease, or TAL-effector nuclease. The result of such DNA repair is the insertion of the sequence of interest into the chromosomal DNA of the cell. Donor DNA can be linear, such as a PCR product, or circular, such as a plasmid. In cases where a donor DNA is a circular plasmid, it may be referred to as a “donor plasmid.”

As used herein, unless specifically indicated otherwise, the word “or” is used in the inclusive sense of “and/or” and not the exclusive sense of “either/or.”

2.1 Transgene Targeting to Amplifiable Loci

The present invention provides methods for generating transgenic mammalian cell lines expressing a desired protein product of interest, including “high-producer” cell lines, by targeting the insertion of a gene encoding the protein product of interest (e.g., a therapeutic protein gene expression cassette) to regions of the genome that are amplifiable. Such regions in mammalian cells include the DHFR, GS, and HPRT genes, as well as others shown in Table 1.

The precise mechanism of gene amplification is not known. Indeed, it is very likely that there is no single mechanism by which gene amplification occurs but that a variety of different random chromosomal aberrations, in combination with strong selection for amplification, results in increased gene copy number (reviewed in Omasa (2002), J. Biosci. Bioeng. 94:600-605). It is clear that chromosomal location plays a major role in amplification and the stable maintenance of amplified genes (Brinton and Heintz (1995), Chromosoma 104:143-51). It has been found that transgenes integrated into chromosomal locations adjacent to telomeres are more easily amplified and, once amplified, tend to be stable at high copy numbers after the selection agent is removed (Yoshikawa et al. (2000), Cytotechnology 33:37-46; Yoshikawa et al. (2000), Biotechnol Prog. 16:710-715). This is significant because selection agents such as MTX and MSX are toxic and cannot be included in the growth media in a commercial biomanufacturing process. In contrast, transgenes integrated into regions in the CHO genome that are not adjacent to telomeres amplify inefficiently and rapidly lose copy number following the removal of selection agents from the media. For example, Yoshikawa et al. found that randomly-integrated transgenes linked to a DHFR selectable marker amplified to greater than 10-fold higher copy numbers when the integration site was adjacent to a telomere (Yoshikawa et al. (2000), Biotechnol Prog. 16:710-715). These researchers also found that an amplified transgene integrated into a non-telomeric region will lose >50% of its copies in only 20 days following the removal of MTX from the growth media. None of the selectable genes identified in Table 1 is adjacent to a telomere in the mouse genome (www.ensembl.com) and the similarity in genome organization between mouse and CHO makes it likely that these genes are in non-telomeric regions in CHO as well (Xu et al. (2011), Nat. Biotechnol. 29:735-741). Thus, the prior art instructs that the loci identified in Table 1, including the DHFR and GS loci, are not preferred locations to target transgene insertion if the goal is efficient and stable gene amplification.

In addition, in the case of endogenous gene amplification, it is clear that chromosomal sequences outside of the selectable gene sequence play an important role in facilitating amplification and in defining the length of DNA sequence that is co-amplified with the gene under selection (Looney and Hamlin (1987), Mol. and Cell. Biol. 7:569-577). In particular, it has been shown that the sequence and location of the DNA replication origin in relation to the selectable gene plays a major role in amplification. For example, it has been shown that amplification of the endogenous CHO DHFR locus is dependent upon a pair of replication origins found in the region 5,000-60,000 base pairs downstream of the DHFR gene coding sequence (Anachkova and Hamlin (1989), Mol. and Cell. Biol. 9:532-540; Milbrandt et al. (1981), Proc. Natl. Acad. Sci. USA 78:6042-6047). Further, Brinton and Heintz have shown that these same replication origins fail to promote gene amplification when incorporated randomly into the genome with a transgenic DHFR sequence (Brinton and Heintz (1995), Chromosoma. 104:143-51). This clearly demonstrates the importance of maintaining both the sequence and proper chromosomal context of these replication origins to promote DHFR gene amplification. Thus the art instructs that the region downstream of DHFR is critical to gene amplification and should not be disrupted by, for example, inserting a transgenic gene expression cassette as described in the present invention.

Surprisingly, we have discovered that DNA sequences, including exogenous transcriptionally active sequences, which are inserted proximal to (e.g., within <100,000 base pairs) selectable genes in mammalian cell lines (e.g., CHO-K1) will co-amplify in the presence of appropriate compounds which select for amplification. Thus, the present invention provides methods for reliably and reproducibly producing isogenic cell lines in which transgenes encoding protein products of interest (e.g., biotherapeutic gene expression cassettes) can be amplified but in which it is not necessary to screen a large number of randomly generated cell lines to identify those which express high levels of the protein product of interest and are resistant to gene silencing.

In addition, we have surprisingly found that the mammalian cell lines of the invention, in which a sequence of interest is co-amplified with a selectable gene in an amplifiable locus, are stable with respect to expression of the sequence of interest and/or copy number of the sequence of interest even in the absence of continued selection. That is, whereas the art teaches that amplified sequences will be reduced in copy number over time if selection is not maintained (see, e.g., Yoshikawa et al. (2000), Biotechnol Prog. 16:710-715), we have found that cell lines produced according to the methods of the invention continue to produce the protein products of interest (encoded by the sequences of interest) at levels within 20%-25% of the initial levels, even 14 weeks after removal of the selection agent. This is significant, as noted above, because selection agents such as MTX and MSX are toxic, and it would be highly desirable to produce biotherapeutic proteins in cell lines which do not require continued exposure to such selection agents. Therefore, in some embodiments, the invention provides recombinant mammalian cell lines which continue to express a protein product of interest from an exogenous sequence of interest present in an amplified region of the genome (i.e., present in 2-1,000 copies, co-amplified with a selectable gene in an amplifiable locus) for a period of at least 8, 9, 10, 11, 12, 13, or 14 weeks after removal of the amplification selection agent, and with a reduction of expression levels and/or copy number of less than 20, 25, 30, 35 or 40%.

The present invention also provides the products necessary to practice the methods, and to target insertion of sequences of interest into amplifiable loci in mammalian cell lines. A common method for inserting or modifying a DNA sequence involves introducing a transgenic DNA sequence flanked by sequences homologous to the genomic target and selecting or screening for a successful homologous recombination event. Recombination with the transgenic DNA occurs rarely but can be stimulated by a double-stranded break in the genomic DNA at the target site (Porteus et al. (2005), Nat. Biotechnol. 23: 967-73; Tzfira et al. (2005), Trends Biotechnol. 23: 567-9; McDaniel et al. (2005), Curr. Opin. Biotechnol. 16: 476-83). Numerous methods have been employed to create DNA double-stranded breaks, including irradiation and chemical treatments. Although these methods efficiently stimulate recombination, the double-stranded breaks are randomly dispersed in the genome, which can be highly mutagenic and toxic. At present, the inability to target gene modifications to unique sites within a chromosomal background is a major impediment to routine genome engineering.

One approach to achieving this goal is stimulating homologous recombination at a double-stranded break in a target locus using a nuclease with specificity for a sequence that is sufficiently large to be present at only a single site within the genome (see, e.g., Porteus et al. (2005), Nat. Biotechnol. 23: 967-73). The effectiveness of this strategy has been demonstrated in a variety of organisms using ZFNs (Porteus (2006), Mol Ther 13: 438-46; Wright et al. (2005), Plant J. 44: 693-705; Urnov et al. (2005), Nature 435: 646-51). Homing endonucleases are a group of naturally-occurring nucleases which recognize 15-40 base-pair cleavage sites commonly found in the genomes of plants and fungi. They are frequently associated with parasitic DNA elements, such as Group I self-splicing introns and inteins. They naturally promote homologous recombination or gene insertion at specific locations in the host genome by producing a double-stranded break in the chromosome, which recruits the cellular DNA-repair machinery (Stoddard (2006), Q. Rev. Biophys. 38: 49-95). Homing endonucleases are commonly grouped into four families: the LAGLIDADG (SEQ ID NO: 65) family, the GIY-YIG family, the His-Cys box family and the HNH family. These families are characterized by structural motifs, which affect catalytic activity and recognition sequence. For instance, members of the LAGLIDADG (SEQ ID NO: 65) family are characterized by having either one or two copies of the conserved LAGLIDADG (SEQ ID NO: 65) motif (see Chevalier et al. (2001), Nucleic Acids Res. 29(18): 3757-3774). The LAGLIDADG (SEQ ID NO: 65) homing endonucleases with a single copy of the LAGLIDADG (SEQ ID NO: 65) motif form homodimers, whereas members with two copies of the LAGLIDADG (SEQ ID NO: 65) motif are found as monomers.

Natural homing endonucleases, primarily from the LAGLIDADG (SEQ ID NO: 65) family, have been used to effectively promote site-specific genome modification in plants, yeast, Drosophila, mammalian cells and mice, but this approach has been limited to the modification of either homologous genes that conserve the endonuclease recognition sequence (Monnat et al. (1999),Biochem. Biophys. Res. Commun. 255: 88-93) or to pre-engineered genomes into which a recognition sequence has been introduced (Rouet et al. (1994), Mol. Cell. Biol. 14: 8096-106; Chilton et al. (2003), Plant Physiol. 133: 956-65; Puchta et al. (1996), Proc. Natl. Acad. Sci. USA 93: 5055-60; Rong et al. (2002), Genes Dev. 16: 1568-81; Gouble et al. (2006), J. Gene Med. 8(5):616-622).

Systematic implementation of nuclease-stimulated gene modification requires the use of engineered enzymes with customized specificities to target DNA breaks to existing sites in a genome and, therefore, there has been great interest in adapting homing endonucleases to promote gene modifications at medically or biotechnologically relevant sites (Porteus et al. (2005), Nat. Biotechnol. 23: 967-73; Sussman et al. (2004), J. Mol. Biol. 342: 31-41; Epinat et al. (2003), Nucleic Acids Res. 31: 2952-62).

I-CreI (SEQ ID NO: 1) is a member of the LAGLIDADG (SEQ ID NO: 65) family of homing endonucleases which recognizes and cuts a 22 base pair recognition sequence in the chloroplast chromosome of the algae Chlamydomonas reinhardtii. Genetic selection techniques have been used to modify the wild-type I-CreI cleavage site preference (Sussman et al. (2004), J. Mol. Biol. 342: 31-41; Chames et al. (2005), Nucleic Acids Res. 33: e178; Seligman et al. (2002), Nucleic Acids Res. 30: 3870-9, Arnould et al. (2006), J. Mol. Biol. 355: 443-58). More recently, a method of rationally-designing mono-LAGLIDADG (SEQ ID NO: 65) homing endonucleases was described which is capable of comprehensively redesigning I-CreI and other homing endonucleases to target widely-divergent DNA sites, including sites in mammalian, yeast, plant, bacterial, and viral genomes (WO 2007/047859).

Thus, in one embodiment, the invention provides engineered meganucleases derived from the amino acid sequence of I-CreI that recognize and cut DNA sites in amplifiable regions of mammalian genomes. These engineered meganucleases can be used in accordance with the invention to target the insertion of gene expression cassettes into defined locations in the chromosomal DNA of cell lines such as CHO cells. This invention will greatly streamline the production of desired cell lines by reducing the number of lines that must be screened to identify a “high-producer” clone suitable for commercial-scale production of a therapeutic glycoprotein.

The present invention involves targeting transgenic DNA “sequences of interest” to amplifiable loci. The amplifiable loci are regions of the chromosomal DNA that contain selectable genes that become amplified in the presence of selection agents (e.g., drugs). For example, the Chinese Hamster Ovary (CHO) cell DHFR locus can be amplified to ˜1,000 copies by growing the cells in the presence of methotrexate (MTX), a DHFR inhibitor. Table 1 lists additional examples of selectable genes that can be amplified using small molecule drugs (Kellems, ed. Gene amplification in mammalian cells: a comprehensive guide. Marcel Dekker, New York, 1993; Omasa (2002), J. Biosci. Bioeng. 94:6 600-605).

TABLE 1
Amplifiable Genes

Selectable Gene Name	Amplified With
Dihydrofolate Reductase	Methotrexate (MTX)
Glutamine Synthetase	Methionine sulphoximine (MSX)
Hypoxanthine	Aminopterin, hypoxanthine, and thymidine
Phosphoribosyltransferase
Threonyl tRNA Synthetase	Borrelidin
Na,K-ATPase	Ouabain
Asparagine Synthetase	Albizziin or Beta-aspartyl hydroxamate
Ornithine Decarboxylase	alpha-difluoromethylornithine (DFMO)
Inosine-5′-monophosphate	Mycophenolic Acid
dehydrogenase
Adenosine Deaminase	Adenosine, Alanosine, 2′deoxycoformycin
Thymidylate Synthetase	Fluorouracil
Aspartate Transcarbamylase	N-Phosphonacetyl-L-Aspartate (PALA)
Metallothionein	Cadmium
Adenylate Deaminase (1, 2)	Adenine, Azaserine, Coformycin
UMP-Synthetase	6-azauridine, pyrazofuran
Ribonucleotide Reductase	hydroxyurea, motexafin gadolinium,
	fludarabine, cladribine, gemcitabine,
	tezacitabine, triapine.

Several considerations must be taken into account when selecting a specific target site for the insertion of a sequence of interest within an amplifiable locus. First, the selected insertion site must be co-amplified with the gene under selection. In many cases, experimental data already exists in the art which delimits the amount of flanking chromosomal sequence that co-amplifies with a selectable gene of interest. This data, which precisely defines the extent of the amplifiable locus, exists for CHO DHFR (Ma et al. (1988), Mol Cell Biol. 8(6):2316-27), human DHFR (Morales et al. (2009), Mol Cancer Ther. 8(2):424-432), and CHO GS (Sanders et al. (1987), Dev Biol Stand. 66:55-63). Where such data does not already exist in the art, we predict that chromosomal DNA sequences <100,000 base pairs upstream or downstream of the selectable gene coding sequence are likely to co-amplify. Hence, these regions could be suitable sites for targeting the insertion of a sequence of interest.

Second, target sites should be selected which will not greatly impact the function of the selectable gene (e.g., the endogenous DHFR, GS, or HPRT gene). Because amplification requires a functional copy of the selectable gene, insertion sites within the promoter, exons, introns, polyadenylation signals, or other regulatory sequences that, if disrupted, would greatly impact transcription or translation of the selectable gene, should be avoided. For example, WO 2008/059317 discloses meganucleases which cleave DNA target sites within the HPRT gene. To the extent WO 2008/059317 discloses the insertion of genes into the HPRT locus, it teaches that the HPRT gene coding sequence should be disrupted in the process of transgene insertion to facilitate selection for proper targeting using 6-thioguanine. 6-thioguanine is a toxic nucleotide analog that kills cells having functional HPRT activity. Because cells produced in accordance with WO 2008/059317 will not have HPRT activity, they will not amplify an inserted transgene in response to treatment with an HPRT inhibitor and, so, cannot be used in the present invention. For the present invention, unless the precise limits of all regulatory sequences are already known for a particular selectable gene, insertion sites >1,000 base pairs, >2,000 base pairs, >3,000 base pairs, >4,000 base pairs, or, preferably, >5,000 base pairs, upstream or downstream of the gene coding sequence should be selected. However, if the location of the regulatory sequences are known, the sequence of interest can be inserted immediately adjacent to the either the most 5′ or 3′ regulatory sequence (e.g., immediately 3′ to the polyadenylation signal).

Lastly, target sites should be selected which do not disrupt other chromosomal genes which may be important for normal cell physiology. In general, gene insertion sites should be >1,000 base pairs, >2,000 base pairs, >3,000 base pairs, >4,000 base pairs, or, preferably, >5,000 base pairs, away from any gene coding sequence.

Various methods of the invention are described schematically in the figures as follows:

FIG. 1 depicts a general strategy for targeting a sequence of interest to an amplifiable locus. In the first step, a site-specific endonuclease introduces a double-stranded break in the chromosomal DNA of a cell at a site that is proximal to an endogenous selectable gene. The cleaved chromosomal DNA then undergoes homologous recombination with a donor DNA molecule comprising a sequence of interest flanked by DNA sequences homologous to sequences flanking the endonuclease recognition sequence in the target site. As a result, the sequence of interest is inserted into the chromosomal DNA of the cell adjacent to the endogenous selectable gene. The modified cell is then grown in the presence of one or more compounds that inhibit the function of the selectable gene to induce an increase in the copy number (i.e., amplification) of the selectable gene. The sequence of interest, which is genetically linked to the selectable gene, will co-amplify with the selectable gene. The result is a stable transgenic cell line comprising multiple copies of the sequence of interest.

FIG. 2(A) depicts a schematic of the CHO DHFR locus showing a preferred region for targeting a sequence of interest 5,000-60,000 base pairs downstream of the DHFR gene. FIG. 2(B) depicts a schematic of the CHO GS locus showing a preferred region for targeting a sequence of interest 5,000-55,000 base pairs downstream of the GS gene. Promoters are shown as arrows. Exons are shown as rectangles, with non-coding exons in white and protein coding exons in gray.

FIG. 3 depicts a strategy for inserting a sequence of interest into an amplifiable locus in a two-step process involving a pre-integrated target sequence. In the first step, the chromosomal DNA of a cell is cleaved by a site-specific endonuclease at a site that is proximal to a selectable gene. The cleaved chromosomal DNA then undergoes homologous recombination with a donor DNA molecule comprising an exogenous target sequence flanked by DNA sequences homologous to the sequences flanking the endogenous target site. This results in the insertion of the new engineered target sequence into the chromosomal DNA of the cell proximal to the selectable gene. A sequence of interest can subsequently be targeted proximal to the same selectable gene using a nuclease, integrase, transposase, or recombinase that specifically recognizes the pre-integrated engineered target sequence. The modified cell is then grown in the presence of one or more compounds that co-amplify the selectable gene and the sequence of interest.

FIG. 4 depicts a strategy for inserting an engineered target sequence into a selectable gene (e.g., DHFR) with concomitant removal of a portion of the selectable gene. A site-specific endonuclease is first used to cleave the chromosomal DNA of the cell proximal to or within the selectable gene sequence. As shown in the figure, the endogenous target site is between exons 2 and 3 of the CHO DHFR gene (although the target site could be within any intron or exon, and the selectable gene could be any gene subject to amplification). The chromosomal DNA then undergoes homologous recombination with a first donor DNA (“donor DNA #1”) such that the sequence of the first donor DNA is inserted into the chromosomal DNA of the cell. As shown in the figure, this results in the replacement of the promoter and first two exons of DHFR by the new engineered target sequence (although the first donor DNA could replace more or less of the chromosomal DNA, such as only a portion of one exon). If such a replacement is made to all DHFR alleles in a cell, the resultant cell line is DHFR (−/−). A sequence of interest can subsequently be targeted proximal to the selectable gene in the cell line using an endonuclease, integrase, transposase, or recombinase that recognizes the engineered target sequence. As shown in the figure, the second donor DNA (“donor DNA #2”) comprises a sequence of interest as well as a promoter and the first two exons of DHFR. Proper targeting of this second donor DNA molecule results in the insertion of the sequence of interest at the engineered target sequence while simultaneously reconstituting a functional DHFR gene. Thus, properly targeted cell lines will be DHFR+ and can be selected using media deficient in hypoxanthine/thymidine. In addition, the sequence of interest can be co-amplified with the DHFR gene using MTX selection. The strategy diagrammed here for DHFR can be applied to any selectable gene in an amplifiable locus.

FIG. 5 depicts a strategy for inserting an engineered target sequence into an amplifiable locus with concomitant disruption of the coding sequence of a selectable gene. A site-specific endonuclease is first used to cleave the chromosomal DNA of the cell within the selectable gene coding sequence. As shown in the figure, the endogenous target site is in the third exon of the CHO GS gene. The chromosomal DNA then undergoes homologous recombination with a first donor DNA (“donor DNA #1”) such that the sequence of the first donor DNA is inserted into the chromosomal DNA of the cell. This results in the insertion of a new engineered target sequence into the GS coding sequence. If such an insertion occurs in both alleles of the GS gene and results in a frameshift mutation or otherwise disrupts the function of the GS gene, the resultant cell line will be GS (−/−). A sequence of interest can subsequently be targeted proximal to the amplifiable locus in the cell line using an endonuclease, integrase, transposase, or recombinase that recognizes the engineered target sequence. As shown in the figure, a second donor DNA (“donor DNA #2”) comprises a sequence of interest operably linked to a promoter as well as the 3′ portion of the GS coding sequence comprising exons 3, 4, 5, and 6. (The figure shows exons 3, 4, 5, and 6 joined into a single nucleotide sequence (i.e., with introns removed), but a sequence including either the naturally-occurring introns or one or more artificial introns could also be employed). Proper targeting of the second donor DNA molecule results in the insertion of the sequence of interest at the engineered target sequence while simultaneously reconstituting a functional GS gene. Thus, properly targeted cell lines will be GS+ and can be selected using media deficient in L-glutamine. In addition, the sequence of interest can be co-amplified with the GS gene using MSX selection. The strategy diagrammed here for GS can be applied to any selectable gene in an amplifiable locus.

FIG. 6 depicts a strategy for inserting an engineered target sequence into an amplifiable locus with concomitant disruption of the mRNA processing of a selectable gene. A site-specific endonuclease is first used to cleave the chromosomal DNA of the cell within an intron in the selectable gene. As drawn, the endogenous target site is in the intron between the third and fourth coding exons of the CHO GS gene. The chromosomal DNA then undergoes homologous recombination with a donor DNA #1 such that the sequence of the donor DNA is inserted in the chromosomal DNA of the cell. This results in the insertion of a new engineered target sequence into the GS coding sequence with an additional sequence that causes the GS mRNA to be processed incorrectly. As drawn, this additional sequence comprises a strong splice acceptor. If such an insertion occurs in both alleles of the GS gene, the artificial splice acceptor will cause the GS mRNA to splice incorrectly, resulting in a loss of GS expression and a requirement for growth in media containing L-glutamine. A sequence of interest can subsequently be targeted to the amplifiable locus in the cell line using an endonuclease, integrase, transposase, or recombinase that recognizes the engineered target sequence. As diagrammed, donor DNA #2 comprises a sequence of interest operably linked to a promoter as well as the 3′ portion of the GS coding sequence comprising exons 4, 5, and 6 joined into a single nucleotide sequence. (The figure shows exons 4, 5, and 6 joined into a single nucleotide sequence (i.e., with introns removed), but a sequence including either the naturally-occurring introns or one or more artificial introns could also be employed). Proper targeting of this donor DNA #2 molecule results in the insertion of the sequence of interest at the engineered target sequence while simultaneously reconstituting a functional GS gene. Thus, properly targeted cell lines will be GS+ and can be selected using media deficient in L-glutamine and the sequence of interest can be co-amplified with the GS gene using MSX selection. The strategy diagrammed here for GS can be applied to any selectable gene in an amplifiable locus.

FIG. 7(A) depicts a direct-repeat recombination assay for site-specific endonuclease activity. A reporter plasmid is produced comprising the 5′ two-thirds of the GFP gene (“GF”), followed by an endonuclease recognition sequence, followed by the 3′ two-thirds of the GFP gene (“FP”). Mammalian cells are transfected with this reporter plasmid as well as a gene encoding an endonuclease. Cleavage of the recognition sequence by the endonuclease stimulates homologous recombination between direct repeats of the GFP gene to restore GFP function. GFP+ cells can then be counted and/or sorted on a flow cytometer.

FIG. 7(B) depicts the results of the assay of FIG. 7(A) as applied to the CHO-23/24 and CHO-51/52 meganucleases. Light bars indicate the percentage of GFP+ cells when cells are transfected with the reporter plasmid alone (−endonuclease). Dark bars indicate the percentage of GFP+ cells when cells are co-transfected with a reporter plasmid and the corresponding meganuclease gene (+endonuclease). The assay was performed in triplicate and the standard deviation is shown.

FIG. 7(C) depicts alignment of sequences obtained from CHO cells transfected with mRNA encoding the CHO-23/24 meganuclease. The top sequence is from a wild-type (WT) CHO cell with the recognition sequence for CHO-23/24 underlined.

FIG. 7(D) depicts alignment of sequences obtained from CHO cells transfected with mRNA encoding the CHO-51/52 meganuclease. The top sequence is from a wild-type (WT) CHO cell with the recognition sequence for CHO-51/52 underlined.

FIG. 8(A) depicts a strategy for inserting an exogenous DNA sequence into the CHO DHFR locus using the CHO-51/52 meganuclease. CHO cells were co-transfected with mRNA encoding CHO-51/52 and a donor plasmid comprising an EcoRI site flanked by 543 base pairs of DNA sequence homologous to the region upstream of the CHO-51/52 recognition site and 461 base pairs of DNA sequence homologous to the region downstream of the CHO-51/52 recognition site. 48 hours post-transfection, genomic DNA was isolated and subjected to PCR using primers specific for the downstream region of the DHFR locus (dashed arrows).

FIG. 8(B) depicts PCR products that were cloned into pUC-19 and 48 individual plasmid clones and were digested with EcoRI and visualized on an agarose gel. 10 plasmids (numbered lanes) yielded a 647 base pair restriction fragment, consistent with cleavage of a first EcoRI site within the pUC-19 vector and a second EcoRI site in the cloned PCR fragment. These 10 plasmids were sequenced to confirm that they harbor a PCR fragment comprising a portion of the downstream DHFR locus with an EcoRI restriction site inserted into the CHO-51/52 recognition sequence. This restriction pattern was not observed when CHO cells were transfected with the donor plasmid alone.

FIG. 9(A) depicts a strategy for inserting an engineered target sequence into the CHO DHFR locus using the CHO-23/24 meganuclease. CHO cells were co-transfected with mRNA encoding CHO-23/24 and a donor plasmid comprising, in 5′ to 3′ orientation, an SV40 promoter, an ATG start codon, an FRT site, and a Zeocin-resistance (Zeo) gene. Zeocin-resistant cells were cloned by limiting dilution and screened by PCR to identify a clonal cell line in which the donor plasmid sequence integrated into the CHO-23/24 recognition site. After expansion, this cell line was co-transfected with a first plasmid encoding Flp recombinase operably linked to a promoter and second plasmid (donor plasmid #2) comprising a GFP gene under the control of a CMV promoter, an FRT site, and a hygromycin-resistance (Hyg) gene lacking a start codon. Flp-mediated recombination between FRT sites resulted in the integration of the donor plasmid #2 sequence into the engineered target sequence (i.e., the FRT site) such that a functional Hyg gene expression cassette was produced. FIG. 9(B) depicts PCR products from hygromycin-resistant clones produced as in (A) that were cloned by limiting dilution. Genomic DNA was extracted from 24 individual clones and PCR amplified using a first primer in the DHFR locus and a second primer in the Hyg gene (dashed lines). All 24 clones yielded a PCR product consistent with Hyg gene insertion into the engineered target sequence. FIG. 9(C) depicts GFP expression by the 24 clones produced in (B) using flow cytometry. All clones were found to express high levels of GFP with relatively little clone-to-clone variability.

FIG. 10. A GFP-expressing CHO line was produced by integrating a GFP gene expression cassette into the DHFR locus using an engineered target sequence strategy as shown in FIG. 9. This cell line was then grown in MTX as described in Example 2 to amplify the integrated GFP gene. (A) Flow cytometry plots showing GFP intensity on the Y-axis. In the pre-MTX cell line, GFP intensity averages approximately 2×10³ whereas in the cell line grown in 250 nM MTX, a distinct sub-population is visible (circled) in which GFP intensity approaches 10⁴. (B) MTX treated cell lines were sorted by FACS to identify individual cells expressing higher amounts of GFP. Five such high-expression cells were expanded and GFP intensity was determined by flow cytometry. All five clones were found to have significantly increased GFP expression relative to the pre-MTX cell line. (C) Genomic DNA was isolated from the five clonal cell lines produced in (B) and subjected to quantitative PCR using a primer pair specific for the GFP gene. It was found that the five high-expression clones had significantly more copies of the GFP gene than the pre-MTX cell line. These results demonstrate that the copy number and expression level a transgene integrated downstream of CHO DHFR can amplify in response to MTX treatment.

FIG. 11. (A) A direct-repeat recombination assay, as in FIG. 5A. (B) The assay in (A) applied to the CHO-13/14 and CGS-5/6 meganucleases. Light bars indicate the percentage of GFP+ cells when cells are transfected with the reporter plasmid alone (−endonuclease). Dark bars indicate the percentage of GFP+ cells when cells are co-transfected with a reporter plasmid and the corresponding meganuclease gene (+endonuclease). The assay was performed in triplicate and standard deviation is shown. (C) Alignment of sequences obtained from CHO cells transfected with mRNA encoding the CGS-5/6 meganuclease. The top sequence is from a wild-type (WT) CHO cell with the recognition sequence for CGS-5/6 underlined. Dashes indicate deleted bases. Bases that are italicized and in bold are point mutations or insertions relative to the wild-type sequence. Note that the mutations observed in at least clones 6d4, 6g5, 3b7, 3d11, 3e5, 6f10, 6hH8, 6d10, 6d7, 3g8, and 3a9 are expected to knockout GS gene function.

2.1.1 Gene Targeting to the CHO DHFR Locus

The CHO DHFR locus is diagrammed in FIG. 2A. The locus comprises the DHFR gene coding sequence in 6 exons spanning 18 24,500 base pairs. The Msh3 gene is located immediately upstream of DHFR and is transcribed divergently from the same promoter as DHFR. A hypothetical gene, 2BE2121, can be found ˜65,000 base pairs downstream of the DHFR coding sequence. Thus, there is a ˜65,000 base pair region downstream of the DHFR gene that does not harbor any known genes and is a suitable location for targeting the insertion of sequences of interest. Target sites for insertion of a sequence of interest generally should not be selected which are <1,000 base pairs, and preferably not <5,000 base pairs from either the DHFR or 2BE2121 genes. This limits the window of preferred target sites to the region 1,000-60,000 base pairs, or 5,000-60,000 base pairs downstream of the DHFR coding sequence. The sequence of this region is provided as SEQ ID NO: 2.

The human and mouse DHFR loci have an organization similar to CHO locus. In both cases, the Msh3 gene is immediately upstream of DHFR but there is a large area devoid of coding sequences downstream of DHFR. In humans, the ANKRD34B gene is ˜55,000 base pairs downstream of DHFR while the ANKRD34B gene is ˜37,000 base pairs downstream of DHFR in mouse. Therefore, the genomic region downstream of DHFR is an appropriate location to insert genes of interest in CHO, human, and mouse cells and cell lines. Further, gene expression cassettes inserted into this region will be expressed at a high level, resistant to gene silencing, and capable of being amplified by treatment with MTX. Methods for amplifying the CHO cell DHFR locus are known in the art (see, e.g., Kellems, ed., Gene amplification in mammalian cells: a comprehensive guide. Marcel Dekker, New York, 1993) and typically involve gradually increasing the concentration of MTX in the growth media from 0 to as high as 0.8 mM over a period of several weeks.

2.1.2 Gene Targeting to the GS Locus

The CHO, human, and mouse glutamine synthetase (also known as “glutamate-ammonia ligase” or “GluL”) loci share a common organization (FIG. 2B). The TEDDM1 gene is immediately upstream of GS in all species (5,000 bp upstream in the case of human, ˜7,000 bp upstream in the case of mouse and CHO). The closest downstream gene, however, is ˜46,000 away in the case of human and ˜117,000 bp away in the case of mouse and CHO. Therefore, we predict that the chromosomal region 1,000-41,000 bp, or 5,000-41,000 bp downstream of GS in human cells and 1,000-100,000 bp, or 5,000-100,000 bp downstream of GS in mouse and CHO cells are appropriate locations to target the insertion of sequences of interest. Because DNA sites distal to the GS coding sequence are more likely to be susceptible to gene silencing, the chromosomal region 5,000-60,000 bp downstream of GS is a preferred location to target the insertion of a sequence of interest even in mouse or CHO cells. The sequence of this region from the CHO genome is provided as SEQ ID NO: 3Gene expression cassettes inserted into this region will be expressed at a high level, resistant to gene silencing, and capable of being amplified by treatment with MSX. Less-preferred regions include the chromosomal region between the TEDDM1 and GS genes or the region <10,000 bp downstream of TEDDM1 (see FIG. 2B). Methods for amplifying the GS locus are known in the art (Bebbington et al. (1992), Biotechnology (N Y). 10(2):169-75).

2.2 Engineered Endonucleases for Gene Targeting

A sequence of interest may be inserted into an amplifiable locus using an engineered site-specific endonuclease. Methods for generating site-specific endonucleases which can target DNA breaks to pre-determined loci in a genome are known in the art. These include zinc-finger nucleases (Le Provost et al. (2010), Trends Biotechnol. 28(3):134-41), TAL-effector nucleases (Li et al. (2011), Nucleic Acids Res. 39(1):359-72), and engineered meganucleases (WO 2007/047859; WO 2007/049156; WO 2009/059195). In one embodiment, the invention provides engineered meganucleases derived from I-CreI that can be used to target the insertion of a gene of interest to an amplifiable locus. Methods to produce such engineered meganucleases are known in the art (see, e.g., WO 2007/047859; WO 2007/049156; WO 2009/059195). In preferred embodiments, a “single-chain” meganuclease is used to target gene insertion to an amplifiable region of the genome. Methods for producing such “single-chain” meganucleases are known in the art (see, e.g., WO 2009/059195 and WO 2009/095742). In some embodiments, the engineered nuclease is fused to a nuclear localization signal (NLS) to facilitate nuclear uptake. Examples of nuclear localization signals include the SV40 NLS (amino acid sequence MAPKKKRKV (SEQ ID NO: 36)) which can be fused to the C- or, preferably, the N-terminus of the protein. In addition, an engineered nuclease may be tagged with a peptide epitope (e.g., an HA, FLAG, or Myc epitope) to monitor expression levels or localization or to facilitate purification.

2.3 Engineered Cell Lines with Sequences of Interest Targeted to Amplifiable Loci

In some embodiments, the invention provides methods for using engineered nucleases to target the insertion of transgenes into amplifiable loci in cultured mammalian cells. This method has two primary components: (1) an engineered nuclease; and (2) a donor DNA molecule comprising a sequence of interest. The method comprises contacting the DNA of the cell with the engineered nuclease to create a double strand DNA break in an endogenous recognition sequence in an amplifiable locus followed by the insertion of the donor DNA molecule at the site of the DNA break. Such insertion of the donor DNA is facilitated by the cellular DNA-repair machinery and can occur by either the non-homologous end-joining pathway or by homologous recombination (FIG. 1).

The engineered nuclease can be delivered to the cell in the form protein or, preferably, as a nucleic acid encoding the engineered nuclease. Such nucleic acid can be DNA (e.g., circular or linearized plasmid DNA or PCR products) or RNA. For embodiments in which the engineered nuclease coding sequence is delivered in DNA form, it should be operably linked to a promoter to facilitate transcription of the engineered nuclease gene. Mammalian promoters suitable for the invention include constitutive promoters such as the cytomegalovirus early (CMV) promoter (Thomsen et al. (1984), Proc Natl Acad Sci U S A. 81(3):659-63) or the SV40 early promoter (Benoist and Chambon (1981), Nature. 290(5804):304-10) as well as inducible promoters such as the tetracycline-inducible promoter (Dingermann et al. (1992), Mol Cell Biol. 12(9):4038-45).

In some embodiments, mRNA encoding the engineered nuclease is delivered to the cell because this reduces the likelihood that the gene encoding the engineered nuclease will integrate into the genome of the cell. Such mRNA encoding an engineered nuclease can be produced using methods known in the art such as in vitro transcription. In some embodiments, the mRNA is capped using 7-methyl-guanosine. In some embodiments, the mRNA may be polyadenylated.

Purified engineered nuclease proteins can be delivered into cells to cleave genomic DNA, which allows for homologous recombination or non-homologous end-joining at the cleavage site with a sequence of interest, by a variety of different mechanisms known in the art. For example, the recombinant nuclease protein can be introduced into a cell by techniques including, but not limited to, microinjection or liposome transfections (see, e.g., Lipofectamine™, Invitrogen Corp., Carlsbad, Calif.). The liposome formulation can be used to facilitate lipid bilayer fusion with a target cell, thereby allowing the contents of the liposome or proteins associated with its surface to be brought into the cell. Alternatively, the enzyme can be fused to an appropriate uptake peptide such as that from the HIV TAT protein to direct cellular uptake (see, e.g., Hudecz et al. (2005), Med. Res. Rev. 25: 679-736).

Alternatively, gene sequences encoding the engineered nuclease protein are inserted into a vector and transfected into a eukaryotic cell using techniques known in the art (see, e.g., Ausubel et al., Current Protocols in Molecular Biology, Wiley 1999). The sequence of interest can be introduced in the same vector, a different vector, or by other means known in the art. Non-limiting examples of vectors for DNA transfection include virus vectors, plasmids, cosmids, and YAC vectors. Transfection of DNA sequences can be accomplished by a variety of methods known to those of skill in the art. For instance, liposomes and immunoliposomes are used to deliver DNA sequences to cells (see, e.g., Lasic et al. (1995), Science 267: 1275-76). In addition, viruses can be utilized to introduce vectors into cells (see, e.g., U.S. Pat. No. 7,037,492). Alternatively, transfection strategies can be utilized such that the vectors are introduced as naked DNA (see, e.g., Rui et al. (2002), Life Sci. 71(15): 1771-8).

General methods for delivering nucleic acids into cells include: (1) chemical methods (Graham et al. (1973), Virology 54(2):536-539; Zatloukal et al. (1992), Ann. N.Y. Acad. Sci., 660:136-153; (2) physical methods such as microinjection (Capecchi (1980), Cell 22(2):479-488, electroporation (Wong et al. (1982), Biochim. Biophys. Res. Commun. 107(2):584-587; Fromm et al. (1985), Proc. Nat'l Acad. Sci. USA 82(17):5824-5828; U.S. Pat. No. 5,384,253) and ballistic injection (Johnston et al. (1994), Methods Cell. Biol. 43(A): 353-365; Fynan et al. (1993), Proc. Nat'l Acad. Sci. USA 90(24): 11478-11482); (3) viral vectors (Clapp (1993), Clin. Perinatol. 20(1): 155-168; Lu et al. (1993), J. Exp. Med. 178(6):2089-2096; Eglitis et al. (1988), Avd. Exp. Med. Biol. 241:19-27; Eglitis et al. (1988), Biotechniques 6(7):608-614); and (4) receptor-mediated mechanisms (Curiel et al. (1991), Proc. Nat'l Acad. Sci. USA 88(19):8850-8854; Curiel et al. (1992), Hum. Gen. Ther. 3(2):147-154; Wagner et al. (1992), Proc. Nat'l Acad. Sci. USA 89 (13):6099-6103). In some preferred embodiments, 7-methyl-guanosine capped mRNA encoding the engineered nuclease is delivered to cells using electroporation.

The donor DNA molecule comprises a gene of interest operably linked to a promoter. In many cases, a donor molecule may comprise multiple genes operably linked to the same or different promoters. For example, donor molecules comprising monoclonal antibody expression cassettes may comprise a gene encoding the antibody heavy chain and a second gene encoding the antibody light chain. Both genes may be under the control of different promoters or they may be under the control of the same promoter by using, for example, an internal-ribosome entry site (IRES). Donor molecules may also comprise a selectable marker gene operably linked to a promoter to facilitate the identification of transgenic cells. Such selectable markers are known in the art and include neomycin phosphotransferase (NEO), hypoxanthine phosphoribosyltransferase (HPRT), glutamine synthetase (GS), dihydrofolate reductase (DHFR), and hygromycin phosphotransferase (HYG) genes.

In some embodiments, donor DNA molecules will additionally comprise flanking sequences homologous to the target sequences in the DNA of the cell. Such homologous flanking sequences comprise >3 or, preferably, >50 or, more preferably, >200 or, most preferably, >400 base pairs of DNA that are identical or nearly identical in sequence to the chromosomal locus recognized by the engineered nuclease (FIG. 1). Such homologous DNA sequences facilitate the integration of the donor DNA sequence into the amplifiable locus by homologous recombination.

The “donor” DNA molecule can be circular (e.g., plasmid DNA) or linear (e.g., linearized plasmid or PCR products). Methods for delivering DNA molecules are known in the art, as discussed above.

In some embodiments, the engineered nuclease gene and donor DNA are carried on separate nucleic acid molecules which are co-transfected into cells or cell lines. For example, the engineered nuclease gene operably linked to a promoter can be transfected in plasmid form simultaneously with a separate donor DNA molecule in plasmid or PCR product form. In an alternative embodiment, the engineered nuclease can be delivered in mRNA form with a separate donor DNA molecule in plasmid or PCR product form. In a third embodiment, the engineered nuclease gene and donor DNA are carried on the same DNA molecule, such as a plasmid. In a fourth embodiment, cells are co-transfected with purified engineered nuclease protein and a donor DNA molecule in plasmid or PCR product form.

Following transfection with the engineered nuclease and donor DNA, cells are typically allowed to recover from transfection (24-72 hours) before being cloned using methods known in the art. Common methods for cloning a genetically engineered cell line include “limiting dilution” in which transfected cells are transferred to tissue culture plates (e.g., 48 well, 96 well plates) at a concentration of <1 cell per well and expanded into clonal populations. Other cloning strategies include robotic clone identification/isolation systems such as ClonePix™ (Genetix, Molecular Devices, Inc., Sunnyvale, Calif.). Clonal cell lines can then be screened to identify cell lines in which the sequence of interest is integrated into the intended target site. Cell lines can easily be screened using molecular analyses known in the art such as PCR or Southern Blot. For example, genomic DNA can be isolated from a clonal cell line and subjected to PCR amplification using a first (sense-strand) primer that anneals to a DNA sequence in the sequence of interest and a second (anti-sense strand) primer that anneals to a sequence in the amplifiable locus. If the donor DNA molecule comprises a DNA sequence homologous to the target site, it is important that the second primer is designed to anneal to a sequence in the amplifiable locus that is beyond the limits of homology carried on the donor molecule to avoid false positive results. Alternatively, cell lines can be screened for expression of the sequence of interest. For example, if the sequence of interest encodes a secreted protein such as an antibody, the growth media can be sampled from isolated clonal cell lines and assayed for the presence of antibody protein using methods known in the art such as Western Blot or Enzyme-Linked Immunosorbant Assay (ELISA). This type of functional screen can be used to identify clonal cell lines which carry at least one copy of the sequence of interest integrated into the genome. Additional molecular analyses such as PCR or Southern blot can then be used to determine which of these transgenic cell lines carry the sequence of interest targeted to the amplifiable locus of interest, as described above.

The method of the invention can be used on any culturable and transfectable cell type such as immortalized cell lines and stem cells. In preferred embodiments, the method of the invention is used to genetically modify immortalized cell lines that are commonly used for biomanufacturing. This includes:

• • 1. Hamster cell lines such as baby hamster kidney (BHK) cells and all variants of Chinese Hamster Ovary (CHO) cells, e.g., CHO-K1, CHO-S (Invitrogen Corp., Carlsbad, Calif.), DG44, or Potelligent™ (Lonza Group Ltd., Basel, Switzerland). Because the genome sequences of different hamster cell lines are very nearly identical, an engineered meganuclease which can be used to practice the invention in one hamster cell type (e.g., BHK cells) can generally be used to practice the invention in another hamster cell type (e.g., CHO-K1).
  • 2. Mouse cell lines such as mouse hybridoma or mouse myeloma (e.g., NSO) cells. Because the genome sequences of different mouse cell lines are very nearly identical, an engineered meganuclease which can be used to practice the invention in one mouse cell type (e.g., mouse hybridoma cells) can generally be used to practice the invention in another mouse cell type (e.g., NSO).

3. Human cell lines such as human embryonic kidney cells (e.g., HEK-293 or 293S) and human retinal cells (e.g., PER.C6). Because the genome sequences of different human cell lines are very nearly identical, an engineered meganuclease which can be used to practice the invention in one human cell type (e.g., HEK-293 cells) can generally be used to practice the invention in another human cell type (e.g., PER.C6).

2.6 Pre-Engineered Cell Lines with Engineered Target Sequences in Amplifiable Loci.

In one embodiment, the invention provides cell lines which are pre-engineered to comprise a targetable “engineered target sequence” for gene insertion in an amplifiable locus in a mammalian cell line (FIG. 3). An engineered target sequence comprises a recognition sequence for an enzyme which is useful for inserting transgenic nucleic acids into chromosomal DNA sequences. Such engineered target sequences can include recognition sequences for engineered meganucleases derived from I-CreI (e.g., SEQ ID NO 37-87 from WO 2009/076292), recognition sequences for zinc-finger nucleases, recognition sequences for TAL effector nucleases (TALENs), the LoxP site (SEQ ID NO 4) which is recognized by Cre recombinase, the FRT site (SEQ ID NO: 5) which is recognized by FLP recombinase, the attB site (SEQ ID NO: 6) which is recognized by lambda recombinase, or any other DNA sequence known in the art that is recognized by a site specific endonuclease, recombinase, integrase, or transpose that is useful for targeting the insertion of nucleic acids into a genome. Thus, the invention allows one skilled in the art to use an engineered nuclease (e.g., a meganuclease, zinc-finger nuclease, or TAL effector nuclease) to insert an engineered target sequence into an amplifiable locus in a mammalian cell line. The resulting cell line comprising such an engineered target sequence at an amplifiable locus can then be contacted with the appropriate enzyme (e.g., a second engineered meganuclease, a second zinc-finger nuclease, a second TAL effector nuclease, a recombinase, an integrase, or a transposase) to target the insertion of a gene of interest into the amplifiable locus at the engineered target sequence. This two-step approach can be advantageous because the efficiency of gene insertion that can be achieved using an optimal meganuclease, zinc-finger nuclease, recombinase, integrase, or transposase might be higher than what can be achieved using the initial endonuclease (e.g., meganuclease or zinc-finger nuclease) that cleaves the endogenous target site to promote insertion of the engineered target sequence.

In an alternative embodiment, a cell line is produced by inserting an engineered target sequence into an amplifiable locus with the concomitant removal of all or a portion of the adjacent endogenous marker gene (FIG. 4). For example, an engineered meganuclease, zinc-finger nuclease, or TAL-effector nuclease can be used to remove the first two exons of both alleles of the CHO DHFR gene and replace them with an engineered target sequence for a different engineered meganuclease, ZFN, TALEN, recombinase, integrase, or transposase. The resulting cell line will be DHFR deficient and unable to grow in the absence of hypoxanthine/thymidine. Alternatively, for example, an engineered meganuclease, ZFN or TALEN can be used to remove the first exon of both alleles of the CHO GS gene and replace it with an engineered target sequence for a different engineered meganuclease, ZFN, TALEN, recombinase, integrase, or transposase (FIG. 4). The resulting cell line will be GS deficient and unable to grow in the absence of L-glutamine. Such a cell line is useful because a gene of interest can be inserted into the engineered target sequence in the pre-engineered cell line while simultaneously reconstituting the selectable gene (e.g., DHFR or GS). Thus, it is possible to select for transfectants harboring the gene of interest at the amplifiable locus using media conditions that select for DHFR+ or GS+ cells.

In an alternative embodiment, a cell line is produced in which an engineered target sequence is inserted into an amplifiable locus with disruption of the selectable gene (FIGS. 5, 6). This can be accomplished, for example, using a meganuclease which recognizes a DNA site in the coding sequence of the selectable gene. Such a meganuclease can be used to target the insertion of an engineered target sequence into the selectable gene coding sequence resulting in disruption of gene function by, for example, introducing a frameshift (FIG. 5). Alternatively, for example, an engineered target sequence can be inserted into an intron in the selectable gene sequence with an additional sequence that promotes improper processing of the selectable gene transcript (FIG. 6). Such sequences that promote improper processing include, for example, artificial splice acceptors or polyadenylation signals. Splice acceptor sequences are known in the art (Clancy (2008), “RNA Splicing: Introns, Exons and Spliceosome,” Nature Education 1:1) and typically comprise a 20-50 base pair pyrimidine-rich sequence followed by a sequence (C/T)AG(A/G). SEQ ID NO: 33 is an example of a splice acceptor sequence Likewise, polyadenylation signals are known in the art and include, for example, the SV40 polyadenylation signal (SEQ ID NO: 34) and the BGH polyadenylation signal (SEQ ID NO: 35). In some embodiments, the resulting cell line harboring the new engineered target sequence in all alleles of the selectable gene will be deficient in the function of the gene due to mis-transcription or mis-translation and will be able to grow only under permissive conditions. For example, an engineered target sequence can be inserted into the GS gene sequence using a meganuclease resulting in a cell line that is GS−/− that can grow only in the presence of L-glutamine in the growth media. In a subsequent step, a gene of interest can be inserted into the engineered target sequence while simultaneously reconstituting the selectable gene (e.g., DHFR or GS). Thus, it is possible to select for transfectants harboring the gene of interest at the amplifiable locus using media conditions that select for DHFR+ or GS+ cells.

2.5 Transgenic Cell Lines for Biomanufacturing.

In some embodiments, the invention provides transgenic cell lines suitable for the production of protein pharmaceuticals. Such transgenic cell lines comprise a population of cells in which a gene of interest, operably linked to a promoter, is inserted into the genome of the cell at an amplifiable locus wherein the gene of interest encodes a protein therapeutic. Examples of protein therapeutics include: monoclonal antibodies, antibody fragments, erythropoietin, tissue-type plasminogen activator, Factor VIII, Factor IX, insulin, colony stimulating factors, interferons (e.g., interferon-α, interferon-(β, and interferon-γ), interleukins (e.g., interleukin-2), vaccines, tumor necrosis factor, and glucocerebrosidase. Protein therapeutics are also referred to as “biologics” or “biopharmaceuticals.”

To be used for biomanufacturing, a transgenic cell line of the invention should undergo: (1) adaptation to serum-free growth in suspension; and (2) amplification of the gene of interest. In some embodiments, the invention is practiced on adherent cell lines which can be adapted to growth in suspension to facilitate their maintenance in shaker-flasks or stirred-tank bioreactors as is typical of industrial biomanufacturing. Methods for adapting adherent cells to growth in suspension are known in the art (Cell Culture and Upstream Processing, Butler, ed. (Taylor and Francis Group, New York, 2007)). For regulatory reasons, it is generally necessary to further adapt biomanufacturing cell lines to chemically-defined media lacking animal-derived components (i.e., “serum-free” media). Methods for preparing such media and adapting cell lines to it are known in the art (Cell Culture and Upstream Processing, Butler, ed. (Taylor and Francis Group, New York, 2007)). Such media can also be purchased commercially (e.g., CD-3 media for maintenance of CHO cells, available from Sigma-Aldrich, St. Louis, Mo.) and cells can be adapted to it by following the manufacturers' instructions. In some embodiments, the cell line is adapted to growth in suspension and/or serum-free media prior to being transfected with the engineered nuclease.

Lastly, methods for gene amplification are known in the art (Cell Culture and Upstream Processing, Butler, ed. (Taylor and Francis Group, New York, 2007)). In general, the process involves adding an inhibitor of a selectable gene product to the growth media to select for cells that express abnormally high amounts of the gene product due to gene-duplication events. In general, the concentration of inhibitor added to the growth media is increased slowly over a period of weeks until the desired level of gene amplification is achieved. Inhibitor is then generally removed from the media prior to initiating a bioproduction run to avoid the possibility of the inhibitor contaminating the protein therapeutic formulation. For example, the CHO DHFR locus can be amplified by slowly increasing the concentration of MTX in the growth media from 0 mM to as high as 0.8 mM over a period of several weeks. The GS locus can, likewise, be amplified by slowly increasing the concentration of MSX in the media from 0 μM to as high as 100 μM over a period of several weeks. Methods for evaluating gene amplification are known in the art and include Southern Blot and quantitative real-time PCR (rtPCR). In addition, or as an alternative, expression levels of the sequence of interest, which are generally correlated to gene copy number, can be evaluated by determining the concentration of protein therapeutic in the growth media using conventional methods such as Western Blot or ELISA.

Following cell line production, adaptation, and amplification, protein therapeutics can be produced and purified using methods that are standard in the biopharmaceutical industry.

EXAMPLES

This invention is further illustrated by the following examples, which should not be construed as limiting. Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific substances and procedures described herein. Such equivalents are intended to be encompassed in the scope of the claims that follow the examples below. Example 1 refers to engineered meganucleases that can be used to target the insertion of a gene of interest downstream of the DHFR gene in CHO cells. Example 2 refers to engineered meganucleases that can be used to target the insertion of an engineered target sequence into the CHO DHFR gene with concomitant removal of DHFR exons 1 and 2. Example 2 also refers to engineered meganucleases that can be used to target the insertion of an engineered target sequence into the CHO GS gene. Example 3 refers to meganucleases that can be used to target the insertion of a gene of interest downstream of the GS gene in CHO cells.

EXAMPLE 1

Targeted Gene Insertion into the CHO DHFR Locus using Engineered Meganucleases

The CHO genomic DNA sequence 10,000-55,000 base pairs downstream of the DHFR gene was searched to identify DNA sites amenable to targeting with engineered meganucleases. Two sites (SEQ ID NO: 7 and SEQ ID NO: 8) were selected which are, respectively, 35,699 and 15,898 base pairs downstream of the DHFR coding sequence (Table 2).

TABLE 2
Example Recognition Sites For Engineered Meganucleases in the CHO DHFR
Locus.

SEQ ID		Location Relative to CHO
NO:	Target Site Sequences	DHFR Coding Sequence
7	5′-TAAGGCCTCATATGAAAATATA-3′	35,699 bp downstream
8	5′-ATAGATGTCTTGCATACTCTAG-3′	15,898 bp downstream

1. Meganucleases that Recognize SEQ ID NO: 7 and SEQ ID NO: 8

An engineered meganuclease (SEQ ID NO: 9) was produced which recognizes and cleaves SEQ ID NO: 7. This meganuclease is called “CHO-23/24”. A second engineered meganuclease (SEQ ID NO: 10) was produced which recognizes and cleaves SEQ ID NO: 8. This meganuclease is called “CHO-51/52.” Each meganuclease comprises an N-terminal nuclease-localization signal derived from SV40, a first meganuclease subunit, a linker sequence, and a second meganuclease subunit.

2. Site-Specific Cleavage of Plasmid DNA by Meganucleases CHO-23/24 and CHO-51/52

CHO-23/24 and CHO-51/52 were evaluated using a direct-repeat recombination assay as described previously (Gao et al. (2010), Plant J. 61(1):176-87, FIG. 7A). A defective GFP reporter cassette was generated by first cloning a 5 ′ 480 bp fragment of the GFP gene into NheI/HindIII-digested pcDNA5/FRT (Invitrogen Corp., Carlsbad, Calif.) resulting in the plasmid pGF. Next, a 3′ 480 bp fragment of the GFP gene (including a 240 bp sequence duplicated in the 5′ 480 bp fragment) was cloned into BamHI/XhoI-digested pGF. The resulting plasmid, pGFFP, consists of the 5′ two-thirds of the GFP gene followed by the 3′ two-thirds of the GFP gene, interrupted by 24 bp of the pcDNA5/FRT polylinker. To insert the meganuclease recognition sites, complementary oligonucleotides comprising the sense and anti-sense sequence of each recognition site were annealed and ligated into HindIII/BamHI-digested pGFFP.

The coding sequences of the engineered meganucleases were inserted into the mammalian expression vector pCP under the control of a constitutive (CMV) promoter. Chinese hamster ovary (CHO) cells at approximately 90% confluence were transfected in 96-well plates with 150 ng pGFFP reporter plasmid and 50 ng of meganuclease expression vector or, to determine background, 50 ng of empty pCP, using Lipofectamine 2000 according to the manufacturer's instructions (Invitrogen Corp., Carlsbad, Calif.). To determine transfection efficiency, CHO cells were transfected with 200 ng pCP GFP. Cells were washed in PBS 24 h post-transfection, trypsinized and resuspended in PBS supplemented with 3% fetal bovine serum. Cells were assayed for GFP activity using a Cell Lab Quanta SC MPL flow cytometer and the accompanying Cell Lab Quanta analysis software (Beckman Coulter, Brea, Calif.).

Results are shown in FIG. 7B. It was found that both of the engineered meganucleases were able to cleave their intended recognition sites significantly above background within the context of a plasmid-based reporter assay.

3. Site-Specific Cleavage of CHO DHFR Locus by Meganucleases CHO-23/24 and CHO-51/52

To determine whether or not CHO-23/24 and CHO-51/52 are capable of cleaving their intended target sites in the CHO DHFR locus, we screened genomic DNA from CHO cells expressing either CHO-23/24 or CHO-51/52 to identify evidence of chromosome cleavage at the intended target site. This assay relies on the fact that chromosomal DNA breaks are frequently repaired by NHEJ in a manner that introduces mutations at the site of the DNA break. These mutations, typically small deletions or insertions (collectively known as “indels”) leave a telltale scar that can be detected by DNA sequencing (Gao et al. (2010), Plant J. 61(1):176-87).

CHO cells were transfected with mRNA encoding CHO-23/24 or CHO-51/52. mRNA was prepared by first producing a PCR template for an in vitro transcription reaction (SEQ ID NO: 20 and SEQ ID NO: 21). Each PCR product included a T7 promoter and 609 bp of vector sequence downstream of the meganuclease gene. The PCR product was gel purified to ensure a single template. Capped (m7G) RNA was generated using the RiboMAX T7 kit (Promega Corp., Fitchburg, Wis.) according to the manufacturer's instructions and. Ribo m7G cap analog (Promega Corp., Fitchburg, Wis.) was included in the reaction and 0.5 μg of the purified meganuclease PCR product served as the DNA template. Capped RNA was purified using the SV Total RNA Isolation System (Promega Corp., Fitchburg, Wis.) according to the manufacturer's instructions.

1.5×10⁶ CHO-K1 cells were nucleofected with 3×10¹² copies of CHO-23/24 or CHO-51/52 mRNA (2×10⁶ copies/cell) using an Amaxa Nucleofector II device (Lonza Group Ltd., Basel, Switzerland) and the U-23 program according to the manufacturer's instructions. 48 hours post-transfection, genomic DNA was isolated from the cells using a FlexiGene kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The genomic DNA was then subjected to PCR to amplify the corresponding target site. In the case of cells transfected with mRNA encoding CHO-23/24, the forward and reverse PCR primers were SEQ ID NO: 16 and SEQ ID NO: 17. In the case of cells transfected with mRNA encoding CHO-51/52, the forward and reverse PCR primers were SEQ ID NO: 18 and SEQ ID NO: 19. PCR products were gel purified and cloned into pUC-19. 40 plasmids harboring PCR products derived from cells transfected with CHO-23/24 mRNA were sequenced, 13 of which were found to have mutations in the CHO-23/24 target site (FIG. 7C). 44 plasmids harboring PCR products derived from cells transfected with CHO-51/52 mRNA were sequenced, 10 of which were found to have mutations in the CHO-51/52 target site (FIG. 7D). These results indicate that CHO-23/24 and CHO-51/52 are able to cut their intended target sites downstream of the CHO DHFR gene.

4. Site-Specific Integration into the CHO DHFR Locus using an Engineered Meganuclease

To evaluate the efficiency of DNA insertion into the CHO DHFR locus using an engineered meganuclease, we prepared a donor plasmid (SEQ ID NO: 11) comprising an EcoRI restriction enzyme site flanked by DNA sequence homologous to the CHO-51/52 recognition site (FIG. 8A). Specifically, the donor plasmid of SEQ ID NO: 11 comprises a pUC-19 vector harboring a homologous recombination cassette inserted between the Kpnl and HindIII restriction sites. The homologous recombination cassette comprises, in 5′- to 3′-order: (i) 543 base pairs of DNA identical to the sequence immediately upstream of the CHO-51/52 cut site, including the upstream half-site of the CHO-51/52 recognition sequence and the four base pair “center sequence” separating the two half-sites comprising the CHO-51/52 recognition sequence; (ii) an EcoRI restriction enzyme site (5′-GAATTC-3′); and iii) 461 base pairs of DNA identical to the sequence immediately downstream of the CHO-51/52 cut site, including the downstream half-site of the CHO-51/52 recognition sequence and the four base pair “center sequence” separating the two half-sites comprising the CHO-51/52 recognition sequence. Note that this results in a duplication of the four base pair “center sequence” (5′-TTGC-3′) to maximize the likelihood of strand invasion by the 3′ overhangs generated by CHO-51/52 cleavage. We have discovered that donor plasmids comprising such a duplication of the center sequence are optimal substrates for gene targeting by homologous recombination.

mRNA encoding CHO-51/52 was prepared as described above. 1.5×10⁶ CHO-K1 cells were nucleofected with 3×10¹² copies of CHO 51-52 mRNA (2×10⁶ copies/cell) and 1.5 μg of the donor plasmid (SEQ ID NO: 11). Nucleofection was performed using an Amaxa Nucleofector II device (Lonza Group Ltd., Basel, Switzerland) and the U-23 program according to the manufacturer's instructions. 48 hours post-transfection, genomic DNA was isolated from the cells using a FlexiGene kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The DNA was subjected to PCR using primers flanking the CHO-51/52 recognition site (SEQ ID NO: 18 and SEQ ID NO: 19). Importantly, these primers are beyond the limits of homologous sequence carried in the donor plasmid and, therefore, will amplify only the chromosomal DNA sequence and not the donor plasmid. PCR products were cloned into a pUC-19 plasmid and 48 clones were purified and digested with EcoRI (FIG. 8B). 10 plasmids yielded a restriction pattern consistent with the insertion of an EcoRI site into the CHO-51/52 recognition sequence. These data demonstrate that it is possible to use CHO-51/52 to precisely insert DNA downstream of the CHO DHFR gene at SEQ ID NO: 8.

5. Site-Specific Integration of an Engineered Target Sequence into the CHO DHFR Locus

A donor plasmid (SEQ ID NO: 25) was produced comprising an FRT sequence (SEQ ID NO: 5) adjacent to a zeocin resistance gene under the control of an SV40 early promoter (FIG. 9A). This cassette was flanked by DNA sequence homologous to the CHO DHFR locus immediately upstream or downstream of the CHO-23/24 recognition sequence. CHO cells were co-transfected with this donor plasmid and mRNA encoding CHO-23/24 as described above. 72 hours post-transfection, zeocin-resistant cells were cloned by limiting dilution and expanded for approximately 3 weeks. Clonal populations were then screened by PCR using a first primer in the SV40 promoter (SEQ ID NO: 26) and a second primer in the DHFR locus (SEQ ID NO: 16) to identify cell lines carrying the FRT/Zeocin sequence downstream of the DHFR gene. One such cell line carrying the integrated FRT Insertion target sequence was subsequently co-transfected with a second donor plasmid (SEQ ID NO: 27) and a plasmid encoding Flp recombinase. SEQ ID NO: 27 comprises a GFP gene under the control of a CMV promoter, a FRT sequence, and a non-functional hygromycin resistance gene lacking an ATG start codon. Flp-stimulated recombination between FRT sites in the genome and the plasmid resulted in the incorporation of the entire plasmid sequence into the CHO genome at the site of the engineered target sequence. Such recombination restored function to the hygromycin-resistance gene by orientating it downstream of an ATG start codon integrated as part of the engineered target sequence. As such, successful integrations could be selected using hygromycin.

Hygromycin-resistant cells were cloned by limiting dilution and 24 individual clonal lines were assayed by PCR using a first primer in the hygromycin-resistance gene (SEQ ID NO: 28). All 24 clones yielded the expected PCR product (FIG. 9B), indicating that the GFP gene expression cassette was successfully inserted into the DHFR engineered target sequence in all cases. The 24 cell lines were then evaluated by flow cytometry and were found to express consistent levels of GFP (FIG. 9C).

6. Transgene Amplification

A GFP-expressing CHO line produced as described above was seeded at a density of 3×10⁵ cells/mL in 30 mL of media containing 50nM MTX. Cells were cultured for 14 days before being re-seeded at the same density in media containing 100 nM MTX. Cells were cultured for another 14 days before being re-seeded in media containing 250 nM MTX. Following 14 days in culture, GFP expression in the treated cells was evaluated by flow cytometry and compared to GFP expression in the parental (pre-MTX) cell population (FIG. 10A). It was found that the MTX-treated cells had a distinct sub-population in which GFP expression was significantly increased. Individual high-expression cells from the MTX-treated population were then isolated using a cell sorter and 5 clones were expanded for 14 days in the absence of MTX. GFP expression in the 5 clonal cell populations was then evaluated by flow cytometry and compared with the parental (pre-MTX) cell population. It was found that the MTX-treated clones had approximately 4-6 times the GFP intensity as the pre-MTX cells. Quantitative PCR was then performed using a primer set specific for the GFP gene and it was found that the MTX-treated clones all had approximately 5-9 times as many copies of the GFP gene as the pre-MTX population. These data provide conclusive evidence that a transgene inserted downstream of the CHO DHFR gene can be amplified by treatment with MTX.

7. Stability of Gene Amplification

The five clonal cell lines expressing high levels of GFP that were produced in (6) above were then passaged for a period of 14 weeks in media with or without 250 nM MTX to evaluate the stability of gene amplification. GFP intensity was determined on a weekly basis and the quantitative PCR assay used to determine GFP gene copy number described above was repeated at the end of the 14 week evaluation period. As expected, the clones passaged in media with MTX maintained a high level of GFP expression with no clone deviating more than 20% from the GFP intensity determined in week 1. Quantitative PCR revealed that gene copy number likewise deviated by less than 20% for all clones. Surprisingly, gene amplification was equally stable in cell lines grown in media lacking MTX. Contrary to what would have been predicted based on the existing art, GFP gene expression was not reduced by more than 18% in any of the five cell lines over the 14 week evaluation period. Gene copy number determined by quantitative PCR was also stable with less than 24% deviation over time for all of the cell lines. These results indicate that a transgene amplified in the CHO DHFR locus is stable for an extended period of time, obviating the need to grow the cells in toxic selection agents that that could contaminate bioproduct formulations.

EXAMPLE 2

Insertion of an Engineered Target Sequence into the CHO DHFR or GS Gene Coding Regions

As diagrammed in FIG. 4, an alternative method for targeting a sequence of interest to an amplifiable locus involves the production of a cell line in which a portion of a selectable gene is replaced by an engineered target sequence. The advantage of this approach is that the subsequent insertion of a sequence of interest can be coupled with reconstitution of the selectable gene so that cell lines harboring the properly targeted sequence of interest can be selected using the appropriate media conditions. A cell line harboring such an engineered target sequence can be produced using nuclease-induced homologous recombination. In this case, a site-specific endonuclease which cuts a recognition sequence near or within the selectable gene sequence is preferred.

1. Engineered Meganucleases that Cut within the DHFR or GS Genes.

A meganuclease called “CHO-13/14” (SEQ ID NO: 12) was produced which cuts a recognition sequence in the CHO DHFR gene (SEQ ID NO: 13). The recognition sequence is in an intron between Exon 2 and Exon 3 of CHO DHFR. A meganuclease called “CGS-5/6” (SEQ ID NO: 14) was produced which cuts a recognition sequence in the CHO GS gene (SEQ ID NO: 15). Each meganuclease comprises an N-terminal nuclease-localization signal derived from SV40, a first meganuclease subunit, a linker sequence, and a second meganuclease subunit.

2. Site-Specific Cleavage of Plasmid DNA by Meganucleases CHO-13/14 and CGS-5/6

CHO-13/14 and CGS-5/6 were evaluated using a direct-repeat recombination assay as described in Example 1 (FIG. 7A). Both meganucleases were found to efficiently cleave their intended recognition sequences within the context of a plasmid-based reporter assay (FIG. 7B).

3. Site-Specific Cleavage of the CHO GS Gene by CGS-5/6

CHO cells were transfected with mRNA encoding CGS-5/6. mRNA was prepared by first producing a PCR template for an in vitro transcription reaction (SEQ ID NO: 22). Each PCR product included a T7 promoter and 609 bp of vector sequence downstream of the meganuclease gene. The PCR product was gel purified to ensure a single template. Capped (m7G) RNA was generated using the RiboMAX T7 kit (Promega Corp., Fitchburg, Wis.) according to the manufacturer's instructions and. Ribo m7G cap analog (Promega Corp., Fitchburg, Wis.) was included in the reaction and 0.5 μg of the purified meganuclease PCR product served as the DNA template. Capped RNA was purified using the SV Total RNA Isolation System (Promega Corp., Fitchburg, Wis.) according to the manufacturer's instructions.

1.5×10⁶ CHO-K1 cells were nucleofected with 3×10¹² copies of CGS-5/6 using an Amaxa Nucleofector II device (Lonza Group Ltd., Basel, Switzerland) and the U-23 program according to the manufacturer's instructions. 48 hours post-transfection, genomic DNA was isolated from the cells using a FlexiGene kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The genomic DNA was then subjected to PCR to amplify the CGS-5/6 target site using the primers of SEQ ID NO: 23 and SEQ ID NO: 24. The PCR products were cloned into a pUC-19 plasmid and 94 plasmids harboring PCR products were digested with the BssSI restriction enzyme, which recognized and cuts the sequence 5′-CTCGTG-3′ found within the CGS-5/6 recognition sequence. 17 plasmids were found to be resistant to BssSI, suggesting that the CGS-5/6 recognition site was mutated. These 17 plasmids were sequenced to confirm the existence of indels or point mutations within the CGS-5/6 recognition sequence (FIG. 7C). These results indicate that CGS-5/6 is able to cut its intended target site within the CHO GS gene. Because the CGS-5/6 recognition sequence is within an exon in the GS coding sequence, many of the mutations introduced by CGS-5/6 are expected to frameshift the GS gene. Therefore, CGS-5/6 is useful for knocking-out CHO GS to produce GS (−/−) cell lines. Such cell lines are useful because they are amenable to GS selection and amplification for producing biomanufacturing cell lines.

EXAMPLE 3

Meganucleases for Targeting Gene Insertion to the CHO GS Locus

1. Engineered Meganucleases that Cut Downstream of the CHO GS Gene.

An engineered meganuclease called “CHOX-45/46” (SEQ ID NO: 29) was produced which recognizes a DNA sequence (SEQ ID NO: 30) approximately 7700 base pairs downstream of the CHO GS coding sequence. CHO cells were transfected with mRNA encoding CHOX-45/46 as described in Example 2. 72 hours post transfection, genomic DNA was extracted from the transfected cell pool and the region downstream of the CHO GS gene was PCR amplified using a pair of primers (SEQ ID NO: 31 and SEQ ID NO: 32) flanking the CHOX-45/46 recognition sequence. PCR products were then cloned and 24 cloned products were sequenced. It was found that 14 of the 24 clones PCR products (58.3%) had large mutations in the sequence consistent with meganuclease-induced genome cleavage followed by mutagenic repair by non-homologous end-joining. From these data, we conclude that the CHOX-45/46 meganuclease is able to specifically cleave a DNA site downstream of the CHO GS gene coding sequence and will likely be able to target the insertion of transgenes to this amplifiable locus in the genome.

SEQUENCE LISTING

SEQ ID NO: 1 (wild-typeI-CreI, Genbank Accession # P05725)

1	MNTKYNKEFL LYLAGFVDGD GSIIAQIKPN QSYKFKHQLS LTFQVTQKTQ RRWFLDKLVD
61	EIGVGYVRDR GSVSDYILSE IKPLHNFLTQ LQPFLKLKQK QANLVLKIIE QLPSAKESPD
121	KFLEVCTWVD QIAALNDSKT RKTTSETVRA VLDSLSEKKK SSP

SEQ ID NO: 2 (Chromosomal region 5,000-55,000 base pairs downstream of CHO DHFR

gene coding sequence)

1	taaaactcaa gatgccagct ttgtagctag cttaggaaac aaagtagtaa aaaataataa
61	tgggtgggtg aaggtctgaa gcatttacag agttctctca agacaaagca cagaggctgg
121	tggccacata acttggcaac tgatttgggg gaacagaata caagaaagga aatttaaata
181	ctgtttttct caatgttgaa ctatatgggc atagtcacag ctgcctaacc tatagagact
241	ggaagctgga acctcggcta tctaagatag aataatcaag aaatgtcaat tatttgagaa
301	aaacatcagg aataaatagc tgctaagtta caagttggtg ctttagacat ttggagagga
361	taggatgggg gctcccagac ctggggctcc ctaataaagc tgtgctggcc tacaagttcc
421	agggatcctc cagtccatgc ctcccactgt tgggactgcg ggcgatggtt tctgacgtgg
481	gtactgaggg cctgaactgt ccacacactt aagccacacg ccttttactg agtcatctcc
541	tcatctcaga acattttcct ttaatctttc ttaatgaaaa ggtcgcattt cttccgaggg
601	ctagcctcct gttactctct atacatgtca cataaaacta catgaaaact ttgaaggcac
661	tatatgtcca tactcagatg aaaagccatt agctgtggtc atacaaaacc ccacagacca
721	actgttggga aacatcagac ttttttcctg cagcgcctgc cctgatcttc cacagagaat
781	tcagtctcac tttttccagg atgacttctg aactatcacc gtaagatgag aatttgaaac
841	aaagatgtaa gtaatgaact tcatgtgttc tgaacacaca gcttagtgca ttgaaattac
901	gtaacacccg cttccttata agccatttct caaaatgttc ccattacacc tgcatcgggg
961	atgggtccca gaatcttcct tttaaataaa caccccagag gattctgaag ctagaacacc
1021	aaggactgac agagagaagc atgcctgtgg gcgactccag acacctggga gctgcctgct
1081	ttcttgctac tgatttagaa ggcatttgcc cccgaatggg gctgggggac tgtcactatt
1141	tctcattctc gggactttga aaggaagcaa aacagaaaac catgcaaagt ataagccacc
1201	atggaataat ggcagacgat ccggttgtgc agattagatt ttacatattg ctgattttga
1261	agctaaagac ctttcacttc ttaaatatat aataaaattc atacaagagt attttgtgta
1321	ggtaactcag tcagatacaa ggtaagcaaa gtaaatgata ggtgcccctt aacaaaatgc
1381	attctcatag ttcatttatc aattatagaa atggtggact ggagggaagg cttgaggtca
1441	ggagaatgtg ctgctcttcc agacagcccg ggttcttttc cccagcaatc tgggactcac
1501	gtctgcctgt agctccaggc ccaggggatc tggcaccttc ttctggcctc tgcaggcacc
1561	catacacaca tggcatacac acacatacac aaattctaaa attaaatagt aggttgtagg
1621	cctacacaaa aacatgcata cattaactaa ataattaata gttaataaat aaaaatcaac
1681	caaacacata cactgattaa gtaacatgac tctgtaaggt caaaggcggc tgaccagctg
1741	tgggaagggt taaataataa caatcacctt tgaaagactg gacctggtga ttaaggatgt
1801	tccagctgtg tcgtggatga gaaatcaaat gcataattga atgagtgcca ggaatagaac
1861	tggagacttt ctggtgagaa tgcttttact ggcagtagag tccctgtcta aacaggagag
1921	agacctgcag tagccctgtg gcggccctgc agtggccctg tgatggctct gcagttgtac
1981	tcttcctgag ataggagaca cactagagag tgtttctaat gagcagctcc tgtactttct
2041	gttcccctgg agaccgcacg tgtttctccg ataatacatt gacatttctg ttaaaccatt
2101	ttcttcttgg aacaaaaatg gagaacaaat cagattggtg tgtggtcttt taaataactt
2161	ggtacttaat aacacaaaac aaaattatca gaggctggat tttaggtgct ctcagcatct
2221	gccacccctg agccatcagt caggtcttgg aggaacaatc tccaaggaga aaacagttct
2281	gtcctcagaa aagctggagg aatatgagat tttctacagc actcatagca aaatcattta
2341	cggaagggat cctgagtaag atggcctctt cttcatcaca tggtcatagt ctgcttcaat
2401	ggggagaata gttcaatcta gcatcgagaa atcgaaggtt cccttttgac tggcaatgcc
2461	ccatagatag atagatatag attatgtata tattgtgtaa aacacacgta tgtatatata
2521	atacacatac atgtatgtgt atacatacat acatacatac atacatacat acatacatac
2581	atacatagat acgtgtgtgt gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt
2641	ttgagactga gtttctctac tatgtagctc tggctgtcct gaaagttgct aagtagacca
2701	gactggccag accagatcca ccctcctctg cctcctaagt gctgagatta aaggcctgca
2761	cccaccccca cccagcccat cttatatttt gcttcatttc aaagtaagct ctatgcatca
2821	tttattcctg catattatta gccatggttc agtcttgttt gtgttttgga atatttactt
2881	aacaaaactt gaaaaacatt tttcaagatt tgtttgtttt taagatttat ttatttatta
2941	tgtataataa taaatattat tatgaaaaac ggtgttctgc ctgcagggca gaagagggca
3001	ccagattgaa ttacagatgg ttgtgagcca ccatgtggtt gctgggactt gaactcagga
3061	cctctggaag agcagccagt acttttaact gctgagccat ctccccaggc ccaaaataca
3121	catcttaagt gtattgccac aagcatacat cttcatggcc caatcttctg tccatcactt
3181	cagacagctc tccttctttc cctggccagt cacaacaccc tcagctatca ggaaaggccc
3241	tatgggggtt gttttgtttt cccactccag ttcccttgcc tgctctgacc tcatgagtag
3301	actcatacag gatgtgctca cttcacttgg gatgatttct ttttcaccca ttgttgctct
3361	gcccagaatt tgttcctttt tattgtctta gtgttaatca actatcaaag ccagcaacaa
3421	aaaatagtag ggaaactttt ttgatagggt aaacctgatt gattgcaggc tttggttgcc
3481	ttgtttggtc tatccccttg agagtccctt acaatgtgag ttagttagtg gctgctaact
3541	agttgaatct caacttcctt tttctttaat gtgggtattt gtaaggaata gcccccttaa
3601	atctagattc tgttctcaaa tcaagcaagc tcaaggctgt aagcatggat tcaccaactt
3661	tcctgctcaa ggaatttaaa tgtctggtct ccatcatatt actttaatag taatagttta
3721	ttatacacat gtgccagctg tatatccctt ttcttcttga tggacctatg aactctgttg
3781	aggtgagatt tgaacccctt agaaggtgct agagaagagg tacctgatgg tcaaggcaag
3841	gctgatactt attcatgggt cccacatctg ctaatgtaag caataacaga taatatgctt
3901	tgtgtttaga cccacagtgg ttgcatgtac actaagtatg tatcatcatt gtcttatcgt
3961	tcctttagaa tacagctaat aattatgacc gctattctca tagcatttat attatatgag
4021	cattgtaaat tattttgaaa tgctttaaga tatacttgag aactatgcat atcatgcgta
4081	tgttgttcta ccagctggga ccttgaaatg agatcccttg aggccagcat aaagagaaag
4141	ttttcatctc aaacaaacaa aagatacact tgataataga tgagggataa atgtcatact
4201	ttttatatag tgattgagaa tctacagatt tgggtatcct ggtcacttag gagaccaagg
4261	gaggactatt agctctagag ctatgaactt tatctccaga ttccaaagcc aatacaaact
4321	ctagccaagt tggggtgctg ttacctgtat ccctctgtca aattccaagt gttttcacca
4381	cctttactgt atctttccaa ctgttctctt ttataaccac acatagttca tggtctttcc
4441	ttctctcact tgactgtgga gtaacctaac ttgcgtgttt ccagttttcg atctcttcct
4501	taaatctaca ctagttaacc acaaagaccc tcttttctga gctgtgtcta ttctatcact
4561	gtcaccattc cttaatgctc tcccagatgc agccaaactt cactttgggc ttgagagtct
4621	tctccaggtg acagtgacta atgtctccag attgagcatc taccatctac cctgtgtatt
4681	acacatgaat agccttagct tttcagcaat agacagatag atccatagtt agccatgtca
4741	acacccttct tcatgctgtt ctcacagtaa taagtcctaa ttcctgtttt ctcccatcta
4801	aactcaaccc tgtcctaaat accttactca aatcctaatt gtatctcttc cacaaacatt
4861	tcccccttct ctccattaca aggtggaaac tcagagatcc aggtgtcttg catgttgttg
4921	attctgtcct caacaaggaa ttccccaggt tcctgcacga aggaaagcat ggaggaccat
4981	acttgaggct actggtgtag tgggaagaca ggcccaaacc atgtcacaga aacccatcac
5041	cagaaagttg ggggaggcag cccagttgtg gagcaggaga aggagaaaac aggcttgggg
5101	aactgctagc tatgctttgt cacagtcaca agaaaaaagg gccctagcct ggcctacata
5161	ttctacaact tcctgaatct ttgctctgaa atgaagaggt ttggatggct gtctgggaat
5221	tcatcttgct tgcagtgaag ctccttgggg tatttgaaac caggaagttt gaaggagttg
5281	atgctaattg ttttctaaag tgtgtgagga gtactggcag agttcaggcc ttgtgaggaa
5341	agaatcctat atctagtctg cactcctggg cacatgagac attcagctat ctcccttata
5401	aagcatagaa agtactcttg tacttgacac agaaataatt tcagtatgta gagcattaaa
5461	aaaaagtatg aatgacttag agagatggct catcagttaa aagcacatac tgctcttcca
5521	gaggtcctga gttcaattcc caacaaccac aaaaactcac acatatgcat gtgattaaaa
5581	ataaaatctc tctctctctc tctctctgtg tgtgtgtgtg tgtgtgtgtg tgtgtgtgag
5641	tgtgtgtgtg tgtgtgtgag tgtgtgagtg tgtgtgtgtg tgtgtgtgtg tgtgtgtgtg
5701	tgtgtgtgtg tgtgtgtgtg tgtgtgatgg tgggcttgtg tttgcaagcc cagcactagg
5761	gagttaaggc ctcactcaca gtgccaggcc agtctaggtt acagtgagtt ctagacagcc
5821	caagctacag agtaaggtac tgacaaagaa agaaagaaag aaaaaaagaa agaaagaaag
5881	aaagaaagaa agaaagaaag aaagaaagaa agaaagaaag aaagaaagga gagaggtgag
5941	agggagggaa ggaactggaa gggggaagga gggaaagaaa agaaaaagaa acaaccaaag
6001	gaacaaacca ctgtatgcca ttatacatta gctttgggct ttacaggtta tacactctat
6061	attgtcatag ccaatgtctc aatattccat aagaggtgtc tagttgtggg tatgttcttt
6121	cttagtcctt ttatttagac tacatgacct gtttttgcct aataggccat tagtaatact
6181	gacttctcca catgctgccc tcaaaactta ctcctggaag atctttattt aagctatgaa
6241	cgaaaatctt aaccctgtga cctgccaccc agaatgcctc tgggaacaac ctcaggcaac
6301	ctatcaagcc gcttttccaa catttggggc aacagggatt aaaattatga ttgttgtctg
6361	cctgctgagt tcaaactcac agagggacca gaagctgact cactgatatc aagcagttct
6421	aaattttcag tttaaaactc taattattaa acaggggatg tcctcagacc agcactcaag
6481	agaaggagat aggcagagct ctatgagttg agttataggc cagcctggtt ttcatagtga
6541	gttttagctc tccagagagt taccagcaag accctgtcac aaacaaataa aaacaaacaa
6601	acaattaggg gatatacata taactaaatg ataaagcctt acctagcaca ttcaagtccc
6661	caggttcaat tgctagccct gggtggggat ttggacaaat ttaaaaagac cttttttgta
6721	tcacacataa atatgactgc actggttgtt gttttccatg gaaacagaat caatgtggca
6781	tgtattttac ggcattagct catatagttg tgcaggctgg caagtgtgga atgtataggg
6841	caggccagga atcagaaatt gatacaaaat tcaggaaaga cctctgggtg caatggtgca
6901	cacctttaat tcaagcactt gaaaggcaga ggcaggtgat ctttgtgagt tccaggccac
6961	cctggtctac atagtgaatt ccgggacagc cagggcttca tagaaagaac ctgtctcaaa
7021	acacacaaac aatcagaggg aagggcttat tttgtttttg agacagggtc ttctatgtac
7081	cccaggctgg cctcaaactc atgctcttga tatgcccacc tcacaagtgc atgttaagat
7141	tacaggtgcc tgacacacac cacttttgtg aagtgctgaa gagtaagccc agggcttcat
7201	ggacgctggg caagcactgt gccagctgag ccacactccc cagtgtgcac gatactttgc
7261	aaagatagat ccatatggat gctgtgcttc tatctaaaca gaatgacaac cacactctgg
7321	caggttctgg ttcataactg agtcttattg gtcacctcct tctccatttt tcgctggtat
7381	ttctcaagga gagaccacaa atgagaagtg aagcctaact tttaatgcgg tctctcctat
7441	gtcacctaaa ttctagctca aacagggttt ctggctctta ccttttcctc gggtttctgg
7501	atacttgaag tgttaacggg catttctctt aaagaccaaa tctggccaga ttcaaatggc
7561	tggccttcaa ctcggcaaac taggaacaat aatgtccgct gcatgtggct tgtagcactc
7621	tgtttctatt catggacttg tgagtgattt ctgggaaaca cgaattataa gataagtcct
7681	tttcagtgga cttcacaagt tcaccctcag gtagtatact gtcaggtaga aacgtctttc
7741	agagaagcga gaggtgacaa gccctctggg ctggccattg tccctgctgg cattgaacac
7801	cctgttcagc acatgaaagc atcgcctgat gctcccaaag ctggagcact ggcagccccc
7861	tgcagtcagg tgtgtagggt gggttagcag gggtgcttag gcgggttttg tagttacctt
7921	ttcaacacaa atgcaaaagc cagagagaga gagagagaga gagagagaga gagagagaga
7981	gagagggaga gagagagaga gagagagaga gagagagaga gagagagaga gcaggaaagc
8041	atccaggctt tgaagcaagc cagccttcag ctctgtcctt gagccattct gagtggaatc
8101	gagtaattgt ctgcttggag aactgaagaa tagcacatgg caaagaacaa tttgtacctc
8161	gaatatattc attagcttgc atgtcaaaag gccacatgca gatagaaacc attatcttgg
8221	cattctttaa aaccttgcag ccttgagact tgaggtgcag aaacccacat gcccatgtga
8281	ctgactacct gtcgatctct ccagccctgc ctggctaaca gggacaatat agggggatgg
8341	tgggagggga cagcttagac tcctgtggac ttggattgaa agaagaacag ggaagacagg
8401	ggactgtgca aataagcact ctattaggac ctatttttgg tgtcttggga ccctcctact
8461	ggtttagctt aaattgagag gggatttggt ttgcctcact agctgtttct tcccactcaa
8521	ttcacaatta cagctttctt cattgtcatt aaaatacatt aaatgtgtac ttgttggggt
8581	aaggctttct gttgaaatct gcataaagac aatgtccaca gcccccagtc agtggaaaga
8641	gcagtaggac cagaaggcat gtgtttccat cccgagtcta tattggaatg tttgttaaaa
8701	cctgcacttg taagagacaa acactagaac catcagcttg caggtctaca ggccagtgtt
8761	gccagtgcag ataatgccca aactggaacc taaagatgaa ggcctttggg agctgaggtc
8821	gaagagtcag ctgtgatctc ccagatgtcc tcctcatgcc ccattgccac tctagcctcc
8881	cacctccaag cacatttggg atccaactgc taacccctgg tgttcttttc ttagttgaaa
8941	ttctcaggga ataacctaag agtctctgtc actcagtcta tggcatccta tgataacagc
9001	caaggctaaa tagccatcat tgttcttttt ccagatgctc agcaatgagg atgcagaggt
9061	gaacaaaggt ggttcagggc tgccctgatg atgaatttga caagccagaa tctaacaaga
9121	tcagtcggta aacagaatcc tccttcctat ccagagatgt tggcttgttc tgtcactgga
9181	tgggcatcat ttactataag tcatacaggc accagacact cagagataaa taacatgaac
9241	tttccagtct tatgcagtcc tgtctagttg acttgccagt attctcaagg aagttccacc
9301	ccagcccctg gcatccatag accaaggact ctggaatgtt ctgggaaagc tccacctgac
9361	ctcctagcac ccatatatcc aaagagtctg gaacgttatg gtggaagccc cacctctctc
9421	tccccagacc tcgccccctc aaaaagtcca ccaaagactc cccacccccc acacaccccc
9481	agatgctcaa gaccacttcc atagagtatt taaactgcct cccagaaaac agaattcatt
9541	ttttcagtct ctcttcccca tgtcctctca gggtgggggg caggggtatt agtattcaac
9601	cacctatact ggcctgtcct tggggttctg acaagatatg acctcagcta cagccactaa
9661	gatcaccacc tgtgtatatc cactatgctc ccttttaaaa gggccctgtc cacctcccat
9721	tctctctgtc tctctctctg tctctgtctc tgtgtgtgtg tgtctctgtc totctototc
9781	tttctctctc tctctgtctc tctctctctc tccttctctg cctgactctc cctccctccc
9841	ctgctctctt ctttcctgct gcttttgtcc ctagaggcta gtctcctctc tccccttccc
9901	ccttttccca ttcactttcc cccaataaaa aactctccac ccaagctcta tcacatggca
9961	tcattctctt gctccatgat tttaaaatca caatgaggag gggagcatgg aaaaattatc
10021	caggaagact ttatccatta aacctgggtg ctttttcttt cttccttcct tcctttcttt
10081	cottotttot ttottcottt ottttttoct ttottcottt ottttttoct tttttcottt
10141	ctttttgttt tgttttgttt tgagacagcg tttctctgta gctttggaga ctgccctgaa
10201	actcaatctg tagagcaggc tggccttgag ctcacagaga tccacctgcc tctgcctccc
10261	atgtgcttga attaaaggtg tgcaccacca ctgcctggct taaaactggg ctttttctaa
10321	gtcagtttga tttggattgc tgcattggca gagaggttta ttggggtgca gaaacctttc
10381	aaccagcttt tgagctaatg atagagagaa gctcaaggaa ttggagcaat gcttgactag
10441	ggatgtcaga gggaggctat ccagaggagc ttacaactga ggtaaactta aaagttaggg
10501	agtttgtcaa cttcaaccca cagaatagag cagagccagg aggagctgag gcttctgagt
10561	gttatggtgg aagcatcacc ccaacccttg acatccatat gcctgaagag tctggaatgt
10621	tatggtggaa gttccaccca agcctccctt cccggtcgcc ctccaaaccc tgctacatct
10681	cagaaatccc accaaatgat gactccctcc cccagagata ttcaagacca ctcccacagg
10741	gtatttaaac tgccccccaa cccccagaaa atagatgtgt ggttttccaa tctctctttc
10801	ctatcacgtc tctggggagc tggcaggcca tttgggagca ttgtatccat taaacgactt
10861	ctcagtggag actctgaaag ccagaagagc ctagacagat agatgtcttg catactctag
10921	agactacaga tgccggccca gactattata tccagcaaaa gtttcaaaca ccatacaaag
10981	tcaaatttaa acagtatcta tctacaaatc caatattaca gaaggtgcta gtaggaaaac
11041	tccaaactaa gattaactat acctgtgaag acacaggaaa taatctcaca ctggcaaaag
11101	aagaaaaacc tctctctctc tctcctctct ctctctctct ctctctctct ctctctctct
11161	ctctctctct ctctctcaca cacacacaca cacacacaca cacacaccaa caccaatacc
11221	atgaacaaca aaataacagg aattaacaat aattgatgtg tgtgtatgtc cctgtgtgtg
11281	tgtccttgtg tgtgtctgtt tgtgtgtctg tgtatatgtt tgtcacctga ggggtggctc
11341	ttccttggtt tgtgaggttt ctacccaatc tataactccc ttttcttcat tcacttcctc
11401	atgtccttac tagtctctat tgtggattaa ggaaactgtg tggagaacag ttttcttcta
11461	gaaaagaaca ctagccatct catgtaatca aattggtgac tatcctaatt attatgagag
11521	agcttccgtc cagtaagtgc tagaagtaga tgcagagatc cacagacaag cactgagcca
11581	agctccagga gtcctgttga aaagagagag gaaggattgt aggagccaaa gagtcaagag
11641	catgacaggg aaacccacag agacagctga cctgggcttg tgggtgggag ctcatggact
11701	cttgaccaac aattagggaa cctgcatgag gccaacctag gaactctgca tgtgtgtgac
11761	agttgtatag catggtctgt ttgtgaggct tctagcagtg ggatcagggc ctgtccttgg
11821	cgcttgagct ggcttttggg aacctgttcc gcatgctgga ttaccacacc cagccttgat
11881	gctgggggaa gcacttggtc ctgcctcaac ttgatgcgcc ttgcattgtt ggattctcat
11941	gggaggactg cccctttctg aaaaagaaca aggagaagtg aataggggag gggattggga
12001	ggagaggaag gagaggaaac tgtgataggg atgtaaaata aattaaaaaa ttaattaatt
12061	aaaaaagaac acttgtactg gtagattggc taaaatgaaa caaagataaa agtacacagg
12121	aaaaagagag gagaaacctg gggagggggg ctccaaagag aggtgagggg gggatgggaa
12181	tggcagctta gtggaggaag gaagacatga cctacacgaa tcgagctgta gtttttatct
12241	ggagcatagg gtaaagatgt ttgaggagaa ggaggaacac atgcttgtaa aacatggtct
12301	tcagaaccag caacaatcat acagagtgtc cagggtccat gggcacatga aggacagacc
12361	aacacatatt taacagtaaa gtgtccatat ttggtatgaa agtgatgggt aaattgtcct
12421	gggactgtaa tttagttgta aaggacttgt ctggcatgtg ggtattcttg ggttccctcc
12481	ttagcactga aaaaaaaaaa aaacacacac acacacacac atatattcta gtgttttgta
12541	gaaaaggatt caaagaaagc catgatttct cttttgataa atccagaata atgtaataag
12601	aacacacagt ggtgtgattt cagcaatcaa gtacaggttg cttgtctgtt tgttgtatgg
12661	gatggttggg tggttgtttg cttggtttgt aagatgggtg ggtgggttgg tgggtggttg
12721	cttggttggg tagttggttg ggtgattggg tgggtgggta tttggttggg tgggtggtgg
12781	gttggttggt cgtttggttg ggtggggtgg gttttgtttt gagacaggga tttactctat
12841	atctcagttt gtctcaaact cactatgtgc acatgagtat gtgatgagat tatctaagac
12901	catagtgtct gtgttcatgg aatgtctctc tagcttagag aatttaaaaa atggccatgt
12961	agggaaaccc ctcagaaaag gagtttctat ggcctccaag aataagaatg gatcctccta
13021	gctcggagtc agcaaggaac tgaagccctt aattttatag acacaaagga atccattgtg
13081	tggctccttc ccagccaagt ctcagatgag tcacagacct gcatggcacc ttatgcagtc
13141	ttttgaggtc ccaagaatag gatgcagata agccatgcca gaatcccaac acacaaagcc
13201	ttagtgatat agtaaatatg tattgtgtct aggctgctgc atttctggtt atgctactgt
13261	gcagtaatac acaactaata cagatgtgat ggttaatatt atgtgacaac ttgagtgggg
13321	cacagaggta cagacacttg gtaaaccatt ctgggtgcac gtaaggatag ttttggatga
13381	cataaacatt tagattagta tgctgggtaa aatacattgt ccatcccaat gggcatgggc
13441	tttgtccaac tagatgacag ctggaataga aaagtctgcc tctctcatag ttctcaggcc
13501	tttgagctca gactagacag aactcacagg ttctctgagc tttccagctt gatgaatgtc
13561	catggcagtc ttcacactta acacctgaca gacttaatga tcatatgaac caattcaaat
13621	ctgaccatca ctcgggtcat tcttttgatt ctgtcacttt ggagaactaa taccgaggac
13681	ataaaatgcc atcacatcgt tattttcttc ctgtctgtga atatttttct tttttttctt
13741	ggtttttttt tttttttttt tttttttttt tttgtttttc tctgtgtagc tttggagcct
13801	atcctggcac ttgctctgga gaccaggctg accttgaact ctcagagatc cgcctgcctc
13861	tgcctcccga gtgctgggat taaaggcgtg taccaccaac gctcggcctg tctgtgaata
13921	tttaaaatga aaactttgga aatgttctga aaccagctgg tgtcagatag tcagagaact
13981	ttcgtaaggt aggtgtgggt tatagcataa tcccacacaa gaggctgaag caggaggatt
14041	ttgtgtttga gggcagctag agccacatgg tgagtccctg cctcaaaaca caaaagcaag
14101	acaaaaacaa gctccaaata agattcactg ggccctttct ttccttcctt ctcagtgagt
14161	ccacttgctt taaaatcagg tcttaaagac gcactagatg ctgaacttaa cagtaataat
14221	aaatatcttc tcttacagta cagattatgc tctataaaca ctgcactgat aaagttcagc
14281	cttaaccttt gttctgtaaa tgtttcctag tttttctact gccgtattat aagacaaatg
14341	tcagcatgaa ggcaggtttt tcagaaaaca cagcagctcc acagatggcc tctaatccat
14401	aatcattaaa gacaagactg caactttttc aactggaaat cattcaagat gtttttctga
14461	agtccctacc aggacacaag ccaccctggt tgctgtgtga catcagttag gtagactctg
14521	aactggcttc ccaagaaatt atacaaaagc aaggtgtcac ctagtattag cataacttct
14581	gataactact gtcttagctg gggtttctat tgctgtgaag agacaccatg accacagaaa
14641	ctcttataaa ggaaagcaat tattgggtcc agcttacagt tcagaggttt aatccattgt
14701	catgattgca ggaagtatgg tggcccacag gcagacatgg tgctggagaa gtagatgaga
14761	gttctatatc agattgacac acttcttcca acaaggccac acctccactc actctgagcc
14821	tatggggcca ttttcattca aaccaccaaa gctacaaggt agcttatacc ccagcttgct
14881	atttctgatg agacttagta aatagtctta aaagcccata aaatgactca aaactagttt
14941	ttttattatt attattagtt caaattagga agaagcttgc tttacatgtc aatcccttct
15001	ccctctccct catcaaaact agttttttgt tttttaggtt ttttttcaag acagggtttc
15061	tctgtgtagc tttggagcct atcctggcac tcgctctgga gaccaggctg gcctcgaact
15121	cacagagatc tgcctgcctt tgcctcccga gtgctgggat taaaggcatg caccaccaac
15181	acctggccaa aattagtttt aagtccagtt ctaggagctc caatgccctc ttttggcttc
15241	catgggaacc aggaacacta tatatatata tatatatata tatatatata tatatatata
15301	tatatattca ggcaaatatt tatgcatata aaaataaaat aaatcttttt tccttttttt
15361	tttaaagaag tgacattgtc ttggaatttt tgtggctgct ctgcccttat gtgtaactgg
15421	acactaccag catctaaaca ctggcctgaa accagccaaa gaaaaccttt gtgccaggtc
15481	ctgtgtcaaa gtattatgtt ccttttagga tatcctatat cctaaaggat ttattttact
15541	gatagcatct taacttcctt tgaaaggttg gtcttctcaa gcagtcctcg tggagctggc
15601	tcctcagcta atgccagggg acaataatga tcccctccca aaaccaaaca gaaaaccatg
15661	gcaactctgg tttccttggg cagcacctgc tttaagaatg agcaaatgac caatcagctc
15721	atgaaactaa atactctatt attactaaaa tatttttttg agacagggca tggaattcat
15781	cacatagttc aggttggcct tgaactcaga gagactcact tacctttgcc tcccacgtgc
15841	tggaattaaa ggcatgaacc accacaccaa acataacact tgaattttgg aagagtcctt
15901	cttccaatag atttgaggtt ttgaaaatgt ggcacagaaa atatgaattc aaatataatg
15961	aaaacaagag ataactttca actaagtttc tataggttct tgctaggaat cctaagcttg
16021	tctgaaactc tagagcttct gtttctagct tctgagtgtt agtattgtag gtatgtgccc
16081	tgcctcagtg tgatgttttt gataatctta aagaaatcaa agaaatttta taaaagacta
16141	gactgtgcta cacaaaaaga atattcagat gccaagaaag agttcttaga aattaagaaa
16201	tatgctacta gtataaatcc tttataaagt ggaatgacaa atctgatgaa atcttactaa
16261	aagtagaaaa acataaacat caaagacatg aataataaga aaatcatatt gtgcatatga
16321	ttaacctaaa acattaactt gcaaaaatag aatagtccca aaaagtaaac aaaataaata
16381	aatcaccaag aacatgatac aaggacaatt cctaggatga taaaacaaga atattcatta
16441	taaaaggccc tatcactaaa gcacaacaga aacagactca aaagataaat cttcattgtc
16501	actggagaga agtccatact atcatagcac tcagaaggaa ataaaaatca aaatgtcaaa
16561	aaggacctca gcctctgaaa cacaaataca aaatatgtcc cgccttcttg acacgcatta
16621	ctcttcaatt aacattttaa gaaaactata aactgttaaa gagagcttag tattttaaga
16681	aatctgtagc tatttctttt ataagcatga caactaagtt tccctgattt aaacagacct
16741	aaaaaaccgg tgaagtgagt ggagaaaggg gatacgaaga cagcatccca catgactgct
16801	cccagtaaag gcaaggtctt catccatttt atcctgaact ctgggaaatt tataaagaac
16861	agaaatgtat ttctctcagt tctggagcct cagtccagga cactaagtct aggtactaca
16921	ctctcacatg gtggaaagta gaaagcaagc tcacttgtca ctcactacct gatgcctctt
16981	tcatcaatcc cattgataag gaagagacct ggcatctcag tttcctaagg actcagctct
17041	tactaacatt agctgtcatt tctgggtcac tgtaacagaa agcctgacag aagcaaccca
17101	ggggaagaag gatgtatttt ggctcactgt ctctgaggat ttcaacttat cccagcaata
17161	aagggataaa ggcattgcag caggaatatg tgtggcagaa gctgtttatg tcacaataaa
17221	caaataaaca cacgctagcg cgcgcgcaca cacacacaca cacacacaca cacacacaca
17281	cacagagaga gagagagaga gagagagaga gagagagaga gagagggggg ggggcagaca
17341	gacagacaga gagggagaga ggcagagagg gagagagaga gagagagaga gagagagaga
17401	gagagagaga gagagagaga gagagaaatc aaaggcccac ctccatcaga ctggtcccat
17461	atcccaaatt tctagaacct cctaaaacaa caccatcaac tgagggagac atttttggat
17521	tgaaagcata atgccattac ccaggcagaa tctgcctgtc tgggggagtc acatttaagc
17581	catggtatca attgacctca tgtaatttca gaatactaca taaaactatc agatattttt
17641	catgatgaat ttctaaagct tgaaattccc tttgaataaa ggaccaacta cagaattttg
17701	ctgagtctac aattacatac atgaaaatgt aactacgaag tggccagcca caatgaaaat
17761	taaagtgttt gggtggtctg tctctattga tgctcttctt tgccctgttt ttttttaata
17821	ttgttgatgg tttgtttttc ttttaagata cttggcccca agaaaaaaaa tgacagcctt
17881	aattaatttt gtttactctc ctgacatttt aaaagacaaa tttatgaaga cctgactgtt
17941	ccatgtagta ttagaaagat gtaaaattaa gggttgctta agctgtgtag aattgaagag
18001	cacagcattt gagtgacagg gtacaattag agatcatcag ggatgtggca caaagtgtac
18061	tcaacctcac cttttcctgc ttagcagaga acagggtgcc tcggtgagat aggaaattaa
18121	tcaaatagaa gaagaaatag taattttaga aggatcaaat tttcctggtt agaatgatca
18181	aaactacaag acttgtaact aaaatatagt caaacccatt tcaactggaa tctgtgctat
18241	tcatgtatag attaactaga atctaatttt taaattttca tcttacttcc aaaaatattt
18301	gtccaaatac tctgtgaatg cattagtttc ttatgggaaa acatcatatc ttttgtacaa
18361	tgtgtttctt agcttgaggt tctctccaaa caggaccaag acgaggccag gaccatgtga
18421	tacaacccat agtcctcaag aaatagttgt cattttctta ttccaattgc atcccaaggt
18481	ctcatctcat tttgcgtgtg cctttgacac cccataccca cataaactaa ggtggtgtta
18541	ttttttgagg ccctgaaggt atcttcagga atccataagt gagccttaag ctgcatctgg
18601	atataggaat ctgaaagtgt cccttctctg catgatctct tctttcagtt tttcaagtca
18661	gtgtgccaca ggaatcagga acgataaatg gagaggggaa gtgcagttgc ttggtataga
18721	caccccagag ggctatttgc atcctgtcct tcaaaatctc tctgagcctt cctgcctaag
18781	ctgttttgag ttgggtttgt ggtaccagaa cccctgcccc cgccccattc tgactaatga
18841	gagagagaga gagagagaga gagagagaga gagagagaga gcagcagagc atagaatgaa
18901	agtaggttag aagggcaggt aaaagcactt tagacaagag caggtataag ggccttggac
18961	tccctcccca gaacacacac atgaaggtaa acgatggtta aaggatacag ataggatgtc
19021	gaagctggac gatcacttgc ttttgtgtgc ttgaagtgac aggctgtggc tttcgggttc
19081	atggggtctg ttgttgagtt cacagtctca ccatgttagc aagcatgtca ctattaagct
19141	ctatccccgc cccccttttt tgagacatgg tcttgctaac atacccagac cggcctagga
19201	agcactttgc agtctcagct cccctgagtg ctatgatcac tcgtgtgagc tacagtaccc
19261	aaaccagaat atgtgtgttg ggtgttatga gagtttacac attgctgcct tgaatgctgc
19321	tctgcttgag ttcctgtagg aagctgagct gggaacctaa gcttcctcct cccagatagc
19381	agtaaccctg cagagacctc ccaccaagac tagctaaccc ctccttcttg tgctgtactt
19441	agcaagaacc ccaaggttct gggtccttgt gctacagttc cagaagagta tgaacaatct
19501	tagcttttct gtatatgtgt ctgtgtctgt cctgtcagat caagtcccag cctcactgta
19561	tgcaacatga aaggctgtga aaactgtgca ttttgagaat gaacatcatt agtctccagt
19621	aagttcaaaa acaaatgaag gcagccactc ataagggtct ttaatgaggc aagggggcaa
19681	aagggtggtt tctgtttgtt caaagaagcc tgtcatacat tttcagaaaa tttagaaaca
19741	cgtatcatgt catttcacgt tagtatgaag tccttataat tcatttcata ttaaatgatt
19801	tcctttggtt agaagcaaaa ttatgcataa aatgtgttcc tttgtgtttg gagcaaaatt
19861	acaagttaca ttattagtta atattctagt tcttattttt cccaatctcc aagaagcaaa
19921	atattcccct aaaccctaaa gcatcaaatt atcctatcac acagtgacca gtcatcgtaa
19981	cctaaatatt aaagcatcag attatcctgt ctatggtgac cagtcattgt aacctaaata
20041	ttattgtaat gtggattaga gttaactata ccttttcatc acactataat gtaaacactc
20101	tccaaatctt tcaaagtctt gaaaacacaa tttataaata ctgtgttctg tttgttttga
20161	gacctgatcc ggttaggaat ttcaggctgt cctcaaactc atcatcttcc tgcctcactc
20221	aggtcctaag tgctgagatt aaaggtctat gctaccacag ccatacgaat gccatgtctc
20281	catcagctta tcacttctta acttttttct tttcttcttc tacatactgc tgagtaggag
20341	catcgatgac ctcagcctag taggaatggt tcccatgtga acccttaatc tgtaggaaga
20401	tgctggactt cttccattaa gactgatctc catttgaact tgacttgtct ctctcttgtg
20461	tggagctacc atcccatata taatcttctg gtttataaac agattgcttt accctcaaga
20521	tcctttgcta gcgcagcaat gtaagtttta atacaaacag taaggtctct gattggagtg
20581	tcatggtttg gttaagtgcc ctttccaagg gcccatatag ttaagggctc aaccaccaag
20641	tgatgcttgt ggataggagg cagggcctag tggacagtct ttaggtcatg gagctatgct
20701	gttgaggggg actgtggggt cctggtcttt ttcccactcc tttttaggtc ctagctatga
20761	ggtgagtggt tttgtcctat caagcacctc tgtcctgcca tggtgtaatt gattataact
20821	acaacctctg aaactaagcc agtataacct atttatctca agatgtaact tacaggtaat
20881	ggtaagataa agctaacaaa agacaaattg ttataatcca ggcaagcctg gccccatccc
20941	ttgggggcat ggcacagagt gtgtcaccca tctgtgcatg gcaagcagta ccctgactct
21001	gtatgctgat tcaaaggtcc cttaaagcaa actcctccca cttcctctct ttttctgcca
21061	tttctctgag gagggaggcc actgtctctc tgtctctctc tgtgtctctt tttctatctt
21121	cctctccctc tcttcccttt ccccaataaa ctttccacat taagttttgt ctgaaggtat
21181	ctgtttgtct ctcacccgcc ttttaggccc cacctaccat gggatctgcc aaaggtctca
21241	cctcgagctg tattcataac acaaatgaca gacaaagatc aaccctgaag actagtagga
21301	tgtagaaggc ctggagctga cctgaagaac actgctgact tcaacattgc ccatccgtca
21361	gttatgtagc attaaagtta tagtggttcc tcagaaagca gtctcctttg aaaacttctc
21421	gttttgtgtc taaatggaat taaatacctt gttcccgaat aattgtttta gttctcttga
21481	aagatcccgt atacttacta ttaagatgta tataaacctc aagctgaaag aatgacttcc
21541	cctatggcca gatcacaaga ctctccactg atgtgcccgt tgcaacctga ttagaggaag
21601	agggtcaaag ttccccaaga ttcagctgag ttcatgcaag ttttagaaaa aaaacaagat
21661	gttcctccac agttagaaag gagtggggct ggagggatga ctcactgaga aaggttattg
21721	tcgtacaagc atgaagacct gagctcgaag cctggcaccc atgtaaaaag aaaccatgca
21781	tggtagtgtg catcttcaat cccagcattg gggagacaga gaaagagaaa gggacatccc
21841	tagagcttcc tggtcagcca gccttggcaa gccagtgaac tccaggttca gtgagagacc
21901	tgtctgggga ggaaaaaggg agggagggag ggagagagag agagacacac acacacacac
21961	acacacacag agagagagag agagagagag agagagagag agagagagag agagattgag
22021	gaagatacct gatatcaacc tcacacactc atgtacccat gtatgtaggt accttcacac
22081	acacacacac acacacacac acacacacac acacacacac acacacacac acacacacac
22141	acggatggtg ttgaattcta aggctcttat ccacacatat atggagacaa atagaagaat
22201	tacagtcgtc cctgcctttg acgctactct gtttctccaa ccctgcttcc cagatatttt
22261	tcaacatcta ctcagccttg agtggttgca ctctgacccc aggacctctt tctgtgactt
22321	ccttggcctc ctgttttgtt tttctgatgc taaaaactga atctggggcc tcatgcacac
22381	aggaagatgc tataccaatg agctacaatt ttgttgccct ttttaatttt tgagatggtc
22441	tcactaaatt gttcaggatg gcccacttgt aattctcctg ccttagcttc ccaagtagct
22501	gggcttttat acagatctgt gcttccacac ctggctgagc agacactcat gatttcattt
22561	ctgctaatca ggtagttttc ttgcccctcg ctgccatttc ctacctgcct ttccttgcca
22621	actaaactgg ttcccacaag cgacaggcta tcatttctca gctcttccac aggttagctg
22681	tgcaatttgg tatgaatcat ttagcaagcc cagttctcct ctttgtaaaa cagatgattt
22741	agatgaaatt ttttcaaagt tctctttgaa ttaaaactat cactgccttg cttgctctct
22801	gactcttgga gaccatggcc tatccctgat tagtccttgg tccacagaag gatgggtggc
22861	attggatgtg ctgaacaatc aggtactttc atgtcacttg gagtcttaca gtaactgcat
22921	gtttcaaatg aatcctttct ggctctatta gtttcttttt tgtcactgtg aaaaaaacac
22981	ctgaaagaaa caaggcacgg tttgttctga ctctcggttc agaggatata gttcaccatg
23041	gaggcaggag cttctcacag ctgtaacagc catggagtca ggtggctagt tacagtcagc
23101	tggccttagc agtcagagag ccaagagagc tcagttgagg agagtccagc caggctgtag
23161	cccttaggac ctgctcccca gagatccact ttctacagta tcttctaaac agtgtcacta
23221	gatggtgacc aggtagtcaa gcacatgagc ctgagggata atatcattca aaccatagga
23281	ttagtctaga actgaaccag atcaagaacc aggttttctt ctcacataat agataccaca
23341	catcatgttc tcatatagag tgtgatctag gtattgtttc tccaaatgga gaagccaaca
23401	ctggatgact tacatagaaa gaaagagagg gaggaaacaa gcaagggagg gggaagagtg
23461	agaattattg gaacagtacc agtgcctcaa aatccttggt ggactagaga attagcctca
23521	ggaagaagcg actaggcttc ttacagcata gacatacagt tcttaccaga ggcacagcca
23581	tcatgggtgc catggggagc atgaagttca gctccatcca gccattccta gcgatttctg
23641	gcaacctctg tcctttgaga cacttcctga agatataaga gtccagggag agacatctga
23701	ttgctttgat cccaggatct tgggatggaa ttggtgttgt ctctgctcca gctccagggt
23761	caggaaggtg aaactggaaa cacaagctag cttttcttac ttagcaaaaa cccacaggtg
23821	acataaaaga cagattgaca cgagaacagc atggcagatt tatttagtca aagttttacc
23881	agacacaagc accttcagaa aggtaaagtc agagacctta ggggaatttt cttgccagaa
23941	tttttccaga agaatcaaca gccgtgtaac aataggacta gataaacaag taagactgga
24001	cctgcagcac aaatgtgaca ataggagttg gaatccccag gactcacata aagccatggg
24061	agccgaatgt aatggtcact tgtagtttca gcctcagatg ggggtgggga ttctccagaa
24121	taagcaggct agcaagacta gccatgttgc caagctctgg gttatattga gacactctgc
24181	ctcaatgagt aagtggaaga atgatggagg ccaacttcaa ccttggactt ccacatgaac
24241	acacatacac aatgcaacca tgcatccaca gtgtatgtac acacacacac acacacacac
24301	acacacacac acacacacac acgcaaatgg acaaagaaag aggtaaaacc tacaaggaat
24361	caactgaaca gaagccaact ggtctgcctg ttcagatcct ttttggcctc tctgtgtgct
24421	tccctttctc ctgggcatgg ggcaggcagg atctgtatgg ggtgagggtc ttcagagaag
24481	cgaacagcct tcctaggttt tatggctcag tttggtggag aggggatcta gtttctctta
24541	atcatctttt taaaaattta ttaatttatt ttttatattc caatcccagt tttccctccc
24601	tcctctcttc ccctccccca cctcccatct gttccttaga gagggtaaga cctcctctag
24661	gaagtctact aagtctgccc catcatctca ttgaggcagg accaaggcac ctctccaccc
24721	ctacactctg gtgtctaggc agaacaaggt atctctccat atagaatggg ctccactaag
24781	tcagtttgtg cattagtgtt agatcttgga cccacttcca gtggcctcat atattgtccc
24841	agtcacatcg ttgtcaccta tattaaggga gtctagttcg gtcttatgca ggttccccat
24901	ttgtcagact ggagtcagtg atctctcact agctctggtc agctgattct gtggtttccc
24961	catcatgatc ttgactcctt tgttcatatt gtcactcttg cctcacttca attgtactcc
25021	aggagcttgc ccattggtta gttgtggatt tctgcatctg cttccatcta tttctggaag
25081	agggttctat cttctctggg gttgtgaatt gtagactggg tatcttttgc tttatgtctg
25141	gtatatgctt atgagtgagt acatacaaca tttgtccttc tgggtctggg ttaccccact
25201	caggatgttt tttttctagt tctgtccatt tgcctgcaaa ttttagaatg tcattgtttc
25261	ttactgctga gtagtactgc attgtgtaaa tgtaccacat tttctttatc cattcttcag
25321	ttgaggggca tctaggttgt ttccaagttc tggttattac aaataatgtt cctatgaata
25381	tagttgagca aatgtccttg tggtatgaat gtgcctcctt tgggtatatg cacaaaagtg
25441	atatttcagg gtcttgaggt aggttgattc ctaattttct gagaaatcga catactaatt
25501	tccatggagg ctgtacaagt ttgcactccc accagcaatg gaggagtgtt ctctttactc
25561	cacatcctct ccaccataag ctgtcatcag tgtttttgat cttagccttt ctgatcagct
25621	taaaatggta tctcagggtt gttttgttaa tcatcttgag aaaaaggaat tctattttct
25681	gtgactggct ctgagagaga gagaagaggg aaaggtggga ggaatgtgtg ctttcaagac
25741	cttgtgttct cccttagctc aaagtactca ccatgaaaaa ccaccagcct ttggaggagc
25801	atgctcttgc agaggcaaga tcctggcttc ctcccatctt gaatttgcca aaatagcaaa
25861	gatgtttggg tgctggacag ccaaaaatga cagctgctca cttcacagct tcctcacgta
25921	tgattacaac tccactcatc atcaagcttt aattacatca tgagcaggct tatggctgag
25981	ccgttatcct cgcatccctt cgtctcatca ctgattcaca caaatcacta ggtgctccgg
26041	ttaatgaaaa catattcatc agtacagtga ctaattcatc aggccaacat ttacatggct
26101	cctctgcatg acaaaaatga atgtttagaa tgaataatga gtcaccagag gtgggggaca
26161	tcttctgagc acaggttgcc cttgtctttc ctggtactca atcccggctg aagagctgaa
26221	caaagctgag gttatttttc ccatgacagt gcattgtggt ttagagatct gtaagcggct
26281	tatcttgatt ggcagtttga ttggttctgg gatgtactaa gagacgtgcc tcatgggcat
26341	ttccagaaag aattaactga gggggaagct cctcgccccg agaatgggta ggagcatctg
26401	gtggggtaca gatgtaaagt ggtccaaggg agaagccgca tggcctgcct gccttcactc
26461	cttgctgctg agtgtgttta tcccatctat cccgttgttg cttctgttgc agttgcaatc
26521	ctgcttctcc aggccccagc gtagactgaa cagtggctgc ccagaaattc ccaattgaag
26581	cagccgaatg gtggactgag cacctctcag tcttcagtct ctctagtttg taggcaacca
26641	ttgttggacc caactcttag tagtaagcca atctactaaa tacagaaagg ccagtgagat
26701	ggctcagtat aggtgcttac caccaagctt ggtgacccga gttcaatccc caagactcat
26761	aaggaaagaa ctaactaccg agagttgttc tctgagctcc acacatgctg aaacatgggc
26821	ctccacatgt catgaacatg ttcacacaat acatatttat ctctatatat tcatttctta
26881	taatttttag aaaatttcat tttatgtata tgagtgtttt atctgtttgt atgtctgtgt
26941	accacatgca tgcctggtgc ctgaagaagt cataagaacg tatcagattc cctctaactg
27001	gagctaaaag aagattgaga ggtacctacc atctgagtgc taggaaccaa acctgtgtct
27061	tctggaagat cagtaagcat gcttaaccac tgagccatca tgccacttat ttgtaacaca
27121	tatccatcct attggttaca gtcctgactc atacagttag atagctgagg aacctagaat
27181	tcttctgctt ttttattaca aaacaaagaa ttttatctga cttacagttc tggccttagt
27241	cagggagctg cattgggaga tggcttctct actgtcagag tccagaggtg gccgtaaagt
27301	atcatatgac atgaggcaga aagtctaact tacttgagag ttaacttgga aatgtccaaa
27361	gagacagggg gctaagtccc tcttattgaa gagaccttcc atagaagtta gcctgacaga
27421	tggccttgcc tgaactgcat tgacagtctt acttggaagg cctgttttgg ttcctaagaa
27481	attcaaggat ccaccagaga agtgtgcagc cagcaagctg gactccctat cccaagcccc
27541	agctcctcct cagggacctc agcagtcctg tgtctagctt acctcagcga tggggggaaa
27601	gatgctgttt tcctgctaag agcacactat tttatattat tgttgacaca ggttggactg
27661	catgtaacag actctccaac aacacagtga agatacaagt gtgttttgct gcatttaaat
27721	gtctccccat ctgtccctgc taagacacct actgtccttc acatgtcact gaaaactcca
27781	ccccttatga gaagtcttcc ctgatgccat ctagacaagc taagagtgct ctgctctgca
27841	ctgagcagct tctcaactct ggggttatca ttgctctgca tcacaattag cacacgtggt
27901	agtggctgtg tttgtgtttt tccacaccat gagtccagac agcatccctc tcaccagcac
27961	gccataggca caagtgctca agagtagcag gacttgaaca tgtgtggttt atcatacaga
28021	cagctgctgc tcagagacca gatcaaattc aaagcaaaat agagagatga tggttcctgc
28081	catgagcgta ctgaacaagg acaaacatca ccatcataag gaactcagct gacagggagc
28141	ggtcaccaaa cttttttttc tgtaaagtga caaaaatagt taagtatttt gccctagaca
28201	tagtgggtgg tacacatgta atctcagcat ttgtcagagt gaggcagaga gttgaatgct
28261	gggctacgta gatagtctca aaaaataaat aaataagtaa ataaataaat aaataaataa
28321	aaggaagaaa taaaaaaaag aatttgttac tcaactctgc acaatggtgc aaaagaaaca
28381	ataagcatta tgtaacctag tgggtattgg ctgtttcact ttactaacag gcattgaaat
28441	ttcaattttg caaaattttc atgttccata ttacccttat ttttattctc ccctataaat
28501	ggtgactcac caatacgcaa ctggataaga ttagggtatt tttattaggg aatatgcctt
28561	acttacagag cacctaacca gccagcagga aacatagtaa agtagcgcat gccgatgaaa
28621	caaggaaaaa gaagaactac catgtgtgac ccctaaccct taaaacctct cccacatcac
28681	cctgaccatg cccattaggc gtggtcacct agccagcccc taggaggcat ggttacggtg
28741	tccccctaca ctcccctaat catttaaaga tgcaaatgca tgcttggtga tgggctaacc
28801	ttggctcatg ggctaatctt ggctcatggg ctaaccttag ctcatgggct aataatcaag
28861	gtttactaat ctctgtcaga cagccatttt ttttttgcag agaagaatcc ccatctttgg
28921	atcatttatt tattcctttt gtatatttga tgcaatttat aaccacaaga acctactatg
28981	tgactgcact gtgccagatg gcagagaaag ctaagccccg attcttgtgg catggactca
29041	cacaactcca gtacaggact gttagtgaca atctccttaa ggcataagca tactgcagtg
29101	gcagcctctg ggttaggaga caaggataca gtttatgaca cctggtatct ggaaggcatg
29161	aaacatgtca aatgctggct acacctaaga atcagcaaca tctagtctgg ccatagccta
29221	ggatgaatgt cacagggtct taggccagaa atgtatggcc gagctgtagc agggtcctct
29281	ctagggccag aattaattcc agtgtgatgg acagccaaga ccacagggat aacaaatgag
29341	cagtgccaat gacacgtgct tctccttatt attgctgcac agtgtttgtt acacatagca
29401	ttttcgcaca gtaatataat gtgcttgggt catcttgctt catatcccat cactccctcc
29461	atctccctag tgcctcccct gttacctttg cttctcagtt ttgtttctgc tttgatgtca
29521	acagcacata caagatttta tgcaatacat cacttcctga atggctctat ttggaaatca
29581	ctaaaaggta atttatggaa catttggggt ctttttgatt ttctaattta ccaaaaaatc
29641	cacctgggga aagacaatgg agttcaagga cttctaagag gggaatgtac catggtatgc
29701	tccagccagg ggaaccagtg cttcccagga gctatggctt acaaagtggg ttatcacatg
29761	aaagcaagac taaaataatc atctcaaata ttcattagat gtgggactcc taaccatctc
29821	acaatgcctc cctcggtcta cattaaataa gaaacctcca ttttgtgctt tgcgagaaaa
29881	tgactgaaga ttatacattt ggccttgaag tggaagtatt tttgaaaatc atgaatagga
29941	aaataataaa tctctcattt caacataaaa tataagggac aaggacatct actcatgctc
30001	caaggacgga cactgaattt tccatcaggt agttgcagaa cgctgtgtcg ctcaatcaaa
30061	aattcaggat gcattgctca gagtgcatta tattaaaaga tagcatcttg gaacacagga
30121	tgctcaggaa atgggaggga cattaatctg catgcagtga tcatctcctg caaagcgggc
30181	atgagagcct gatgggagac aagccatcca gatgcccata cccaggggag ctgtactggg
30241	ctgcagccct gcgccattca gccatgcacc aggctactcc ctcctcttcc agctttctcc
30301	ttctgatggc cataggatta gaagataagg gactctagtg caggtcaact gctgaccagt
30361	gtgaaaatgc acagactaca tgctggtaga tcagcacttc aaactactgt tcaccatcat
30421	ctctggaata agcactacat ttacagggtt caaacctcaa tgaatataaa caaacaaaac
30481	acacctccct tccttcactg tctcccattt ctttggttcc catctccaca tagaatttat
30541	aattaaaatt tctaagtatc tttccagaaa tacttcacac atgttataag caaatgtgct
30601	tttaaagata ctattttaaa ttatgaaaat ggttatatta gttgagataa aagaatagaa
30661	tgggaagttc cagaatttaa ggcctcatat gaaaatataa agcgctttct cttttaagtc
30721	tagggtaggt gtactagatc agcgctcagc tccataccat gaagccatcc aggagtcaga
30781	cctctctgac agccctgcca ttgtcacaga gaagtttctg tcaccagtgc tcatgctgtc
30841	agaggagcga aggagaaaag atgtgagacc tcccaagtca aagtcatcta tggataaaac
30901	cttagttgca tggcacacca gtgttaggga gtcggggaaa cacagccata gcccagcttc
30961	ctctctgttc ttgctcttat taccaccaga aagaggttgc ttagacaacc caaaccaaga
31021	cacagggctc tgtgggaggg aatcagtccc aggcttctgg cacatgctat gtcaccggaa
31081	agccccagcc ctactccgaa tccccacaag tacagcaaat atcagattat agcatttaaa
31141	ggggcactct tgccaaagag aagcaccatt ggaatagcca tgcttgagaa ctggtcctac
31201	ttactgcaga accatggata caggctccct tttgtagatg ggcttaataa atacttctat
31261	aagtgatact ctgctttgtg aaaatgacct cgtcaatatt caaagtaatc ctctggttta
31321	ggactactat gaacctgtgg ggttcattgt tcatgtggtt aaacagcaaa gagtagttag
31381	acagttgtcc tacgtcacag agggggacat atgctatgct tggttaaata gctgtcctgg
31441	tcagagggga ggcatgctat tctgcccttt ctgacagacc ctgattgcat agacatttca
31501	gtgagataaa ggaaggaagg gaagaaggag gaaagacaac attttttgct tctgttaagg
31561	tagagactat ctgtgatcca gttcagcaca gtgcctgtga gtagaagcta caggtcaggc
31621	aggagccaag gaaatgtatt gcttttctaa ttgaacaaag gacacacagc tgccatttat
31681	tttcttcatt ttgacccttc agccctgcac tgtggatatg acatcaagaa actaagcagc
31741	cattttgtga aaatgagatc taagttagta aatgtggctg aaaaagaagc cagctgcatc
31801	ctccctggat ttacgagggg gaaatgtagg catactaaat taaaacacta aaattgaccc
31861	aaagctattt tgactgatat ttaaatatag attctgctcc tggacattcc agagttcata
31921	ggacagttgc ttctgttcag aggattcctc ttcggggttg cctctccttc cttaggcctg
31981	cttgtcctgc ccaaagctgc ccaagtgcat caggccccaa accaacttct ccatcctgac
32041	gcacagcaga ctaaatatgc aactttgtgt ctcttcatcc caggacaaaa ctttcaccca
32101	gcccctgaca tctgagactc tactacaggt tatctattaa atcttttata aagaccaaga
32161	aacaaagtgt tggcatccaa actttggtaa atcatagcct tttaataaag tcaaatggac
32221	caatgtactc taacaaaaaa atatgggtct ctcatttctg aatggcagat ttcaagccct
32281	aagaaccaca atgctcacct actgggcaac actgagttac agagacccag ctcccccacc
32341	cctcaccaag ccagagaaac actctatctg aacaatcctt ggtccatgga gcaagaatta
32401	gacatagaat ttgtatctca ttgtttttta ggaaaacccc aaaggctatt atgaagtcag
32461	tttttctggg caccttttct ttcccatgac aacgagttgt gggcagtctc agcagaatac
32521	tgaagctgtg gcttggggag acagagcata tactggattg gagttcatgg gtgggtgcat
32581	ggaatcaatg ccgggcatgg gattcaagac cttatgcatg tgggtagatg ctttgttact
32641	gggataaatc ccccacctgg gatctgactt caagcacaat ctttggaagg cggcattggc
32701	tctctgctaa tttttctagc acttttattc cacttatttt ctgcttgttt gctttgggag
32761	ttttgttcgt tataagacag tcttgctgtg tatcctaggc tgatcacaaa cctgtggcag
32821	tccttttgtc agcaggccaa aattcccact ttatctctga agacagaaag tagattgagg
32881	aatatatgat aaagacactc atcaaagcca ggcatctatc tttacttttc ttaaagcatg
32941	tttttgaatg gcataaaacc atgtagacaa ggagtcttat gttgtacatg gtcctacttt
33001	gtcacttaca atataggata ctttcaataa gcttggtagc ccttgcccta ttctacttat
33061	tctgttctct cttcctcggg tcttggggag ccttcttacc aggtggggtg gcataaaggg
33121	aaaagtcaca aagctcttcc tattcctggt tcccctccta agtgtacctt gctggtggcc
33181	ttgctagcaa atgtagtata acatctgact tatctcctct cagatatggt tgttgtactt
33241	agataaattt aatctagaaa ctcaagctgt atgtctttgg ggaccagcat tacagagctc
33301	ttcccttcct gtccttacct caccttggct actgtagtaa gttaatcctg atgattcctc
33361	catgagtcct gaaactgatt agttccaaga gctggaggat gagaagggat atagcctggt
33421	gcagggacac tttccaatga ccacaagacc ttgcacaagg tacacatgga atgtgttaga
33481	ctgtctcctt tctgtcccta gcctcagttg ccccagtgtt tatcaatgtt tattaacatt
33541	gccctagcaa aaatactaca gactaggaag cttgggtaca attgaaaaga gcttctcagg
33601	gttctggata ccgggaagtg caaaggttca gcatctggac agggctgcta ttgtagtttc
33661	aaatggttct gctgcaacac ccctttgaga gaatgaacac tgcttttcac atggtggaga
33721	gtgcacagac accaacccaa ctcctgaagg ccctttctcg agggctctaa tccatcatga
33781	gggccatact ctcaggactc attacctccc caacatcccc tctctaaata gtaccacact
33841	gcatttgcat ttcaatatat cactggagat atataaatct ccagaccaca gcataccata
33901	aatcagataa ggcaggcctg ccttctatag cctttcactc agcaaaggtg tttctagccc
33961	aaagcagtct ggactctcac tctgaaacct cttgggagtg gtggccagaa atgacttccc
34021	atcatccctc tctcctgacc tggtccagca ccaggtcacc aggaaatcct ccaagtttca
34081	ttatccccac ccccaattgt ctcttgtctc tagcaaacct cttccaatac ttccttcctt
34141	ggtgggtgta gcaagccaga tgatagcctg ccaaagaagt tcacagcctc atttctggag
34201	cctatgaata tgttacattg tgtggtaaaa ggaactttgt aggtgtgatt aaattatgaa
34261	tcttgaagtg ggcagattat ccaagtgagt ccagtgaaat tgcaaaggta catcaccaac
34321	agtgaggcag gaaggccaga gggggagaag gaagcagaga ggcagaggga ggaaaagaca
34381	agccagggga ggggagtggg gggaaagaaa ggagagagag agagagagag agagagagag
34441	agagagagag agagagagag aaatatcaca cacacacaca cacacacaca cacacacaca
34501	cacacacaca cacacctgaa cctgattgtg gaggaagaaa ccactaacca aggcattcga
34561	ggcagccttt gaaagtcaca agagacaggg aaaacagatt ctctccctcg gcccttcaga
34621	atcaacacag ccccacaact gctgatttta gtcatgttaa agccaagttg gacttctgac
34681	tgccaaaact ttagacgagc aaataaatct gcactatttt aagataccaa tgtgatttgt
34741	tcatgaaaac aatcaataag gaactaataa agtagaagtg aaaattggat cacttctgaa
34801	gtttggtaat atccacagaa actggacaca tgctgacttt gtgagccata gctccacacc
34861	caggtatgcc ccctacagaa atgtgtatat aggtgggcag gagatgtcac ctgctgtgtt
34921	catagtcgca cctttagact ttcccaagcc tgagaatagc ccaaacacct accaggagca
34981	aaataaattg agatatacag acgcagtggg atactacact tctaaaagaa tgagaaaacc
35041	acgctataca ctgtatatcg tcggaacagt aacacagggg tgacaatcag gcaataggac
35101	atattctcta tggctttaga aaacataaaa atagcataac agttctgtta gtggcaatgt
35161	gttctgtttt gtgatctgta tgatgcttcg gtttgtgcaa aagctctgga cttacctttt
35221	aaatgtatgg tggtctatac cttttaaatg tatgctagat atacatgagt aaaaatgatt
35281	aaaagagatg gaggggagga gactcatgcc ttcataaaag tttgttctgt cctttctggc
35341	actgtccaag tgaatgtgtg taaacaaaga gtgacccacc ccaggtagtc caccttctta
35401	gaacctactt ctgctacaac atgtcctgtg aatgtgcacc aaatgtttac taagggatca
35461	tgccacaggg ttttgtttaa ataaagtatg tctacctagg ggtatattga ttgtctttcc
35521	ttttgagggg gggtctcaaa actacaaact agtttgtttt gagacaagta tgtagcccag
35581	gatggccttg aactcacacc ttctgtcctg cctctttccc agcactagga tggcaggtga
35641	gactatcagc ctggccccag gaaactatct ttgattgaca ttatctggtc agaaaagatc
35701	taccttttcc tccaccaggt cctccaaata catgaagagc tgaaacagtt ctgtctaccg
35761	aatttccttt tttcttgatg tttctgtgga atttaataca taaattttaa tttgcatttt
35821	tagcttttct attaagcctt aattagagta taatgaagtt atgaatttat aaaaataaaa
35881	acaaaacggt tgctcccaca atcactcagt cttgaagtga ggttctgact ttacctgaag
35941	tgggggaaga gagtgaggaa agggacctgc ggaagctgaa tctcagaccc acaagatgga
36001	tctgagatcc atccaagcga acgtggacgc agacccggag tagggacatc caggggtcat
36061	cttcatctgt cctcgctgtg cttctgcccc tttgctcctc taccagtctc agctgtcaaa
36121	gctcagtggc ctggagggga gatggggcgg ggcttaggat cgaaggcgga gcctcggaga
36181	gcatcttctg gcccccgggg cctggactgg cccgccgccc ccacctgcag cgcggcggag
36241	cgcgggcgcg tcactcccag cggaagcgcc agcctcgcgt ctggcgaggt gcgcgcttcg
36301	cggctcccgc tccagagctt cgtggcccgc ctgtgtctgc agagcagggg cgggggcccg
36361	gcggcaccga ctgggcactg agatccaagt agccactgaa tcgtagacag tcacccagct
36421	cggacagcgc gtcggggcgg gagcagatcg ggaaggtgaa ggaccactgc ggatccgaca
36481	gcgcgtccca ggtcagtcct cccgctgcac ttggggaaac tttgggatgc ggtgacggct
36541	gcgagatgag gacactgagg gtcgcgaggc cgcgtggccc ctgtgaaccc cgcgaacccg
36601	tacctgccgc gcacctgaca ccgcagctgc cagggcgggg accgaNaccc tgctgccgcg
36661	gaccactgcg ggccaccaag ggctagcggg cttcaggggc ctctcgggag cctccggctt
36721	gcccgcgccc agccgcgcgc ctccggtcct cgcgggtccc cagctccttt tggcggctcg
36781	cgcccggacc ccgcggggct gcggattccg ccgtcttcgg gcctcgtggc gctggaggag
36841	cggcccgggg gcccatggct gcagggtggc ggccccgcgg cgggagcggc gcgtgctcgg
36901	ccggtggagc gcgcgggtcg cggggttcgg ctggagcgcg tggccgcagg tgcctgtggc
36961	cgctgggcag cggaggtgag agcgcgggct ggggacgcgg agcggattgc aacctctggc
37021	tgcaggaacc agggtcgctg ggtgagcagt cctgtccccg cggcttccgg gcgtgcacat
37081	ccctggcacc cggcatccag accccatcag ctggaggcgg gctgcagagc ggcgcctgcc
37141	cgggccgagg accagtgcct cctgctctga cacgccatct caccaacgag ggcggggtgc
37201	tagattggcg ggctgcgcgg ggaccactgg ccagggcctt ctggcacaag cccttttcgt
37261	ggacagctgc ctgctctggc ttggagtgga ggagacgaaa tgagtacccc gcccccatca
37321	gcgccccaac actgtcgccc cagtcacctt cctttgccct tctccgacag caccttggac
37381	ttgctccctc ccgaattggg gaaaatctga ggaaaccagg cagggacctt ggagataccg
37441	cagcctgcat actcaacagc ctggaaatcc agtcaccttg gtacctcgct gcttcccaga
37501	cactttggag gagcaggttt gccatttcta ccccacatcc gtaccccatc ccccgtccgt
37561	ctctgctgag gaagggactc ttatgagaga agttgggatc taggtacccc ttaaggtagc
37621	cccagagtct gtggtaacta ggctcatagg taactaaaag gcatcctagc tctgtagctt
37681	tgtgagggaa acaaacctta ccaactaatt ccttcccttt ctgaatattt cttagaagac
37741	tggagaccaa cggaagccga ctgttctggc cagtctttgc accctttgct tggctctgac
37801	tctccttcct aggcagagaa acattttgct tatgacctct ggctggcctc cttccaatcg
37861	ctgcctggcc ttggactgcc catcaggact gtgatttttt ttttttttta agacctgatt
37921	aggaaaggct gcaagcctcc ggttctagaa ggctcaaact caggggtata ctcttctctg
37981	atacccatgt gctccctaat tccactgtgg caacacctct gcccttcact cccacaagaa
38041	aattggttgt caaacctctt ggggaagatg atggaggcat ccctgtggga gcagatgcag
38101	gatttggaag caaccaggaa acaaccagga gtgaggaatc ttttttaaag gctcacatga
38161	ttctggaact aagaaaagat ggagatgcca ccagtgtatg aagcttggcc tctcctcggc
38221	ccatcccacc caactcaggg aactggcata tgcaggacct gtattgggtg atgcatattt
38281	ggaacctagt acttattgaa ttcctaagca gtaaacacat tccgaatttg aaattcctca
38341	caatcatcta ctgNaatgta gatattaaac ccccaactta tgaatgatag ccccaaaatt
38401	gttaacattg agagagccca ggttccctgc cacctcttcc acaacaggac aggaactagg
38461	acaatgaata ggaccatttg agctttaggg tcatgtgccc actttacagc tccatagcca
38521	gacaactgtt ttataagaga gggcacaaag gaaaatcact gtcctgtcca aatgaataga
38581	aagctgggga tggtggcagg acaaaggcaa caggaaaaat catctccaac aaggctttcc
38641	aagcatatca gtcttatact actgccatgt tgggtaccac acaaatcagg tatctcaaac
38701	tggacgctgc ctagggaggt ctgtcatcta aaaaggcagg gagatattga gataaaatac
38761	acagaagcta gtatttaact ccaggctggc agataatagg aatgaccttg ggagggtgtg
38821	cttacctttc cttctctctt gaacaaaatg tggactggac cagatgagca ccaaggctcc
38881	accaactcta acagaccttg tgtggtgggc ttgcctgcaa acagacttga gctaggttgc
38941	tgtgcgtggg atccattcca gactcattta caaactcgta gtcagtgaaa tgtgataaac
39001	cgaacactgt agggatttct aaacaaggaa ttaaaaaact cgactccaaa tgggagagat
39061	gcaggcaaca aatcgacagt gtttatgtgc ctctgaatag ctttgatttc cttcggtagg
39121	agctgacagc tggctgacag aaagctcacc cagggagaga agagagaaaa atcaagtatg
39181	agattaggaa taatgttttc aggtaacttt ctattcccat tcggagtggg tgtctggaag
39241	ggcgagtgta gttatggctt gaattgctcc atttatccac agatattttc ttcccaaggg
39301	ctcctgattc taagatgctg ggctttgctt ctgtctccta gtttcctggt agcagggtag
39361	agagctgggg gtcccagcat tcagcctgca tattcttcct ctatcctcac tatctgctgc
39421	ctccattatt tgtggtcttt tggatctatt tggtcagaga gtcagtcttt ggtttcttgc
39481	cctggaaact gcttgttgct acttgtggtg ggggcagcat ttggaagtcc aggtgctctg
39541	cccacaaact ttcaacccat catttgtttt tcatcccttt ctcattgcca ctttgtgtgg
39601	tgcctgggac ttctgggacc tatagttcaa gggtcatata taccaatggc tcacatgaca
39661	gcactgatca ctctgccagc tctcctctct ttgcaaaact tatttcagat ttttcatttg
39721	acaatacctt tcctccagtt gtctttattc ttggcagcat atgccttgta acctttaaaa
39781	aggaaggtaa ataatttgag aaaaaatgta ccaagtcctc agtgatacat tcttactaaa
39841	gactcccagt tttaacaagg agttgggctg gagccatggc tcaacagtta agagcactac
39901	ctgctcttcc aaaggacaca aattccattc ccagaaccca catggcccct tccaaacatt
39961	gataactctc gttccagggc acctcatgcc ctttcctggc atctgagaga accagcataa
40021	acatacatgc aggtgaacat tcatacacat aaaatgaaca ttaaaaaaga aatgaaatag
40081	agaaagggtt tacataacta tttaataact aagactgcct aataatgtag ggacccataa
40141	agaaaatcta gtaagttttt acaagattcc actcaatcag accaaacatt actgttactg
40201	acagagtaaa aagtcacttc caatagtcca agaacaactt tgtttcattt ctcaggcact
40261	gtctgttttg tggcatatgt gcatggtgtg tgtgtgtgtg tgtgtgtgtg tgtgtgtgtg
40321	tgtgtacagg tgaatgctgc tcgtgtatga gcacatgcag gtgtgtgttt gcatggtgtg
40381	tagacagagt ttctgacctg cctggtccca cagctgtttg gccacaaata aacatacaga
40441	ggcttatatt aattagaaac tgtttggcct atggcttagg cttctcactg gctatctctg
40501	tcttaattat taacccataa ctactaatct atgtatttct acgtggcgtt atcttaccgg
40561	agaatacttg gtgtcctatc ttctcagcaa ctacatggcg tcttctctct gcgtcttctc
40621	cccagaattc tcctcgtctg gttgccccgc ctatactttc tacctggcta ctggccaatc
40681	agtgttttat tcatcagcca ataagagaaa catatgtgaa gaaggacatt tccctatcaa
40741	tggtgtgtgt gtgtgtgttt gtgtgtgtgt gtgtgtgtgt gtgtgtatgt gtgtacatgg
40801	gtatgtgagc acatgtgggt atatgggtgc atgtgcacct gtgtgtgtgc atggtggcta
40861	gagttgaggt tagatgtctt ccttggctgc tctccacctt ttttttattg aagctctcac
40921	tgaacttaga gctcactgat tcagctagtc tagctacccg gcctgctctg ggggtcccct
40981	gccttcactt tccatgtggc taccatatct actttacatt tatgtgggta atggggatct
41041	gaactatggg gtcctcatgc ttgcatggca agtgctttat ggactaagac atctttctag
41101	cctttacctt tttttttttt gaaagagttt ttttttgcta actgggaact caacaccaga
41161	tagctagtct actggtcact gaggcccagg gatctactat ttctgcttct cttcccaagt
41221	gctgggacta cagactgtac caccatatcc atatttcttt tagcatgagc tctggaagtc
41281	aaactcaggt cctcacgctc acaaagtaag tgttttatct accaagccat cttcccatct
41341	ctgttgtttt aaaaggcttt gaatatggga tgtgatgaag ggaggtgaaa ttctgagata
41401	aatttcttga aaagaagaat gaatcaagta ggagaacctc ctcctggtgc tgtctttcag
41461	ttccatgtcc acacagcata aacattatga ttatcattcc acagattgta attagtcttt
41521	ctctgttttg ccagtctgct cccaaaaaat gacacagaga gacttcttat taatgatgaa
41581	agctttgcct tagcttaggc ttgtttctaa ctaactcttg taacttaaat taacccattt
41641	ctattcatct acctgctgcc acgtgattca tgacttttac ctctctctca ttctgcatat
41701	cctgcttcct ctgcttctgg ctcatgatcc cgcttttctt cctctccgag tgctctgtcc
41761	ccagaagtcc cgcctaacct cttcctgcct agcaattgcc catttggctc tttactaaac
41821	caatcacagt gacacatctt cacgcagtgt aaaggagtat tctgcaacaa caggtgatga
41881	agccaacatt ccaagaggcc agggcttgcc tagggcacat agctaactta agaaaattag
41941	gatcgcattc tacatctgtc tgactctgaa ttggatctga actgtgactt gcatggaaga
42001	cccaaagacc ctgagaaagt acaatgacaa aggggctgac tctgtccaca tggtgttagc
42061	ccaggtttcc cacaggagga aaacccatcc taggcaagag aagtggtctt catcaaacac
42121	tctatgaaaa gcaaatcaga ctcaaatgtc aggatttgtg ctttacagat cgatccggta
42181	agatgaaaga acttcctgaa agtgtgtgaa ggcctaaagt cagggctgtt catggaaggc
42241	actgactaca gaatgaggtg ccagaagcct agtcagagcc tctagggaat aaagtgtcag
42301	atgatcttct aaaaaagttg aagtttcacc agtaacagaa tggccccact attaaaatgt
42361	gagcaaactc agaagtcatt gtagcatata gaagcacaga cctatggatt gctggatgga
42421	gcccaggtat tcactccatc ctgaatagcc agctggggag ctagctcagt cagttaagta
42481	tttgctatgc aaatctgagg accagacttt ggtctcctgc atccacagaa atggtgcaca
42541	cttgtaatct cagcactggg gaagcagtca gccagatcca acagctgcct agccagcgga
42601	aacagcctta tcagaaactc atgggtcctg gtgaaagata ttatctcaaa taacaaggtg
42661	ggaagctcct gaaggacact ggaggttaac ttctggataa acataggctc gccccaccac
42721	cagtgagcat gtgcctaaat ccgtacataa caatgatgta aagatggaat tcattccagt
42781	gaaaagtaag cctcctggac tctttttttt tttttgttgc tagatattct cgagacctca
42841	ggagagaagg tttgccatca tctatataac atggtactca acttccctgt agtccacaac
42901	attcctattt ctatatgatg gagaagaggc cactgcccct cccagacatc tcagtctcaa
42961	atttgttacc agttccctct cctaataagt gcttagggtt agtgttgtag agaagggctt
43021	tacatgaagt gtgtgtgtgt gtgtgtggtg tgtgtgtgtg tgtgtgtgtg tgtgtgtgtg
43081	tgtgtgtgtg tgtgtgtaac ctaaaggctt tccatgtttc cacactgaaa ggttcttaag
43141	actgagaaca accagataag agtccaaatt ctagaaacca tgggaaagtg taatattgaa
43201	agtcagaaca aggcatggtg gtgctcacct tgaaacccac cacttggggc agaggcagtc
43261	agatctctgt gagttcaagg cccagcctgg tctacagact gtacatagtg agttccaggg
43321	ccagaactac atagtgagat cttgtctggc caaaaatata taagtaaata aaataaatca
43381	gtacatggta acttgttctt atttcagtgt ctgtttctca agcatgactt tggcttaagg
43441	atttttccca acttgttttt gtgattgcca ctgtatcatt tctttgtgtg aagttactaa
43501	gtggtttctg tatttgatat tatgttctga cctagtttct tttcatatta aacccatttg
43561	tatatgaaaa ctgcaaagaa gtgggttttt tgttttttgg gttttttttt gtttgtttgt
43621	ttgtttgttt tttcttggtg ttctcatgtg acctttccaa tgtttgcttc cagaatagac
43681	ctgcaagttg ggatccacac tgccatctga agtcctgcac cccaagtttc aggtatgttt
43741	tgatggcaga atagcttttc tagactgtga caataggggc ataaagccac aaagcattcg
43801	ctttcctaca ggttatgcac ccactctctg agtgattggc tgtgcatcat gaatattatc
43861	aaaatggagg cagttcagtt tggagtgctg tcttttatgc gcttattcat ggcaatgcca
43921	atggaacatt cggcaacata tactactaat catgcatggt aactgaactg tgttgtgcaa
43981	ggaagacctc atatgaccta cctttgcata tgctgacctt ttctgtgaca gactcctata
44041	atactgagag tggtactgta tggaagagtg tgtgaaaatg tattgtttaa ataacagaca
44101	gatgcctcta aatacaacac ccaagcagag aaatggagca tcactggcac tttggaggcc
44161	tctgggtaac ctttccagat cacactgttt tccttcctcc accaataacc actttccctt
44221	tggatgctac tcatagttaa catctttact tttgttgttg tcccactgat gctaagaaaa
44281	ataacttcaa ctagcaagca caacactaga tgaattaaga gtgatattga ctgtgtgtgg
44341	tgagtctcag aagactagct gcctcaggat tcatgaatgc ttacaggaac cctttagcaa
44401	ggtcaggaat gagtcttagg atccatgtgg ctcatagtct ccagcctgga catggagtag
44461	cacagtgtct gagtgcccca agggaatggg cttgttcagg ctcccctccc cgtccccagt
44521	tccaacaggt ctcagatcca ggacatcaga gctgagtgaa gagcagagct aaaaggagca
44581	ccatcggagc cctagaagca gaataggggg ggacacagca cacagagaca agaactgagg
44641	ccaggctgct gtgtgctttg ggcctaagtt gacagatgaa acatggtagg gtgaccacat
44701	ggaggatgtc tgtgcacatc catcaaactg gcaggtcccc ccagcatttt ctgggagctt
44761	ggggtcctct tttccatgat cttcagcttc tgtattctat gtgcgctgtt accatttcat
44821	cttggtagag tctatccttc tgttatttct tgagagtatg tcccaattct tgcctggagg
44881	tttggctaaa tatagaattc taagcagagg gtcatttctc cttcagatat ttaaagacac
44941	tttctgtatt gtgcctcatt gccattgttg atatacctga atctaaattg atcccttggt
45001	gcgtgactta tccccacagc caagggcccc ttcccttctg gtctgtgctc tggaagtctg
45061	caggcacatg gtatgggtag ccactgtttc attcatagtt caatgctccg ataggccctt
45121	ttgatttgat aactctatcc ctttccccca ttcccgttga tgatttcttc ttttgttccc
45181	cttttgatat agtttccttg ctgatgctgt gctaaaatat tcctaccaaa aacaacctgg
45241	ggaggagagg cttcatttgg cttacaattc cagctcacag tcattgaggg aagtcagggc
45301	aggaactcaa ggcagggagc atggaggaat tgcctgctgg cttcctctct gacttactca
45361	caggttcttg taggctagct ttctgataac atctcaggac cacctgctta gcaatagtgt
45421	ggtccacagc aggtttgaac cttctgcatc agttactaat caagacattt gcccaaagac
45481	atgcccacag gccagattga tgtaggcagt tcttaaatca agtctttttt gtcaagtgac
45541	tctagactgt caagtcgaca gttgatgcta actaggacac tattctacca cttttcttgg
45601	tagaaatatt attcggatat tggagttctt ggactagttt ttctggttct ccttttcttt
45661	cttttcctgt tatttatatt tgttttatga gatagggtct ctctgtgaag ttgtcctaga
45721	ccttctggcc ctcctgctta taattcctaa gaactgatat tacaggcagg tgccatgagc
45781	ccaacgtttt ttcttttctt ttcactgcac tctgtttgag agtctcatcg tcacagtcat
45841	tcacatcttc tattgtcttg tttttctttt taaatgtgca ttggtgtttt gcctgtatgt
45901	atgtctgtgt gagggtgtca gatcttggaa ttacagttcc aaataatatt tctaccaaga
45961	aaaagtggta gttgtatcct agttggcatc aaatgtcacc ttgacagcct tgagtcacct
46021	gagaagaaag acttgattta ggagctacca tgtggttgct ggtaattgaa cccaggacct
46081	ctggaagagc acccagtgct cttaactgct gagccatctc tctggcttcc ttctattgac
46141	ttttgcaggc ttctttcttg ttcttttgca atttcatggt ctctgactgt tcttcacaga
46201	ctcttacctc atgcttaaga tgtctcttac tccttcaagg atactgagtt tttgaagttt
46261	taattctcct gactactgtc ttttccctcc tgtttgtcat tctctgtttg ccctggcctc
46321	tgtctttcat gcaggaagac ttttcatttg cttttaggtt tttattttaa ctattggttc
46381	atgactaaag ggctagatga aaaggccagt gagaaggctg gagcatatgg gtgatacttg
46441	tcaaccggga gcctcactgt ggaatgcttc agtggcatgt gaaatcctgt ggtatttgct
46501	caggcaagtg cagctgttga atgcagacca gagcagcttc cttcgaagga gtcagatgtt
46561	gctgactgtc tttctgcagc tggtcaggaa ggtgggatag acttcagctc ttttcaaaca
46621	gtggtcacca aacaaccact tgcccagaga ctttgtgctt taccattctc agagaacaga
46681	cctctggatg gccccatggt ggaagcagcg cacctgtcta tcacaggtgc tctgaaggag
46741	ttggaagaac tacccattgt ccacatttcc cacattttca catgccagct tcactctggg
46801	atctgggtga cagtggggct gacataatgg caggggttgc agtttcagac tcagagtatg
46861	tggtaggaat gctgctgtct gagggaagac tcatctgagc agtggaggct ttgcctgttc
46921	cctggcatca tttgacctgc ccctccttag aactgggaac cccagttcta aagctccctg
46981	ctttaaagat tctgtgttgg ggtaagttct tagctttctc aggctaggtc ctctgctctt
47041	gggtttccac ggcactgttg ttttccctct ggctttgtga gtggttgtct tttgaaaaac
47101	tagttagttt ggaaaatttt gggagggagt caaataagat gtatgcattt tgccatgtaa
47161	gtcctaacca agccatctgc tgtggtattt tcctgagttt ggttctgccc ctataggcag
47221	agtctgtcat cacagataat tgcattttga acttgagcat ctcccttcct tctttgtctg
47281	cctgaaaaag tctctttata aaaaaatgta atgttaattt aaaaagtatt cattattctt
47341	gtgttgtgat acatgagtat atatatgcta tgatgcatat gtgcaggttg gaggacaact
47401	ttctgtagtt ggttctctct ttctcccttc atgtaggttc tggggatcga acccaagtca
47461	tcaagcttgc acaacagcac ctttaccttc taagccttct catcagccct ttttttattg
47521	attgattggt tgattgattg attgattgat gctagggata gagcctaggg tcttttacat
47581	gctaagaaaa tgctctacca ctgaactgca ctcctagccc aacctgctaa attcttacac
47641	tgtcttcaaa aagaagctct gatgctggat tctgcaaagt ccatttttat ccctaaattc
47701	ctaaagctgt ttaaatctcg tgagtcttac tgtacagacc agctctgtgc accatcttcc
47761	acaatctcca tgacctcctc aggatgggct ggtatctctg cagctctgcc cagtgcctac
47821	caggaactta caggtgtcac caatgaattt attggtgcat gctcacttca tcttgtccct
47881	atccactttc tgctttgact ccttctggta agagacaagt gtgttaacta cttgtgctat
47941	caccacacag aaatccatat cccataatct tagtcctttt tatttactta tttttgagac
48001	agggtcacac tctgtagctc ccacactggc cttaaacact gacctcgaac tcatggtgat
48061	tctcctgcct aaacttctca aataccatga ttacaagagt gacacaccat gctgggagtc
48121	ataatcttaa gtttaaaagt gagggactgg tcagtttact gtgctaggtt gacattgtat
48181	agaaatgaac agccatgttg gtctggaaat gttcctagtt ttcatttgta caaggatatg
48241	cagtgtgtga aatagggaga gtcttaccta tgtgggtttg atcacagcaa ttaataaaat
48301	atgctctaaa taatgaaaaa agccagtaac tagtagtgtt tctgaatcct cactaaagct
48361	ttaatacatc ataaataata tatcactgca gattatgtct acatgttata catatcacat
48421	ttatagtaca atctgatctt tgtcacctac tgtaagcaca actgaaaaac aaattttctc
48481	atagctcaat attaagtcat tattatcccc ataataagta attattatcc ccataatgaa
48541	actatctatt gagggagtca gaatctgaga tagttaaata aatttaagca tgtattttta
48601	gtgtcaatgg taaaaattaa atgttcataa agcctgtatg actcctttta aagtagtttt
48661	aattttatgt gtatacatat atgcatgttt tgccttcttg tatgtctgag taccacttgt
48721	atgtctggtg cctgaggagg ccagaacgta tcagatcccc tgaaactggt attacagttt
48781	tgagctacta tgtggctgtt gggaattgaa cctggatgct ctgaaagagc agccagtgct
48841	cttaatgact aggccatctc tccattttct taaaaaaaaa tttaaaacat ttactctaag
48901	atttactttt atgtaggtgc gtgtgtgaat gtgtatggtt tatgcattgg ggtggggagg
48961	atggattagc acagtcacag aagactagag gagggtctct actattgctt tctgtcttct
49021	acccttgaga cagggtctct cactaaacct gaaactcacc tttgcagctg gggtagctgg
49081	tcagaaagat cctggaatct gtctttctcc ctggccctaa tgcttgagtt acaggcccat
49141	gtgaccatac ctgtcgtttt actggggttc tacagagtca aacccaagtc ctcacgcttg
49201	catagccagc gattttaccg actgagacat ttatctgccc caattcataa ttcttctctg
49261	cttccattaa taatcccatc tatgtcccct tcatacatat ttctgaaata gacaaaatga
49321	atacaagtta gacatcgagt ctgattaatc ttcaacttct ttgataacca ggtattgatt
49381	tctgactttt gaagatggat gaaggcacag aagtctccac tgatggaaat tccctgatca
49441	aagctgtcca tcagagccgg cttcgcctca caagactttt gctcgaaggt ggtgcttaca
49501	tcaacgagag caatgaccgt ggcgaaacac ctttaatgat tgcttgtaag accaaacaca
49561	ttgaccagca gagcgttggt agagccaaga tggttaaata ccttctagag aacagtgctg
49621	accccaacat ccaggacaaa tctgggaaaa gcgctctgat gcacgcatgc ttggaaagag
49681	cgggcccgga agtggtttcc ttgctgctca agagtggggc tgacctcagc ttgcaggacc
49741	attctggcta ctcagctctg gtgtatgcta taaatgcaga agacagagat accctcaaag
49801	tcctccttag tgcttgccag gcgaaaggaa aagaggtcat tatcataacc acagcaaagt
49861	caccctctgg gaggcatacc acccagcagt acctcaacat gcctcccgca gacatggatg
49921	agagccatcc gccagccacg ccttcagaaa ttgacatcaa gacagcctcc ttgccactct
49981	catgttcttc agagacggac c

SEQ ID NO: 3 (Chromosomal region 5,000-55,000 basepairs downstream of CHO GS gene

coding sequence)

1	GGGCTCAGGC ATTTATCGTT CAGAGATTGA CTGAGCTGTA AAGATGGAAA GACAAACTTT
61	TTTTTTTTTT GATTGAGTCG GGGTTTCTCT ATGTAACAGC CCTGGCTGTC CAGGAACTCA
121	CTCTGTAGAC CAGGCTGGCC TTGAACTCAC AGAGATCTGC CTGCCCCTGC CTGTCGAATG
181	TTGGGATTAA AGGTGTGAGC CACCACCGCC CCGCTGACAA ACTAGACTTT TAGAATGTAT
241	TATGAGATAA GGTTTTGTTA TGTTGCCCAG GCTGGACTCA GATCTGTAGC AATCTATCTG
301	CTCCAGACTC CTGAGTGCTG GGATATACAG ACCTGAGTTA CCTGTACAGC TTTCTAATCA
361	TCCCCCGCTC CCCCAGAGAC AGGGTTTCTC TTTATTGTTT TGGAGCCTGT CCTGGCACTG
421	GCACTCACTC TGTAGACCAG GTTGGCCTCG AACTCACAGA GATCCACCTG TCTCTGCCTC
481	CTGAGTGCCG AGATTAAAGG TGTGCACCAC CAACACCCTA CTTTCTAATT CTTAAAGCAA
541	GGCTCCCAAC TCCTCCCTTG TGTGTAATCA ACAAGGTTCT TAGACCCTGT CTGCAGTGTG
601	GATTCCCACT AATAAGACAG TGGCGGCACA GTGCTGTGTG GCAGAGCAAG CGTCCATCTA
661	GTTCCTATTG TCATTCTATG ATTTGCTCTT CTGGGAGCCT TGTCATTCAG CAAGTTCCTG
721	GGCTTGTCTT GGGATTGCAA TGTGCCTCAG CTTGGCTAGT TCCTCTGCGG CAGAAGCAGT
781	GTTTGAACTC AGTGGGCACT CAGTCACTAC ATCTAACTTG TTTGAGGGCT CTCTGCATTT
841	GCTTTCCAAT TAAGGTTTAG GATGACTCCT CCCTGTGACT CTTATCATCC TGCCTATTAA
901	TGCTAAATTA GAGAGGCATT CAAGATAACT GCCGAAGATC TAATAAATAA ATGGGGTGGG
961	TGGGTAGGAC TATAAACCAG TTTATAGCAT GCAAGAAAGC TCTGAGCACC ACATTCAAAA
1021	ATAAAGTGCT GTGAGCCTGG TGGTGGTGGC TCACACCCTG ATCCCAGAAC TCAAGAAGTA
1081	GACAGAAGGC TCAGATTCAA GATTCAAGTT CTTCCACTAT ACAGCCAATT TGAAGTCAGC
1141	CCAGACTACA TGAGACCCTG TCTCAACTAA GCAAATGAAA GCAAACTGGG GTCCAAATAG
1201	GCACTATTCG ATGTTTTGAT GCAAGTTTGT GACTGAGGAG TGGAGGTGGC AAATGAAGAC
1261	TTTTTTCTTC CTCTTCTTCT TCCTCCTGGG TCCCGTTTTT TTTAGGGTGT TCTTAGGATA
1321	TGTATGTCTC ATTGGCACTA CTAAGAAGTG TGGGGTCTAG GGAACTTCCT GTTATGTATA
1381	CAAGCTAATC TTCAAACAAT TGTGTGGGCT GTTTTGGTAA CTACTCAAAT AATGCTATAG
1441	AAAATTGTAC AATATATTGG GGAAGGAAGG GAGTTTTACA CAGGAGTCAA CATGACTCTT
1501	GTCTCTGGAA AGCAACTTGT GATCCAATGA GGAGCTAAAT TTAGAGACAC AATTCAGGAA
1561	GAGAATCCAA TCAGAGCTTC CTTGTAAAAC AACTCACCTT CACAAACAAG TTCATTCCTA
1621	ATCGAATTTA AGGTCTAGAA ACTGCCAACC TATTAATGTT TCTATAAATA CACTTGGGGT
1681	CAACTACGTA GCCAAGGAAA TCTTTAATAA ATTGAACACA AATTGTCAGG GGAAGGTTAT
1741	TGCTGGGACT CCTGGAAGCA TGTATAAGCA GGGTAGGGGT GACATAGGGG TGGGGGGCAG
1801	TTAACTCACA GATATTAGTC TCAGATATTA ATGGCTTGTG TGTGAGCTGT CTGCCACACT
1861	TAATGTCAGT CACCTTGCCC GGAACTATTT TTCTCTCTGA TTCCAAATGT AGCTATTGGT
1921	CTATTAAATG ATTAACTTCC ACAGAAACTG ATAATATCCT TATGGAATCT GACTGTGGTA
1981	AGCCTGTACA CCCCCGCCCC AATTTCCTTC TAGATTTAGA ATTCCATTCC ATGAGCCATC
2041	ACACCCACGC TGAAAAAAGA AAACCTGTTG AATCAAATTT GTGTTTTGGA GGGTAAGAGC
2101	CACCCTTCCA ATTTATAAGG CTGTCTATTT CTTTGGGGGG GGGGAAATGA ACCAGTATCT
2161	TCTATTAGTA AAAGGAGTGT TTGAGCATGG GCACTACAAC CCACTTCTTT CAGGGAGATT
2221	CATTTTTCTC TGAGAACTCA GCCTCTCTGT GCTGGTGCCA CAGGAATTCT TAAACTCTTT
2281	CAACTCTCCA ATTAACCAGA GAGCAAACCC AGCACTTTCC ATCTATGAGA AATCTACACC
2341	ACTCATGGAA TCATTGTGTG CCCTCTCTCA CTGCCTAACA GGGGTACCCT TGCCAAAGAA
2401	AAGCAACTTA ATGCCAAAAA GGTGCATCAC CTGGCACTGC TTCCGAGGAT GGGCAATGTG
2461	CAAGCACTTT GTTCAGTGGC TCTGCCTTGG GGTCTCTTGA GGGGCGGCAG GTTACCTGGG
2521	GTGGGGGCGC ACACTCTCTG AAGGTGGGCT GCGTTCAGTT TCCTGCTTCA GGGGCTCCTT
2581	CATAGTACCG CCCCCTGATG AGTTTCTGCT CAGACTGGAA GGTGTCAGGT CCCAAAGAAA
2641	CCTGGGACAA GGCTCACTCA GTACCTGTCG CTTCTCCCAG CACGTCTCAC CCCACCCCTA
2701	CCCTAAACTT CTCTAGCCCA GAGGCTGGGC TCCCCCTTTC TCTTTCCTAC ATAACCCTGC
2761	CATTTTAGCT GTGAGCTCTC TCCGTCTTTA GCTCCTCTAC TGTTCTTTTA TCCTCTCTTT
2821	TCTCTCTCCT CTTCTTCTCT CACCCCCACC CCCACCCCCA TCTCTCCCCC CATGGTCTGG
2881	TTCAGTCTGG ACCCTTTCAG ATGCCTCTGT CTGAACTCTC CCTCATATCT CAATAAAACC
2941	CTTCTCTTCA GCCACGCCTT GGAGAGGTCA TAGGCTCATT TTCGTTCAGA AGGCCTATCA
3001	AAGAATCTGT GGGCTTATCT TTACATTCAC AATAGGCAGC TTGGCCCTGA GACCACAGTC
3061	CAGGTTAAAG TGTTACCTTG GAAAGAAAGT CTTTTATTCA AGGTGTCTGG TTTCTTTTCT
3121	TGTTTTTGTT TTTGTTTTTG GAGACAGGGT TTCTCTGTAT TATTTTGGAG GCTGTCCTGG
3181	AACTCGCTCT GTAGACCAGG CTGGCCTTGA ACTCACAGAG ATCCGCCTGC CTCTACCTCC
3241	TGAGTGCTGG GATTAAAGGC GTGAGCCACC AACGCCCGGC TCAAGTGTCT GGTTTCTTTT
3301	GATGTCTTTA GTTTCTTTAA TCCCATAATT CCTTTAATTA TACCCTCTTG TCTGTCGGAG
3361	AATGACATCA AGGATATCCA GTTCAAGGTT TCCTATGTAG TTCAGTCATA GAGTGCTTGC
3421	CCAGCTGCCA GACTCTGTCA GATGCCCAGC ACCACACACA TACAAAGCAT TTCCAGCTCT
3481	GTGTCTGTGT CAATTACTCC TGTCTGCTTC TCCATCCCCA GACACCAGGA GGGCCCACAA
3541	GAAGCTTGGA GCAGGGAAGA ATAAAGAGAC AATATCCATA GACACACAAA ACCTCCAAAG
3601	TACTTATGCA TTGAGGAATT ACAGCTTACA AATCCAGTCA CAGTATCTAT ATTCATGTTA
3661	GCCTGATTTC AATCCCCCAG CTACATATTC TTCCATGAGC TAGCTCCTTT CCTATTCAAG
3721	ACTCCCTTGA TAATAGTTGT TATCAGACTT TACCCCTATT AAAATATTTG GACCGTTTGA
3781	GAGCAATAGC TCACCTCTAT AATCTAGAAC CCAGGAAGTT AAAACAAGAT GTTTGCTGCA
3841	AGTTTGATGC CAGCCTGGGC TACATAGCAA TTTCCAGAAC ATCCTGAGCT ACAGGGCAAA
3901	ATTCTATCTT AAAAAACAAA AAGTAGACAG ATCAGGTGTT TCACCTTGTT TCAAAAAATG
3961	CAAAAAATAT TTTTTAATTG TAGAAATATA TACGCTAATT CCTTTGGTAC CCTAGGCCAA
4021	GTGACTAGAT GGGTTAGTCT TCCTTCTGGT CCTCACAGAA GAAAGTTAAG TTCTCAGCAG
4081	GAATAATAAA AAATATTAAA AAAAAAAACA AGCTGCAAAA TTCTGTTGTG GTTCTGCCAA
4141	AGTGTTCTCA GGAGTGAGGG CATACTGGGA TTTAGTCAAG CAGATATTTC TGTTTGAATA
4201	ACTAGGATCT GGGAGCCATG GGACACCACC CCCACCCATA AGGGCTACTG AAAACCACCC
4261	CTGGAAATCT GTAAATATTG CTAAGGCTCT ACCCTTTTGC TCAGAGAACA ACCACCCACA
4321	AGGATAGGGG ATAAGTTAGT TCTGTAGTAG AGTGCTTGCT TAGCACACAG AAAGTCTTTC
4381	TCTCTCTGTC TTTCTCTCTG TCTCTGTCTC TGTCTCTCTC TCTCTCTCTC TCTCACACAC
4441	ACACACACAC ACAAACAAAC ACATGAGTGC ACAAGAAACT TCTAGGTGCT ACTAAACTAA
4501	TGTAAAATCA TGCAAAGTTC ATAGAGAATT CAACAGCTAG TGACAGGATG ACCCGAACAC
4561	AAGATTCTGC CCTAGTCCTT GTATTCTGTA GTCCCCAGTT TCTCTTTACT GCCACAGTCT
4621	CCTATCTCTG ACAGCCTCCC TCTTTGCAGA TCTGGCAGTT TCTGGGCCTG GAACTGCTTT
4681	GGTAGAATGT CTGTACAGCA TGCACTAGGC ACTGGGTTTG ATCCCCAGCA CTGCATAAAT
4741	CAACTTTGAT GTCACACCTA TAATTTCAGC ACTTGGCAGG GATCGAAGCA GGAGGATCAG
4801	AGGTGAATCA AGGCCAGCCT GGGCTACTTG AAACCCTGGG GAGAGGGATA GAAGAAGGGG
4861	GAGGGGGGAG GGAGAAGAAA GGAAGGAGGG GGAGGGAAGA GGAGAGGAAG AGAGGAGGGA
4921	GAGGGAGGGA AACAGGGAGG GAGGAAGAGA AGGAGGGAGA GAGGGAGGAG GGAGGGAGAG
4981	ACTAGTGTAA GCAGAACCTG TAAGTTCTCT CCTCAGCCTC AACACACCCC AGCTCCCTGC
5041	TGTCTCCCGG TCCAGGGCTT CAGGGCCTGG CAGGACAGGC AGCAGGTTGT TTTGCTCTCA
5101	TAAAGCCATG TTACATAACT AACTAATGTT TTGAGCAGTG GAGCTGAGCC AATCTAGGTC
5161	ACATCAAGAG GGAATGGGGA AAGAGGATGA TCACGGAAGT GGTGAGAGGA AGGGAAACAA
5221	GAAGGGAGGA ATAAAAAAAA GAGGCGAGAG TGGAAATGGG GTGCGATTAT TTAATATCTG
5281	CTGCCTGTTC ATAGTTCCTG GTCCTTAGGG ACAGCATATA TTATCCTGAA AAGTCCTCTC
5341	TCTATTTTAT CTAGGCATTC TGTCATCCTA TAGCCCCCAC TCTGGATGGC TGAACTCTGT
5401	GCCAGCAGCC TGCAGGTATC ACCCCTTATT GGAGTGAGGT CTATTCCTTA TTGGAAGCAG
5461	TGGCAGGCTG GTAGGAAACA AACAGGCCTG GTGTTGTGGA ATGCTGTCCT CCCAGCATGA
5521	CCATCATTAG ACCTTATGGA AGCAGAGCGA GGGGGGCATT GTCCTCCTCC CCAGGCTCCT
5581	GCAAGCCTAC TCAGCTCAAC TGGTTCCCCG GGCCAGACTT AGGTGCAAGA GTTGCTTTGG
5641	TTTGTTATTG GTGGCCTGTG TAGCTGAGTA GACACATGCT CACCTACATG ATATATGATG
5701	GCTTGCAACC TTCTAAAAGT TCAGTTTCAG GAGATCCAGA ACCCTCTTTT GCCCTCCAAG
5761	GACACCAGAC ACCCATGTGG TACCCATACG TACATGCGGG CAAAACACTT GTGCATATAA
5821	AATAAAAAGA GATGGCTCCG TGGCTAAGAA TGCTCCCTAC CTCCAGCTCA CCCACATCTT
5881	CACAACTGAC TGTGAATCCA TCCATGGTTC TCTTCTGACC TCGGAGGGCA CCTGTGCCCA
5941	TGGGGCATAC ACATACACAT ACACAAAACA AGTATGTAAA TAAATAAATA TTTAAAATTG
6001	GGGCTGGAGA TGGCTTAGTG GTTGAGAGCA CTGGCTGATC CTCCAGAGGT CCAGAGTTCA
6061	ATTCCCAGCA CCTACATGGT GGCTCCCAAT CACCTAAAGT GGGACCTGAT GTCCTCTTCT
6121	GACATAAGGT CATACATGCA GATAGAGGAC TCAAATGCAT AAAATAAATA AATAAATCTT
6181	TAGAAAATAA GTACATAATA AATAAATATT TAAAATGACC CAAATTAAGA AAAAAATGAA
6241	GCCAGGCAGT GGTGGTACAC TCAGAAGGCA GAGGCAGGCA GATCTCTGAG TTTGAGACCA
6301	GCAGTTCCAG GACAGCCAGA GTTACACAGA GAAACTCTGT CTCAAAAAAA AAAAAGAAAA
6361	AAAAACAGAG AAAGAAGAGA GGAGAAAAAC AAGAACAAAA AATAACAAAA CAAAAACATG
6421	GCTTTCCCTT CATGGCATCT GCTTCATCTG CCTATTTGGT AATGATCAGG GCACTACACA
6481	CCCAGTGCTT CATACCCTGG CCATGTTTCT GTTCTTGGTG TCACCACCAA GTTTACTAAA
6541	GATGGTTCCA GAGTGACATT AGCAGCCCCA CACCCCAATT GCAGCTAGCA GTTGAGGAGA
6601	TTTCTGGCTT TTTGTCTAAG AGGAAGGTTC TTTGGCTAGG AGATATACTG AGAAGGACTA
6661	GGAAAAGGGG TGTCTAAGAA ACTTGGAGAG CACATTTTTC AAGTCAGAAA GAACATAGAC
6721	ATATTCTGGG GGTGGGGGTA GTAAGATAAT GGACCCTCCT AAGGGAAGGA TTGTGGGGTT
6781	TGCCTGAAGG GGCTGAAGCA GACCACTGAG CAGGCCAGAC CACCAGCAGC TTTTGAGAGG
6841	TGGGAACACT GCAGCTGAAG TCACTTGTCA CCTTCCCAGG TAGTTCTTAC TTCCAGCTCT
6901	GGCAGGGCTA GATAGCCTAG GAACTCCCAG ATAGGAGTTC TAGTTCTTCT TCTCCCAAGC
6961	TGACAGAACG TGAGCTCAGA GTCTAGGGAC ACTCCAGGTT AAGGACGGGG CCATTCTTGA
7021	TTGTCAGCAC AGATAGATTT TAATTAGAGA GCAATGACAT GACAGATAAA CAGCCCCTTA
7081	TCTAAAGGGG TACATCCCAA GACCCTGGAG GACTCTTGAA AACCCAGATA GGAGCCAGCC
7141	ACGGAAGCAT ATACCTTTAA TCCTAAGATT TGGGAGGCTG AGGTAGGAGG ATCTCTGTGA
7201	GTTTGAGGCC AGTCTTGTCT ACAAAGTGAA TTTTGGGACA GCTACACAGA GAAACCCTGT
7261	AAGAAAAAAA AAAAAAAGAA AGAAAGGAAG GAAGGAAGGA AGGAAGGAAG GAAGGAAGGG
7321	AAAGGAAGAA AAAGATAAAG GAAGAAAATC CAAATAGGAA AGAATCCCAT ATATACCATA
7381	TTTTTCTTAA ACATACATAG GTTTATTCAT TCTCTCTGTG TCTGTGTGTC TGTGTGTCTG
7441	TGTGTCTGTG TGTCTGTGTC TGTCTGTCTG TCTGTCTGTC TGTCTCTCTC TCTCTCTCTC
7501	TCTTTCTCTC CCTCTCTCTC TCTTTCTTGT CTCATAAATC TCAACACTCA GGGACCCAGA
7561	AGATATCCCA GTGGTTAAGA ATACACACTG CTCTTGCAGA CCTAAACTCA GTTCCTTGTC
7621	CCTACTTGGG GCAGCTCACA ACCACACCTG TAAGTCTAGC TCCAGGGAAT CCACACCTTC
7681	TGGCCTGTGC AGGCACCTGT GTGAAGGAGC ACATATCCTT CCCCATAATT AAAAAACAAT
7741	CATTGAAAAA TAAAACTCAA CCCCCTCCCC CGGGACTCAA ACCAGAGGTA GTCTCCCTGC
7801	CGTAGGCGCT CAAAAACTGG ACTTTCAGGT GTGAGCCTCT AGGCCAGGCT GCTTTTCTTA
7861	ACTGGCTACC GTGCTCTTGC CTGAAACTTC CAGCTTGAGA CCTCATAGTA AAAAGAACAT
7921	ACACGTCTTC TGTCTGTACT ATTTTACAGA CGGCTGACAT GTTCATACCA CGTATTTTAG
7981	CAATTTCAGC ACTTGGTATA TTTTCTGTCA TTCTCAAATA ACTTTCACCT TGCCACTTAG
8041	GGCAGTCCAA GGCTCCTCTT AGATATATCC AAATTATCAG CCACCACTTC TGCCTTTACT
8101	AAGTAAGACA GGGTACTTAA CATGGAGTAC TTAACACAAG CACTGTGATC TGAAGGTGGA
8161	GACTGCTTGC TACTCAGTCA CAGCTTAGCA TTGCTAGAAC AAATCCTGAA CAAAGGGTAA
8221	TTCATGACCC AGGCAGGGCA GAGGCGGATG GCTGTTCTTG CTCCTCAGAA ACCCCTGTGT
8281	ATAATTTCAA GCTTAGGAGT TGTTTGTCTT TGGATGGAGA GGGTCAGACC TAGGGCTTCA
8341	CTCACACTAG GCAAGCACCG CAGGTCTACC TTCGAAGAGA AGAATTTTCA CTTAGCGTTT
8401	TCAGATATAG GTCAACCTCA GCTGGCTGAA ACTTTGACTA AGTGAGCAAC TGTGAGGGTG
8461	GGGAACACAT GCATGCATTT CTTCATGTTA TAACATCTAT TTATACATAA ACATATCATA
8521	TAAATATATT CTATTGCATA TAAATATACA TAAATGCACA CTCATGTATA GATATCAATC
8581	ACATAATTTA TGCTTTTATT CATAGATTAT CTCTGGGAGG TGTACAATTA CTGACAATAC
8641	CTGCACATGA TAGTACACGT TGTTCTAGTT AGGTTTCTTT TGCTGTGACA AACACCACAA
8701	CCAAAAGCAA CTTGCAGAGG GAAGGGTTTA TTTCAGCTTA CAGTTGTATT CATTATGAAG
8761	AGTTGGGAAG TCAGGACAGG AACCTGGAGG CAGGAACTGA AGCAGAAACC ATGGAATAAT
8821	GCTGCTTACT GGTTTACCCA CCATGACTCA ACCTGCTTTC TTATATCACC AGGACTGCTT
8881	GCCCAGGGAT AGAACCACAC ATGGGGACTG TACCTCCCAC AACAATCATT GATCAAGAAA
8941	TGCCCTAGAG TCAGGGATGG TGGCAAATGC TTTTAATCCC AGCACTCGGG AGGCAGAACC
9001	AGGCCTTGAC TGTGAGGTCA AGGCCAGGCT GGTCTACAGA TTGAGTTCCA GGACAGCCAG
9061	GGCTACTCAG AGAAACCATG TCTCATGGAA AAGAAAAGGA GGAGGAGGAG AAAGGAGAAG
9121	GAAAAAGAGG AGGAGGAGGA GGAGGAGGAG GAGGAGGAGG AGGAGGAAAG AAGAAGAAGA
9181	AGAAGAAGAA GAAGAAGAAG AAGAAGAAGA AGAAGTAGAA GAAGAAGTGT CCACTGGACA
9241	ATCTGATGGT GGCGTTTCCC AATTGAAGTT CCCCTTCCAA GATAACTCCA GGATGTGTCA
9301	AGCAGACAAA AACAAGAACC AAGACACATG TTTATAATCC CAACACTGGG GAAGTGGAAT
9361	AAGAGGTTTG GCAGTTTAAG GCCATTTTCA GCTACATAGG GAGTTCCAGA CTATCCTGGC
9421	TACATGAGAC CCTGTCTCAA AACACCAAAA TGCAAGGGAA AAACAAAAAG CAAAATAATG
9481	AGTACAAATA GCAGTGACAT TCTGGGGAGA CAGCCTGGAG GGGGGGATTG CTTATTATCT
9541	CTCCCTACCG TTTGGAGTTT TTAAAATCAT GAATCTAACC CCAGAAAAAA AAGCATTGAG
9601	ATTCTGGGAC ACTCGGGTGG TAGAGAAGAT CATCTGATCC TGTCACCTTT CGGGTACGTC
9661	ACTTTATTAA TCTCTCTGAG ATTCAGTTTC ATCACCTCTG AAGTGGTTTG TGTCGACGTA
9721	CAGTCCTCAG GACTAAGTAA GGCCACTTGG TGGCTGTGCC AAAGCACTGT GTCAGGGACA
9781	CGGCAGATGT CTGACACATC TTGTTAGATT CCTTTTCTGT CCTCCGCTCC CCTACCCCAG
9841	AGGTGGGTAC AGCCCCATGG CACCTCATCT TTAATGGCTT GGGTTTCTTT TCTCCAGCCA
9901	GGAAAGTTGT CGCTTTGGTG ACAGCTATTT TAAGTCAACT GACCTTTCCT GCAAATGATC
9961	CAGATGCCTC TATCTTAGGC TGGTGATGAC GAAGATGGCC TATGACGGGG TTCCTGGGGG
10021	TGTGTTGGGA GGTGGGGCAG GGGTGGGGCC CGGCATTTGT CAGACCCATA TGATCTTCTG
10081	GCTCCCGGGC TCTGCAGATT TCTCCTGCTG GAGATGCCTA CCTGCCAGCA ATCTTGGAGA
10141	AGACAGAAAT AGCAGCTTTG GGTTCCAGGT CCCCTCCTCC CTTTGGCCCA ATGTAGCTAG
10201	AGCTTTGGTT TCCTGCTGCT GTCTTGGTGC CTGGAGCCCT CTCTGGATGG TCATGGAGTC
10261	TTGTCAGAGA AGCAACTTTG GGCTGGCAGA CAGTCATTCC AGAAGACATG ATCTGGAAAA
10321	ACTGCTTCAT CGTTTCCTTC AGAGGCACTG TCCCGAGCCC ATTTCCTTGT CTGGTTCCTG
10381	AAATCTCAGG GATGCCATCA GAAGAAGGTG TTCTTGTGTT TACTTTGGAC ATGGTTTTCT
10441	GTAGTGCAGA CTGCCCTTAA ACTCTACGTA GCTGAAAATG ACCTTGGTCT CCAGACCTCT
10501	TGATCTGTCA GCATCCCTGG GAAATCCAGG GTTCTGTAAT CCTCCCCTCT CACCTTGACT
10561	TACTGTACCA GCATCAAACA TCCTAAACAA ATCCAGTGTT TAGCCAAATA CAGCGGTGCA
10621	TGTCTGTAAT CCCAGCCACC TGGGAAGCCG AGGCAGAAGG ATTAAGGGAG CTGGAGGCCA
10681	GTCTGTGCAA TTTAGCAGGA CTGTCTCAAA ACAAAATTTA ATGGTTAGGG GTGGGCATGT
10741	CATTTATTTG ACTCTTATCA CATGAACACA CCTGTAATCT CATCACGAAA CGACAAGGCA
10801	GGAAAATCAA AAGTTCAAAG TCATCTTTGG CTACATAGCA AGTTCTAACC TGACCTAGGG
10861	TATGTAAGAC CTTGTCTCAA AAGCAAACAA ACAAACCCCA AATAACAACA ACAACAAAAC
10921	AAAAAGCAAA CAAGGAGAGG GTGTGCAGCT AGGGATATAA TTCAATGGGT GAGGGCTTAC
10981	CTCACATGCA CGAGGCCTTG GTTTCAACTT CCAGTTGAAA TGAAGTTTAG TGGTAGAGTT
11041	CTGTGCAAGG CTGTAGTTTC AGCTCTCCAT ACTGCAAACT GGAAAGAACA ACAGTGACAA
11101	ACAGAAACAA AAAACCCCCA CAAACAATGT GCTTTCTCAC TCAATAAAAC CACCTCTTTA
11161	CATACAACTA CAACTGCTAA GAAAGTTCTT CAGTGTTCTA GAGCCTGAGC ACCTCAAATG
11221	GTTTCCATAA AGCTGTATGC AAACACTGAT AAGCCACGAG AAGCAACTGT ACAAAGCACC
11281	CTTTGATTTT CATAGTTTAT CTACACAAGG ATTCTAGGAA AGTGTGCTAG GAAAATTTTA
11341	TGTATCAGCC TTGCGGGTTT GTCCAATAGT TTTAGATTTT GCCAGTGAAG ATTTTCCTTT
11401	CTTTATTTTT TACATGGGAA GGAAGTTTAA TTGGGGGAAG GGACGGGAGT GGGCTTTATT
11461	TTTATTTTTT AATGAGACTA GCATTTGCAT TGGTGGACAT TGAAGGAAAC AGTTTCCCCT
11521	CCCTAATGTG TGTGGGCCTC ACCTAACTCA TTGAAAGTCT TAGATAAAAC TAAGCTGAGT
11581	GAGTGAGTTG GCCCATACCT GTAGATGGAA GGAAAAGGGT CTTGAGTTTT GGTTTATCCT
11641	AGAGAGAACT TGATCCCCCA AACACCAAAC TTTCAAACCA AACCCCAGCC TCCTCAGTGT
11701	GAAGGGATGC TGTTACATGA CCACCTATGG ACTCAGACAA CCTCTCTTCC CTGAGTCTGC
11761	TGGCTTACTC ATCAGAGTCT GGGCTCACGA AGCCGCCACA CATATATGAG CCTCGTTCTC
11821	CCCACTCTTC TCTTGTGGCA CTGAGGTTCA AACCAAGGAC CTCGCACATG ATAGCAAATA
11881	CTGTACTGAA CCATAGAGCC AGCCCTTGTC AGTTTCTTAA CACAAACATA TAGATGTATA
11941	TGTATATGAA TATTTCCATG CTACCAATTC CATTTTCTCA GAGAACCAAA GAATACACCA
12001	AGTAGTCACA CTTGAAATTC TGTTCTGAGA TTGAATAAAA CCTGATCAAA TGTGAATTCG
12061	GTCCCTTCTC CCCCATCCCT GACGCCACCA CGTTGCTATA CAGACCAGGC ACAAACTCTT
12121	CTCCTTGTGA ATGTGTGTAA CACATGTTAC CACTGTGCTT GGCTTTTGTA GTTAGAAGGT
12181	TGGTTGATAT TTAAAAAAAA ACTTTAATAT TTAGTCATTA CTTTTTAGTA AAGATTTGCC
12241	TTGCTTTTAT TTTATTCATG TGCATGTGTG TGTATCTGTG TGAGTGTATG CCACGTGTGT
12301	TTGGGTGCCT CTGGAGATTG GAAAAGAATG TCAAAATCCC AGGACCTGGA GTTCCAGGCA
12361	GTTGTAAACT TCCCAATGTG GGTAATTATA ATGAACTTGG ATCCTCTAAA AGAGCAGAAC
12421	TCACTCTTAA CTGATGAGTT ATCCTTCTAC CCCCAAATTT ATTTGTTTTG TTTATTTGTT
12481	TATTTATTTG AGAGGGTCTC ACTGTGTAGC TCTGACAGTA TTAGAATTTA CTATGTAGAC
12541	CAGACTTGAT AAATGTCTAA CCCTAGAAAA AAATAGTTTT GTTTTGATTT TATGTCTGTG
12601	CCATCCACTC CTTGAACATA TATTTGGTAT CTGTGAAGCC AGTGAAGGCT GTTGGTTCCC
12661	TTAGGACTGG AGTTACAGAT GGCTCTGAGC TACCATGTGC ATGCTGGGAA ACAAACTCAG
12721	GTCCTTTGGA AGAGCAAAAA ATGTCCTTTG ATGGTGGTGG TTTGAATGAG AATTGCCCTA
12781	TCGAGCATAA AAACTTGGCA GCTTTGGCTA CATGGTTCTG GATTAAGAGT CAAGAAGGAT
12841	ACAAGAAAGC GGTTGTGGAA TCATCCCCCA TGGTTAAGGA AAACCACCAA AGCCAGGCTT
12901	GTGGCAGGGG AGTTCCTGCA TGGAGGCCAA GAGAAGCCAC TATGTCAAGC TGTGAAGGTG
12961	AAGCCTGGAT TGTGTTGGAG ACCCAAGCTA CTGGAGATGT AAGAGATGTG AGATAATGCC
13021	CAGGAGAGCT GCAGACAGGG CATGGAATCA GGCCAAGCGA GAGAAGTGTG TTGCAGTCAG
13081	CAGAACTGGG AGGGAAGAGT CATCTAAGTC CTTTGTCATC AGACATAGAG ATACAGGATC
13141	TGAAATTTGC TCTGCTGGGT TTTGGTCTTG ATTTGGCCCA GTACTTCCTA ACTATGTCCC
13201	CTTTTCTCCC TTTTAGAATA CTAATTTATA TTCTGTGCCA TTGCCGGTGG ATCAGGATGG
13261	TTCTCAGATA CTGTTTTAGT TCCATGCCTG TCTACTTCCC GTCATGACAG TCATGCACTA
13321	ACACTCTAAA ACTGTAAGCA AGCTCCCAAT GAAATGTTTT CATTTATAGA GGTGCCTTGA
13381	TCATGCTGTC TCTTCACAGC AATACAACAG TGATTAAGTC AGCTGCTGAG CAATCTCTCT
13441	GGCCCCAGAA GTATGCATGT GTGCAATTGT GTGTGTGTGT GTGTGTGTGT GTGTGTGTGT
13501	GTGTGTGNNN NNNNNNNNNN NNNNNNNNNN NAGGAAATGT CATTCTGTAA ATATGTTTAT
13561	CTTATTGGTT GATGAATAAA ACACTGTTGG CCAATAGGGC AACAAAATAG GTGGGGCCAG
13621	GATATAAGGA GGATTTTGGG AAGTGTAGGC AGAGGGGAAT TGTCATATGA TCCCAGGAAG
13681	AGACATAGAT GGGCAGAAAC TGCCTCTAGC TAACCATAGA GGTCTGGAGG TCTGTACAGA
13741	CAGGCAGGAA GTGATGTAGC TGGAAGAATC AGAATATAAG CAGGAACAAA CAGGAAATCG
13801	AGCTCTTCTT CTCTCTCCAC TTCAGAGATG CTGAACAGTT GAGATGCAGG ATGCCAGAAG
13861	AGTAAGAGGT CCCTGGACCT TTCTCCAGTA AGATAAGACC ATGTGGAAAT AGATTGATAG
13921	AAATGGGTTA GAGATTAAGT CAGAGCTAGC CAATAAGAAG CCGTAGATAT TGGCCAACCG
13981	TTTCATAATT AATATAGCAT CTGTGTATTT ATTTGGGGGA CCTGGTAGAC CAGAAAACTC
14041	GTGTTAGAGA CATCTTATCA AAGTTGAAAA AAGAAAAAAT GTGATAAAGT TAGGAAAAAA
14101	TATAGTAAAT GTTAAAAGCT AAATTCTAAA ACTACAACTT ATTTATCATT TCCTAAATGT
14161	TTAAAAATAT TATTTTATAA TGAAGATACT TAAAATTCAT TTCTCTGTCT TTTGAGACAG
14221	GGTCTCAGTG TCCTGGAACT CATTATATAC AGCAGGCTGG CTTGGAACTC ACAGAGATCC
14281	ACCTGCCTCT GTCTCCTAAA TGCTGGGATT AAAGGTGTGT GCCACCAAGC CTCAATTAAA
14341	ATGCGTTTCT TTTTCTTTCT TTCTTCCTGT CTTTCATTTT TTTGTTTGTT TAGATTTTTT
14401	TTTTTAGACA GGGTTTCTCT GTTAGCATTA GTTGTACTGG AACTCACTCT GTAGACCAGG
14461	CTGGCCATGA ACTGAGAGAT CTGCCTGCCT CTGCCTTCTG AGTGCTAGGA TTAAAGGCAT
14521	GCACCACCAC TGCCAGGCTT AAAATGTATT TCTTTTTTTA ATTTAGAAAT TTATTCTGTT
14581	TAATCCACAC GCTTTATATA GCTTTAGTTA AGAAATAAAA TAAAATGAAA CAGTGAAACC
14641	AAGAGACTAT GTCCAAGTCC AGGTCCTCCC AGCCTGCCAA TGCCAAGAGC TCTTTAGTTC
14701	TGTGTACCAA TTGGAAGAGT AAGAAAAAAA TATGGATGGG AACCACACAG TTTCATAAAA
14761	CAGATTTATG GAACTGAAGG GTCCTTGCTG AGTCTAGCAA ATTGCCTTTA CAAAAGAGAA
14821	AGAAAAAAGG GGGAGGTAGA AAAACAAAAC AAATCAACCC AAAGAGGACA AAATCCCAGA
14881	GTTCTAAATT GACTTAGGAA CCTGTCACAC TGGGACAGAA GCTTCAGCAT CCATGAGCTG
14941	TGCCTCCCCT GCTCTCTAGA GCTGGGATCT CGAGGTGTCA GCAGAGACCC CACAGGTAAC
15001	AGGAGCAAAA ACACTCACTC AGACCTTTGT GGTACTTCAA CAGTGGTCTC ACTTCTGGGC
15061	AAGCTTACAA ACCTATACAA AGTTGAAGGT GTACTTTACA TGAGTGCTAA ACTTCAAGAG
15121	GAAGGAAGAA AAAAAGGGAG GTGGAGGGGA CAGAGAGAGA GAGAAAAAAA CAAAACAAAA
15181	CAAAAACAAC CACCTCAGGA GAGGCAAGGG CATTTAAAGG AACCACAAGA ATGCCAACGA
15241	TATTAAAATG TATTTCTTAA TAGTAAATTT TATGGGAAAA GAGAGTCTCC TCTTCCTCCA
15301	AGTAGGCTAG GTAAGTACCT TGCCACTGAG CTCTATCTAT ACCCTTCAAA GTGGACAAAA
15361	TGACAAAGAT AGTTCATCTC CCCCAAAGGC CCTGTTGGGG TGCTGATTGT CACATCTGGT
15421	GAGATTTCTG TTTTTGTTTT TATTTCAAGA CAGGGCCTCT CTACATAGAT AGTCCTGGCT
15481	GCCCTGGAAC TCACTCTGTA GACCAGGCTG GCCTGGAACT CATAGACCCA CTTGCTTCTG
15541	TCTCCCAAGT GCTGGTGCTA AAGGTGTGCA CTGCCACTCT TTTTAAGTAA CTATGAGTTT
15601	CAAAACAAAT TAAAGAGCAC TGTTAAAGTG GCTTGTTGTG TAAGCCTAGC TTCAAGTCAA
15661	AGGCCCGAGG CTCCCCTACC AACCAGCTGC TATCACCTAG ACACTGTCTG TAGATCTTGC
15721	ACTGACTCAA AACTGTGGCC TAAGGTCAAA ATAATGGTCT TCCTGGATTC TGATGTGAGT
15781	GAGATTGTGT AGGAGGGCTG GCCGCTGGCC TGGCTTGAGT CACTCTCAGC TGGTTTCATC
15841	CCATTCCTGC AACTCTGTGT AAGAGGTGGA TGATCCTTGC TTAACTGATG AAGAAACCAA
15901	AGCTGTAGAA AGGATCATTT GCTTAACTCT TCACAGATGG CAAGAGGCAG AGTCAGGATT
15961	GGCAGAGTCA CTTCTGCCAA CTTCACCCTC CTGCTAACTC CACCCTCCTG CTAACTCCAC
16021	CCTCTTGCTT ATACTTGACA GTGGAGGAAA AGCCACTGAG GGAATTAAAA GTTGTTACTG
16081	GTAATGGTCA GGAAAAAAGC TGAACAAAGG AGATTAGATT CAGGGATCTT TTTCTGAAAA
16141	GAAAGAAAGA AAGGGGGACT ATAGTCTAGA AATGCTGAGA TAAAAGGGTG GATTATCATA
16201	TCTACTCTCA AACTAAAGAA GCAACTACTA GTCTCAAATA CTTTATATTG GTATGGATTT
16261	TTGTGTATTG GTACAAATTT AAGGTTATTT TTGTTATACT GTATATATGT TTTTCTTTCT
16321	TGTTTAAGGT ATTGTACCTG TATAGCTTAT TTAAAAATGC AATGTAAACA TATAGTCCTT
16381	GAAAACTATT TAAGATAATA AAGAAATACA GGTTAATAGT CATCTATAGC AATCAAACTT
16441	ATAGTCATGT TAGGTATGTT TTCAAGGGCA TACAGAAATA AATTTGAGAT AGATAGGTCA
16501	TCTTCAAACA CTCCAGAGAT CTACAGAAAA TGGCATTTAT AAAATGTTTT AATGACATAA
16561	GATTTTTCAT GATAGTGAGA AATGTCTACT CTTGGCAGCA CCAATTTACT TCAAAAATGG
16621	ACAATGGGCA TTGAAGAAAC TCCATGTGGA TTTTGCTTTC TTTGTGGCAA AAATCTAGCT
16681	ATCTGGGCAA GAAACTTCCC TTACCTTGAC TGCTGTCCTA ACTGGACAAG CAGGACATAA
16741	AAGAAATTGA CTGCTGAACT TTGCCAAGAT AGTATACATT AGTCTTTCAA AAATCCCTGC
16801	TTTACAAAAA AGTCTATCAG ATATTCTAAG CTTCTAGGCC AAAGATGGAT GCTTCAATGT
16861	TAACAGAGGA ATCTTCTGTG ACTGATGTTT CTGTCATTTC TATAGTTTTG AAAATTGCTT
16921	GCTCTGTTCT TCCCTGTTTG CTCAGGTAGT ATTATTTCCT TCTTGAGTGT CTAATGGAGT
16981	TAAAGACTAG ATAGTTATAG CTACAGTTTT CCTTGTAACC AAATTCAGAA AAGAAACTCC
17041	CAAAAGAGGT GTAAAAGTAT GAGGCTGAGA AATATAAAAA CTTAAATTTA TCTAAGAAAA
17101	TGTTTTGTTA TCTAAAAAAA AATAATTTTG GGTTAGTAAT ACAAGTTAGG ATAGAAAATG
17161	AATTAGGTAC AAAACTTTGG ACTCATCAAG AAAAAATAGA TAATGGAGTA TTTTCTCTGA
17221	ATTTGCCAAA TACAAATAGA CTGGGTATTG TAAATGTAAT TCTTACTTGA TAATTGTTCT
17281	TATTGTTTAT AGTTTATTAT GTTAGAGTCA AAACCTTTCT TTTTTATTTA GACAAAAAGG
17341	GGGAATGTAG AATATTTCTT TACACTGTGT GAAGATGTAT CACTGTGATT GGTTTAATAA
17401	AGAGCTGAAT AGCCAATAGT TAGGCAGGAA GAGGTTAGGT GAGACTTCTG GGAACAGAAG
17461	TCTCAGGGAA GGAAACAGGC TAGGTCACCA GCTAAATGAA GAGGAAATAG GACACTCAGG
17521	AGGAGAGGTA ACAGCCACAA GCCAAGTGGT GGAATATAGA TGAATGGAAA TGGGTTAATT
17581	TAAGTCATAG GAGCTAGTTA GAAACAAGCC TGAGCTAAAG CTGAGCTGTC ATAACTAAAA
17641	GTGGAGCTTT CATAATTAGT AAGTCTCTGT GTCATGATTT GGGGGCTGAC GGCCCAAAAA
17701	AGCCTGCTAC CCAAGTTCTT TTCAATTTTC AAGTTCTAGG ATTCTGGCCT TTTATTGGAA
17761	AACACTGTCA AGTTTCTATA GAGGTCTGAC TCCACAGTGT TGCCTGTGCA ATGAAATTTA
17821	TTTAATTTAT TCCGAGGCCT TGTGCACTCT GGATAATCAC TGTACCACTT AATCTATATT
17881	CCCATCCTTC ATTATAATTT AAAATGGTCT TATTAATCTG GTCACTTGGC TTTTTTTTTT
17941	TTTTTTTTCT GAGACAGGAT TTCTCTGTGT AGCCTTGGCC ATCCTAGAAC TTGCTCTGTA
18001	GACCAGCCTG GCCTGGAACT CACAGAGATC CACCTGCCTC CCCTCCAGAG TTCTGGGATT
18061	AAAGGCGTGT GCCACCACCT CCCAGTGAGT TTATGTCTTT GCAAATTATA CATGGTTTCA
18121	GTTTTTTTTT CTGTTTGTAA GTCACTTTAT TTCAAATGTA AAGTTTAAAA CAAGAAGCAA
18181	ATTACTATGA ATTTTTGTTA ACAGTCATTT TCCTTAACTA ATAAGTTTTA AATTTTCATT
18241	AATATGTTTT GATCATATTT TTTCCATGCC CCAACACCTC CAAAATCTCC CCACTCATTC
18301	AGTTCTTTCT CTATCTCAAA AAATGAAAAA TCCAAGCAAA CAACCATTAG ACAAAAAATA
18361	ACAAAACAAA ACAAAGCAAA GCAAAATAAA AGCACACGGG CTGGAGAGAT GGCTCAGAGG
18421	TTAAGAGCAC CGACTGCTCT TCCAGAGGTC CTGAGTTCAA TTCCCAGCAA CCACATGGTG
18481	GCTCACAACC ATCTGTAATG AGATCTGGTG CCCTCTTCTG GTGTACAGAT ATACATGGAA
18541	GCAGAATGTT GTATACATAA TAAATAAATA AAATCTAAAA AAAAAAAAGA AAAAAGCACA
18601	CAAAAAACCC AGAGAGTGTG TATTGAGTTG GTTAACCCCT ACTCCTCTGG AGTGTGATTG
18661	ATACAGCCAG TGCCGCTATT GGAGAACACT GATTGTCCCT GTCCTTACAG GTATCAATTG
18721	TGTGTAGCTC CTTGGTTAGG AATGGGGCTT TGTGTGCACT TCCCCTTTCA GCTTTGTAAA
18781	GGGTGTCCGA TTGAAGTTCG TATCTTCTGG GAGAGCATAA AATCAAAAAA AGATAAATGG
18841	ACTCCAGTGA AAAAGGAGCA AGCGGCACCT ATCTTTAAGG TAGAGAGGCA GAGGAGTGTG
18901	GTGTGGCCTG TCACAAACAC CCAATTCCCA ATCAGCTGGC GTCTACCAGG CTGCTTTCAC
18961	TTAGATGAAC CCTGACCTCC ATGTCTCCTT AACATTGCCA TTGTTTAACT GTTAGTGAGT
19021	CTGCCCTCTG TTCACTGAAA GACTTTCAGA AGGTGGTGTC GCCTGCCTTT AATCCTAGCA
19081	CTCGGGAGTC AGAAGCAGGT AGATAGAGCT CTGTGAGTTT GAGGCCAGGC TGGTCTGCAG
19141	AGTTCCAGGA CAGGCTACAG AGTGAAACCC AGTCTCACAA ACACCGCCTC CACCACAAAA
19201	AAAAAAGGAA ACAAGATAGA GTGAACAAAC CCAGCTACCT AGACATCTAT CTGGTAAACT
19261	GACTCATCCC AATCCTCCCT GCCCTCCCAA AGAGCTTGGC TGGCTCACTT CCCCAAATGC
19321	TCTTCCCCTT TAACATTTAA CTAGTTCTTG TCTCTTGTAT GGTTTCCTTT TAACTGTATC
19381	CACCACCCCT ACCTTGACTT TTGTCCTGGT TGGTTTTTAA TTGTAAACTT GACACACAAA
19441	GTCACCTGGG AAAAGGGAAC CTTAATTGAA GAATTGTCTT AGATTGGCCT GTGGGTGTAT
19501	TTATAGGGCA TTGTCTTGAT TGCCAATTGA TTCGGGGTGG GGAGTGGGAG GGTAGGGTGG
19561	GGGTGGGAGC AGCCCACTAT GGGACTCACT TTCCCTAGGC AGATGGCTAT ATTAGAAAGG
19621	TAGCTGAGCC TAAGCCAGCG GGTGAGCCGA GCCAGCAAGT AGCATTCTTC TATGGTTTCT
19681	TTCTTTCTTT TTCTTTTTCT TTTTCTTTTT CTTTTTCTTT TTCTTTTTCT CTTTCTTTTC
19741	TTTTCTTTTT TTTTTTTTCT TCCCGAGACA GGGTTTCTTT GTGTAGCTTT GGAGCCTATC
19801	CTGGCACTCG CTCTGGAGAC CAGGCTGGCC TCAAACTCAC AGAGATCCTC CTGCCTCTGC
19861	CTCCCGAGTG CTGGGATTAA AGGCATGCGT CACCAACGCC CAGCTCTTCT GTGGTTTCTG
19921	CTTCAGATTT CTGCTTTGAG TTCCTGTCTG ACTTCCCTCA ATAATTGTTT GTAACCTAGG
19981	AGTGTAAGAC AAATGAACCC TTTCATCCCC AAGTAGCTAT GGATTTAGAG TGGTTTATCA
20041	CAGCCACAGA GTGAAACCAG AACAACTTTC TAGTAGCCTC TTGTTCTACT CCAGCTGCTC
20101	CTCTGACTAT TCCTAAAAGG TAGTTGGGCT CAGGGAACCA CATCCCGAGA GATTCAGCCC
20161	ATATGAAAAT AGCTCCATTG TGTTGAAGAA ATGTGACCCT CCAGGATTTC AGGCATCAGG
20221	ATTCCATGTT GAAAATGAAA ACAATTATTT TCCTCTCTCT CAAGATTCCT TTAGTCACCT
20281	TCCCTTACCC CAGTTCCTGG CTTTCCTTCT AAACAAATGT TCAGGGAGGT TCAAACAAAC
20341	AGCTGTGAAG AGCAGCATCC CATACCCCCA CCTTCCGACC CAACACTTGC CAGTGCTATA
20401	AGTAGACTGG GATCATCCCT GGACACTGTG TTAAATTACC CATGACCAAC CTTCTAGCAA
20461	GCTCTCCTTT TCAGGATTTT GTTGTTTGTT TGGGTTTGTT TGTTTGTGAC TTGATCTCAT
20521	GTAAGCTGAC CTGGAATTTG CTTAATAGCC AAGGATAGAC TTACAACCTG TGATGCTCCA
20581	GCCTCTGACT CCTGAGTACC AGGGATTACA CATGTGTGGC ATCACAATGA AAGATTTTAG
20641	TTTGCTGAGA GAAAAAGTTT TTAAAGATTT TAGTTCACAG AGAGAATAAG TTTCCCACAG
20701	GCCTTGGTCC AGGACAAGGA AGTTGGTCCC AACCCGAGGG CAGACAAACA ATCCTTTTTG
20761	GGTCACACCT GGCTGGCCAA CAGACAATAA AGGACTTCTC AGGGTACATT CTATGGTTGA
20821	CCACTCTAAC ATGAGATCAT ACTTTGTAAT CAATCACTTT GTGCCCCTTG CCTGTATGCT
20881	GATCTGCGGT TTTTTACAGG CTCCTATATA AGGAGTCTGT AACCCTTGCT GGGGTGTGCA
20941	GCTTCCCCGA TATTGCTGAC ACCCGAATGA GCATTCGTTC AATAAACCCT CTTGCTTTTG
21001	CAGCTCTTGG TCTGGTTTCT GAGTCTTGGG GCCTCCTTGG GATCCTGAGA CCCTTAAGGG
21061	TCTGGGGGTC TTTCAACACT TAACTTTCCT GTTTTTAAGT AGGAAGATCT GAAATCCCAG
21121	ATTCCTGACT CCATTGCACA TTTTCTGTAT TAGAGGCTGT AGCTCTGTAT AGTGGGTTGT
21181	GTGGCTTACA CATGCTCTGA GCTGGAGATT CTAGGGACAC TTAGGGTAAA GTGGAGTGTC
21241	AGCCCCTTTC CCTGCTAGAC TGAGGCCTTT CTGTTCTTTC CTAACTGGGA GGCTGTATAG
21301	CACCCAATGT GTTCATTAAA CTCCATATGT TAGCACTGCA TGGAATCTGA CACACACACA
21361	CACACACACA CACCCTCTAC CACCACCATC ATCAGCACCA CCCCCATCAG CACCACCCTC
21421	ATCCCCCCAC CCCCCACCCT GCCCCNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNC
21481	AACTGGAGGG TAGCATTAGC ACCCAGATGC CATTAATGTG CCAAATATTT GCTTGCTTGC
21541	TTGCTTGTTT GTTCCAGCAT CCTTAGTGAA TGCTCCTGCC CTCCTGGTTA AAGATGGCTT
21601	TGGCATCTCT TGGCATCTTT CTTGTATTCT AGGCCTGAAA TAGGGATGAA TGGTGAAGGG
21661	CAAGGAGCTC AAGTGTCACT TACCACCTGC ACTTGTCCCT TTAAGGGGTT TCCCTAGAAG
21721	CAGTCTACAT TTCATTAGCC AGAGCTTTGT CACCTGGCTA CTTGTGAAGG AGGTGGTGAA
21781	GAAGCCTTAC CTTTGACTCT GCCACTTGGA GCCAAGTCAG GATTCTCTCC CTGGAAAGGA
21841	AATGGAAGAT TAATACCTTG TTGGTTGTTA GACCTAGCCC ATTATGCGCC ATGAGGAAAG
21901	AGAGACAACA GTGGGTCACT GATTGATCAG GGTTACAGGA CAAGGAGCCT TGTTTCTCCT
21961	AACAGCTCTG AGCGGAGACA GAAGTGGAGT ATATAGGCAT AAAATTCACA AACATTTGCT
22021	GCCACGTTAC AGGTACATTT TTTCACCAGT CAGAAATCAA AGATTAGGGA CTTTGCTTGT
22081	GTGTTCCATC ACTGTCAACT GACATACACG GCAAGCCTTT TAGTCCAACC AATCAGAATC
22141	ATTTGTTCCT TCTGTTGTTA GGAGCAGCCA TAATGATTCT AAAGAACTAA CAATGCATAA
22201	TGACTATTTT TGTAGTTTAG GGATGAGGTA TGTCAGCCAT TGGACAGTTC TCAGCTCCCC
22261	TAGGGCTTGG GAACTTGAAC TTTATTTCAT CCTGCATGTA ATGGAGTCTG AAGTCAAAAT
22321	GGCAGTACTT AGGTCAAGGT GCTCGTGCCT GCTGCCTTCA AGGTGGTTTC CCATTCCCAC
22381	CATACCAGAG ACTTCCTACT GCATCTCCAG TCAAGGACAC AAACACTTTT AAGTCCTGAC
22441	TGTTGATTCA ATCTATATAG TTACCAGCAT AGAGGCTAAG AGTCACACTG GCTTGCAGGG
22501	GACTTCTCTA GCATATGTGA AGCCCCGTTT GAATCCTAAA CACAAGAGTC TAAGCTTTGG
22561	AGTCAGAGAC AAGCATGTTC AAATCTGTAC GTCACCACCC TATAGACATA GACAAGTCCC
22621	TTGGGCTCAG TTTTTTCACT ACAGAGAGTA ATTGTTATTT CAGATTCCTA GGGTTGTGGT
22681	AATTAAATAG TTGAAAGATA TAGCCCATGG AACATAAAAA AAACTCAAAA CCAGGCACAG
22741	TGGCACATGT CTTTAATTTC AGCACTCAAG AGACAGAGGC AAGTGGATCT CTGTGAGTTT
22801	GAGGCCAGGC TGGTCTATAT AGAGAGTTCC AGGTCTACAC AGAGAAACAG GCTCAAAACC
22861	AAAGCAAAAG CAAAACCTCA ACTAATGTTC ATAAAATTAT GAAATTGCTG GTACCAGTGA
22921	CATGACTCAT TGGTAAAGAC ACTTGCTAGC AAGTTTAATG ATCTGAGTTT TATCTCCGGG
22981	ATCTACAATG TAGAAGAAGA AAAACAACTC TCAAGAGTTG TCCTCTGATT TCCACTTATG
23041	CAAAATAGCA TGGGAACACA CTTAAGCAGG TAGGTAGGTA GGTAGATAGA TAGATAGATA
23101	GATAGATAGA TAGATAGATA ATAGACATAA TTAAGAACGT TCAGTTGCAG CACAGTTCAT
23161	ACTGAACTGC ATTTGGACAC CTCTGTGAAA AGTCAGGAGC TCTCCTGTCC TCCTGGTGAC
23221	ATTTAAACAT TGAAGGCAAC TATTTTAACT GTCAGTTATA TACAAATCCA CTGGCCTTGT
23281	AAAATTTTAA AACATAACAG AGGAGGCTAA AGTCCTGTTT AACAACCCTC TCCTTTTACC
23341	ATCCCAGGAA GCCAAAATTG TTCACAATTT GTTCTCTTCC CTCAGGCCTT CCATATTTCA
23401	AATACCACAT AAAACACCTA TGGAAAAACA TGAGGTATTA AAAATGTCAC TTGGAAATCC
23461	TTCTTCAAAC AAGCTTGTTC TTTCTTTTTT CTTTTATGTA CAGTGAATGG AATCCAGGAC
23521	CTTTGCAGAT GCTAGGCGAG TCCTTTACCT CATTCCTCTT TCGATTTAAA ACTTTTTCTT
23581	GTTTTGTGGA GACAGGGTTT CTCTGTGTAG CCATAGATGT CCTAGAACTA GCTCTGTAGA
23641	CTAGGCTGGT CTCAAATTCA GAAGCCAGTC TGCCTCTGCC TCGGGAGCGC TAGGATTAAA
23701	GGTGTGGGCA GAGTGCTAGG ATGAAAGGTA TGCACACCAC CACTCCTGGT TGATTTTAAA
23761	AAGATGCTTT TTAAAAAAAA TGATGTGTAG GTAGTGGGGG GAGAGACGGT TTCATGCCTA
23821	AGAGCACTGA CAGCTCTTCT AGAGGACTCA GGTTCAATTC CCAGCACCCA CATGGCAGCT
23881	CATAACCATC TGTAACCCCG GTCCCAGGGA ATCCAACACC CTCTTCTGGT CTCTGTGAAT
23941	GACAGATATG CATGGGATAT ACAAACATAT ACGCAGACAA AACACTGTAT ACATTAAATA
24001	AGTACAAATT TAAAATATGT GTAGGCATGT ATGTCTGCAT GTGGGTATGT GTACACTGAA
24061	TGCAAGTTCA CTTGGAGGCC AGAGATATAT AGATCCCCTG GAGTTGCAGT TACAGATACT
24121	TGCGAGCTGC TGTGAGTGTG CTGGGAACCA AATCCTCTGG AACAGCAGCA AGTGCTCTCA
24181	CCTGCTGAGC CATTTCTTCA CCCGCTTCTT TCTACTTTTT ATTTTGAGAC AAGGTCTTAC
24241	TAAGTTATAT ATTCACTTGG GGCTTGAATT CATTTTGTCA GCAGGCAGAC CATAAACTTG
24301	CCTTCCTCTT GCCTCGGGCT CCTGAGTAGC TGAGACTTCA CCATGAGGTC TGGCTTTGAT
24361	TACATTTTTC TTTGTTTTCT TTTTGGGGGT GGGGCTGATC ATGAACTCTA AATAGCCAAG
24421	GATTGATAGT GAAGTCCAGA TTCCCCCACC TATCACCGGG TGGAATTACA GGTGTGCACT
24481	ACCACACCCA ATTTGGTTTG ATTTTTTTTT TTTTTTTCAG GACAAGCTCT CCTTTTATAG
24541	CTCTGACTGG GTTGGAATTT ACTATGTAGA CTAGGCTAGT GTCAAAATCA CAGAGATCTT
24601	CCTGTCCCTG CTTCCTGAGT ACTGGGATTA AAGGCATGTA CCACCACACC TTCGGGTGTG
24661	GTGATGCACA GCTTTAATCC CAGCACTCAG GCAGGCGAAT CTCTCTGAGT TTGAGGCTAG
24721	CCTAGTCTTC AGAGTGAGTT CCAGAACAGC CAAGGCTACA CAGAGACACT TTGTTTCGAA
24781	AAACAAACAA AAACAAAAGA GGCTAGCCTG AAACTCCTGA TTCTACCAGC ACCTCCCAAG
24841	GGCTGGGATG ACAGGTTGTG GCCCCATGCT CTCTGCCGGG GCCTCTCTTT TCTTTCTTCT
24901	GTTTGAGGTA GAGGCTTACT AGGTTGGCTG GGTGAGTTGT GAACTCACTC TGCAGCCCAC
24961	ACAGGAACTG ATCTTGTGAT CCTCCTGCCT CAGTCTCCCT AGCAGCTAGG ATTGCAGGCC
25021	TGCACCATCA GGCCCATCGT ACACTGTTTT CTGAGTTTGA AAATTGCCTC TGTTGTTGAC
25081	TATAAGGCAT GCTCTCCTCC TAACATTGTC CTTGGTGCCT CTGCCACCCT TTGGGACTAG
25141	AGAGAACAGA TCTTATTCCT ATTTCACATG CTGTGCCAAC CCAGTAACAA ACTCAGATTC
25201	CTGCTTCCGC CCCCACCACC CCCATCTAAT TGTTCAGTGT TTCTGTGAAG ATAAACACGA
25261	TCATCTTTGT GAAAGCCACT TAAGTTCCTT TCAAGGTTGG GATATAAGTT AGAGTGATAG
25321	CTTGTTCCCA GGGTGGGGAG AGCATGTGAA TTCCCCTCTC GCTCAAGTAG GCTATACTAA
25381	TTTTCATTTA GATATTTCTG AGGCAAAGTC TCATGCTGGC CATCCACCTG CCTTAGCTTC
25441	TCAAGTGCTT GGATTACAGG CATGAGCTAC AATATCTGGC TTAGTTTCAA GGTTGTGAAA
25501	ATTATACTGT GTTCTGATGA CCTGAGTTCA ATTCCCTGGA CCTGGGTGAT GGACGGAGAG
25561	GACAGACCCC TGCAGATTGT CCTTTGACCT CCCTGTCACT ATGTGAACAC TCGTGTACAC
25621	ACACACACAC ACACACACAC ACACACACTA AATGAATGTA ATAAAATATA AAAAGGTGTT
25681	CACTAGTTAA TAAGACATGA GAGAAAAAGC TTACCATCCC TAATCAATGG GGAAGCATTG
25741	AATATAAGTG ACTGTGGTCA TGGAAAGCAG TATAGAGGTT CCTCAATAAA CTGGAATATA
25801	GCAGCATATA CTTGTAAGCC TCCCACAACA GGAGAAAGGT AAAGAGGGGC GGCCACTCTG
25861	GAATATTATT AATATCCTGT TTCATAAACA AGTAAATAGA ACAAACCCCT CAACAACAAG
25921	AACCGGTGTG CTGGCACACA CCTGCAATCC CAGCATTTGG GACTTGGAGG CAGCACAATT
25981	GAAGTTCGTT CTTGGTCATC CTCAGCTATG TATGAAATCT GAAGCCTGCC TGGCCTACAG
26041	GAGACCCTGT CTCAAAAAAA TAAACTAAAT AGATTAAAAT GAAAATTAGA AGCAGGTAGT
26101	GTGGAAGTTG AATAAGAATA GCCGCCATGG GCTCATGTAT TTGAATGTTT AGTGGCACAA
26161	CTTGAGTGAG TTAGGAGGTG TGGCCTGTTG GAGTTGTGTG TCACTGGGAG TGAGCTTTGG
26221	GATTTTAGAA GCCCAAGCCA GGCCCAGGGA CTTGCTCTCT TCCTGCGATC TGAGGAACTG
26281	GATGTAGAAC GCTTAGCTAC TTCTTCAGCA CCATGTCTGC CTGCATGCTG CCATGTTCCC
26341	TGTCAAAATG ATAATGGACT GACCCTCTGA AACTTGGTCT CTTTTGGCTG AGGAGTTAGC
26401	AAGGTAAGAG GTGGCTGTGG CTTGCTCTTG TTTCTCTCTC TCTGATCTTT CATCATTTTC
26461	TCCCGTATCT GGCTGTGGGT TTTTATTATT AAGAGTAATT AGAACTCATG TTACAGTGGT
26521	ACATGCATGC CACAGACCCA GTGTGGATGC CAGAGGACAA CATGTGTAAA TTTTTTCTTT
26581	CCTTGTATGT GCGTCCAGGC TAGTTTCAGA CTTGTGGGCT TCTGCTTCAG CCTCCCAAAG
26641	GTGGGGACCA CAGGCTTATA TACCTACACT CACCTCTTTA TTCCCAGTGG ATGTGTGTGT
26701	GTGTGTGTGT GTGTGTGTGT GTGTGTGTGT GTGTTTGTGT GTTTTACACA GACCTGTACC
26761	ACATTCATTT GGTTACTTTT TTTTCCTGCA TTTTGTTTTT AGGTAGGGTC TCACTATGTA
26821	ACCCTGACTG TCCTGGAACA TGCTATTTAG ATTAGACTGA CCTGCTGGTC CCTACCTTCC
26881	GAGTGCTGGG ATTAAAGGTG TGTACTACCA TACCTGGTGA TTAGTTTGTC TTTTGAGACT
26941	GGGTCTCTTG TAGCCCAGGT TGGTCTTGAA CTCCTGGTTT TCCAGACTCT ACCTTCCAAA
27001	TATTGATATT GCAGGTGGTC ACTACCATGT GTGGAATTTA TTTTTGAGCA GTGTTCTGTG
27061	GGTGGATGAT AAGGTCATGT CTATGGTAAA ATTGTTTCTA ATAATGATGA ATAGCTTCAT
27121	GTGTGTATGC ATCTATCAGG TTTGTTCAAC CTGAAGTGTA GGCCTAATAT TTGGATTTAT
27181	TTAGCCAGTG ATAGCTATGA ATTGAGCCCA GAAAAAATCA TAAACTTGAC TAAAACATCT
27241	TAAGAATTTT GTAACTTCTT TTGTAACTCA ACTGTATTGT TTCTGAGCAT GAATGTTGTA
27301	AATGACAATG TCAGCTGCCA TGTCAAAAGG TTGAACATTA CTTGGCAGTG GTGGCACACA
27361	CCTTTAACTC CAACACTCAG GAGGCAGAGG CAGGCAGATC TCTGAGTTAG AGGCCAGCCT
27421	GGTCCACATA GGGAGTTCCA CACCAGCTAA GGTGACAGAG TGAGACCTTG TCTAATTTTT
27481	TTTTAAGGTT GGACATGTAT AATTCCAGAG AATAATTTTT CACTAATCGG AAAAGAGGCA
27541	GTTTCAACTT GGAGTTCACA AGATTTAATC TTTCTTTGAA GATTTATTTA TTTTTAGTTA
27601	TGTGTGTGTA TATATGTATG TATGTATGTA TGTATTGGTG TGTTAAACCC CTGGGGCTGG
27661	AATTACAGGT GGTTGTGAAC CTGATGTTGT AATAAGCTCC CAGACCGTAG CACAAATGAC
27721	TCTATGAAGA AAGTACCATT CAGGCTGTAA AATCCACATA GACAGCACCA CCTGGAAAAA
27781	CTAAAACAAA AATCCAATCC ATCAAACTCC ACAGATCTGG GAAAGTATCT AAATGCACTA
27841	ACCTTGATTT TTGGCTTCTG TAGTTCTGCT TCTGGCTAAC TATTCTTGTT AACTGAAGTA
27901	TGTGAACCCA CAACATGGTT TTTGTGCTTA AAAGTTCTCT GTTCTACAGA ATGAATTCCA
27961	GGACAGCCAG AGCTGCATGG AGAAAATCTG CCTCAAAACA AAACAAACAA ATAAAAACCT
28021	TGAGAAAGGC TCAGGGCTAT ACTGGTATCC CATACACTCA GTGTAGTCGC CAACTGTCAA
28081	AGACTTTTTG TTGACTTAAA CCCATTTCTA AGCAGTATTC TCTTATGGAT ACCCCTTACA
28141	AGTGGGTGCT GGGACTTGAA CTCAGGTCCT CTGGAAAAGC AGAGGATTTC TCACCTGCTG
28201	AGCACCTCTC CAGGCCCATA AGATCTATCT TAAGACAAGA CCTGAGCAGC CTTATGGAGA
28261	TGGCAGTCTG GGGAACCACT GGTGCGCCTT TTCTTCTGCT GGTCACAAAC TGCTGTGGGA
28321	ATTTCCATCT GAAGTTCCTG CCTCTTCTCA CATTCCATGA TATGAGAAAG CTATCAATGT
28381	TCTAAATCTG TTTGCTTTCT GCTTTGCAAG ACCTTTCTCT TTCCTAGGTC ACCCTCCAAG
28441	AGTTCTTGAC CTCAGCCCCG ACTGGTGTCT TGGGATGGGT GACTGGGTTC TGGGGGCTTC
28501	CCTGTGCCTT GGAATATGGT AAAAGAGCAT CTCAGGTATT CACTCAGTAG ATGCTAGTAG
28561	CACTCCCTCC CTCCATTTCT GTCTACAGAT GTTGCTAGCT GGCCCCTATG AGGTAGTCTT
28621	TGCCCCTTTG TTATTGCTGC AGACTCAGAA AAAAGAGGAA ATATAGAACT CCTCGTGGTC
28681	TTCTACTCAA TATCCAAGCA AGGGGGAACA ACTGAGCATC CATACACTGC TGTTTTGGCT
28741	TCTCAATTGC TTGCTTGTAC ATCACCAAGA AGCTTTCATT GGTCAGTGTA AACAAGATCT
28801	GGGAGTTGAT GGTAGAGCAG TTGGATGAGT GACTCTGTCT TTCACCTTTG TTGAGTCATT
28861	TGGTGTGTGC ACATTGTGGG TCCCTGCCTC GCTTCCCATT AAATGTCAAG GTGAACTTTA
28921	TGAGGTTGAA ACTTTTATAT GTAGTGCAAC TGTACTCCTT CCTCTCTATC TCTTCCTTCA
28981	TTTTTCTTCC TTCACCTTCT CTTCCTTTAA AAAAAGAAAA ACTTTAAAAA ATGTGAATCT
29041	GATGTATCCC AGGATGGCCT CAAACTGTTT GCTTTCTCAG AAGATGACCT TGAACTTTCA
29101	ATCCTCCTGC CTCCACCTCC CAAATGCTGG GCTTACAGGA ATTCATCACC ATGCCTGGTT
29161	TTCCTCTCTC CTGGTGAGTG AATCCAGGGC TTCATGCTTG CCAGGCAAGT GTTCTGCTGA
29221	CTGAGTTACA TGCTTAGCCT GTATCCACAT CTTGACTGAG TAATTTCTGC ACCAAAACTT
29281	TAGGTTTCAT CTCAGTGACT CTGCCAATGT GTTTCCATTT TAGAGTGACG ACTGGCCTTA
29341	GAGGAGAGTG TAAGAGAAAT AGAGTCTCTT TCCTTGGTCT GCTTTTTAAA TTTTAATTTC
29401	TTTTTAGACA TCTTATATTT ATTCATGCAT GTGTGTGTAT AACTAGCAGA ACTCAGCTGT
29461	CTCTTTCTAC CACTCAGGTC ACCAGGCTTG GTGGCAGGGA CTCTTACCTG CCTTCGAGCA
29521	GGCTCTGCCC TCCTTTTGGA GAAACTGGTT TGCAGAAGGA AGAGACAGCA CAGCTCAGAA
29581	GACAGCCGTG CTTTCAGATG CCTGAGAATC CTGCCAAGGA CACTGCTGCA TTCTCCTATT
29641	CTTTTGTAAG GGTCCCATCT CTGCTGAGCT AAACTGGGCT TTCTCAGCCC TTCTCCTCTG
29701	ACAGTATTTT AAAACCCTAC CTAAAGGGGG ATGGAGAGAT GGCTCAGCAA TTAGGAGCAT
29761	ATCCTACTCT TCCGGAGACC CCTACTTCTG TTCCCAGCAC CAATGCTGGT CAATTTACAA
29821	CTGTAACTCT GCTCCAGGTC ATCGGATGCT GCTATCCTCC TCAGGCAACT TCACTCATGT
29881	GCACATACAC ATACTTAAAA ACAAAATAAG TCTTTAAAAA TCACCTAAGA AATATAAAGG
29941	CACATATCAT AATTCAGCCT GCTGTGACGT ATAGCTATAG TCCCAGAATT CTGAAGGCAG
30001	AGGCAAGAGG ATCACCTCAA GCTTGGGGCC AGCGTGGTCT ACAGTGAGAC CCTGGAGACT
30061	TTAATCTCAA AATATGTAAC AAAACAAATA TGTAAATAGA CATATATCAC AATTTATATT
30121	TAAGTAAAAT GGGGGGCATT GGAGAGATAG CTTTGTGGTT AAGAGCATGT ACTGTTCTTG
30181	TCAAGGACCC AAGTTTGATT CCCAGTGTCT ACACTGGTTG GTCTCCAACC CAATTCCAAG
30241	AGATCTGCTG CCTTCTTCTC CTCTCTACTG GAACTGCATT CATGTGCAAA TGTCCATATG
30301	CACACACATA CCCACATGCA TACACACAAA CACATACATA CTCATTTTGC CTGACATCGT
30361	GGTAAAGTGG GAAGACTTGT TGCCCTATTA CTTGGTCTTC ATTTGCCTAT GAGCACCATG
30421	TTGGCATGAA CTCATTCATT AATATCTTTC CTGTACAACT CCCCAATAAC CAAGATGACA
30481	CTTGGCACAC ATTAATTGCT AAGTATAATG AAAATTTAGT TTAAATTAGC TAAATAATTT
30541	AAAGTTCCCC CTCAAGCCTC ATGCCTGATT TAAAGTAGTA CTTATTAATG CTGGGCCTGG
30601	TGGCATACAT TTCTAATTCT AACACTTAGG AGGCTGAGGC AGGAGGATGG CCAATTCAAG
30661	GCCAGCTTAG CCAGCTTAGT AAGACCTTGT CTCCAAGCAA ATTACAGCAA AGTCTGAGAT
30721	ATAGTTCAGT AATTAGGGTG TTTGTCTACC ATGTGTGAAG ACCTGAGTTC AGTTTCTAAC
30781	AACAAAACAA AACTAAACAA ACCAGAACCT AGAGGTTATC ATTTATTTTT TTATTTTTAT
30841	TTTTTTTTGG AGTTTATGCC TTTGGATTAT CCATTCTATG TCCAGACATC AGTACTGCCA
30901	TGTTACAGTC AATAAAAGTC TTCCTTCATC ACCCTTAATC TTATCACCAC TAAAGTCTCT
30961	ACTTGACAGA CATGCCATAC ATAATTATAG CTGTTACCTT CTATCATAAA GTAGACATTT
31021	TATTTTATTT GTGTATTCAT TTTCATTTAT TTTGTTGTTG TTGTTGTTTT ATGAGACAGA
31081	GTTTCTCTGT GCAGCCCTGG TTATCCTGGA ACTCACTCTG CAGACCAGGC TGGCTTCAAA
31141	CACACAGAGA TCCACCTGCC TCTGCCTCCT GAGTGCTAAG ATTAAAGGAG TGTGCTGCCA
31201	TCTTCCCAGC AACATTCTAA ATTATTTTTT GTTTATGTTT TGAAATGGTC TAATGTAGCT
31261	GAGGTGGGCC TCAAGCTTGT TATATAGCTG GGGAACCTTG AACTTGTGTT CTTCCTACCT
31321	CTAGAACTCT GGAGTGCTGG AATTACAGGT ATGAACCATC ACATTCCAGT TTTAATCAAA
31381	TCCAGACTTC ATGGGTACTA GGAAAGCACT CTACAAATTA AACTTCACCC CTAGTTCATA
31441	TATATATATG TGTGTGTGTG TCCATGTATG TATGCCTACA TGATTTTATG TGTGCCACAT
31501	GTGTGCAGGT GCTCTTGGAG GTCAGAGGGT GTCAAATCCC CTGGCACCTG AGTTATAGGT
31561	GGTTGTGAGC CACCTGATGT GGATTCTGGG AACTGAACTT TGGTCCTCTG CAGGAGAAGT
31621	CACTGTTCCT CTGAGTGAAC GTTTCTACTT TTTAATATAC TTCCCATTCG AATTAGAAAG
31681	TAGAAGCTCT CGGAGGTTGA GACCTTACCT AAAGTCACCC AACTAGTAAG AAAACTAAAA
31741	TATCAACTTG GTTTTCTGAG TTTTAAATAT TTTTTCCCAA TGTGTAATTA CACAGGAGAA
31801	TTAATGGGGA CACTTCAAGG TAAAACAGAA GCTTTAGACA TAGCAAGGCA TGGTGGCACA
31861	CATCCCATTG AGAGGCAGGA GGATCAGGAG GCCAGCTTTG GCTGCATACT TAAGAGGCAT
31921	CCAGGGCTAC ATGAGGCGCT ACCTAAAAAA ATTAAATTAG GCAGGGCGTT GGTGGCGCAC
31981	GCCTTTAATC CCAGCACTCG GGAGGCAGAG GCAGGCGGAT CTCTGTGAGT TCAAGGCTAG
32041	CCTGGTCTTC AGAGCGAGTG CCAGGATAGG CTCCAAAGCT ACACAGAGAA ACCCTGTCTT
32101	GAAAAACCAA AAAAGCACTG GTCATTGTCA TTTTCTTTCC TAACAGGGCA CTGGAACCCT
32161	GATGTTGGTT GGCTCCTAGA TTTCTTCTCC ACAGCAGAGA GTTCTTGCCC TGTTAGAGCC
32221	AGAAGGATGC TCTGGAGAGT CAGTATATAG CAAAGCAGGG TCATCTGGAG TAGTAAAAAC
32281	CCTCTGGCAC AGTCAGACCT CATTTCCTCT TGTCCTGTGC TCGTGGCTCT AGCATTATGC
32341	AAGGAGAGGC GCAAACAGCA AACAATTTGG AAGGGCTAGC ACTTGAGCAA CTCTTTGTAG
32401	CTTCCTCTTC TCTACTCTTT TGCCCCTGGC TTCTACTGGA ACAGGTGACT TTCCATTGCA
32461	TTGCATTCTC CAAACTCAGA TGATTTTGAG AATGTGGCAC TACTAAAAGT CACATGGACA
32521	TACAAGGTAC AACTAGAACT ATCCCGGGAA ACAGTGATAC ACGATCTAGT TTGAGGCCTT
32581	GAGCCATAGC TTGTCAGAAG CTCAGAAATG ATTGAGTCTC TGGGAGCCCT CACCTCAGCA
32641	TCCCTGCTTG CAAAAGGCTT CTTGAAGTAG TAAAAACTGC TGGGACCTTG TCTAGGCTGG
32701	GTAACCTTGC ATAATTACTC AACCTTACTG AGCTCAGTCC CCTCCTCTAT AAAATAAGTG
32761	CAACAGTATT TACCTTAGTG GCCCACCTGA AAACATCACA GCTGCCATAG CTAGCTCTTG
32821	GCTTTTGTTC TATCTCCTCC TCCCCCTACT TTCTCTTCCC TCCCTCCCTC CCTCCCTCAT
32881	TTTTCTTTAT TCCTTTCTTT GTATTTTTTT CTTTTTTCTT CCTCACACCT CTCCTTATTC
32941	CCCACCCTCC TCTCTCTCTC TCCCTTCCCA CTTCTCTTTC TTTCATGGCA GGATATCATG
33001	TATCCTAGCT ATACTTGAAT TCACTATATA GCTGAAGAGG AGCTTCCAGC CCTTTTGCCT
33061	CTGCCTCCCA AGTGCTGAGA TTATAGGTGT CCACCTCCAC GTCTACTTAT GCTTTGCTAA
33121	GGATCAAACC AGGGCTTTGT ATGTGCATGC TAGGCAAGAG CCAACTACAT CGCCAGACCT
33181	ATATAATACC CCTTTCTCAG CGAAACTGGG GTTGCTGATG GCTGGTGTTG GGGGAAGGCA
33241	CTAAATATTT AGCAGAAGTA TAGGAAAACT CTAGAAGTCT AGAGATCCTC AAAGTAAGTT
33301	TGGAGAGCCT TGGCCTTTTC TTAGTTGAAA GTCATGGTGC CTACTCACTT TGACTGCTCA
33361	AGGAATATCC ATTCACCACC TGGAAATAAG AAAGGAGGGA GAACCAGCTA GGGATGTGAC
33421	TTAGTAGTAG AGCACTTGTC TAGCATGAGC GTGGTCCTGG GTTCAAGCTC CAGTACAAAG
33481	GCTGGGTGGG GGGGTGGAGA AAGGCTTCTT TCCCATGGCG TTCTAGAGAT GGCGGGGAGA
33541	AACCACCAAT CCACATCTAT CTACAACAGT TCAAGTAGAA CTAATCTTGG TGGTATGGCT
33601	ATAGTAGTCC TAATCCCATC TCAGGGATGC TTCTCTTTGC AATTGATACA AAACACATTA
33661	CAGAAAACCA CAGTGAATCA AAATGCAGAG TTGTGGTGCC TAGTTCCAAT GGATGCATCT
33721	ACAGTACAAC TCCCATGCCT AAGGCTCAGG GATCATTGTG GAAGACAAAG ATCCTCCCAG
33781	GAGATCAGGG AGTTTGCTGT CTCCTAGGAA TTTCAGAAAA TACATCTGTA AAGGCTCACC
33841	AACGTGAATT CCTAAACATG AGCTGAACAA GGATGACAAT AGACATGCTA ACAAGGATGG
33901	GAAAAAGCCC TTGAAGCCTC AGACCTACAC AAAGAGCCGC AGTTGATTAA GGAATGCTGA
33961	TTGTGGGAGA AACCATCTTC CCAAATTGTT ATCTAATACC ACATAGTCAG CCCTGAAAAC
34021	ACACATGCAA ATAAGATTAT ACAAAACAAG GGGGTTGTAC ATATGTATTT AGGAATATAT
34081	ATATATATAT ATATATATAT ATATATATAT GTAACAATAA TTAATAGAAA AAGAGACCAT
34141	GAATTTGAAA AAGAACAAGG AGGGGTACAT GGAAGGGTTT AGGATGCTTT GACCCTTTAA
34201	TATAGTTTCT TGTGTTGTGG TGACCCCAAT CATAAAATTA TTTTTGTTGC TAGTTCACAA
34261	CTGTAATTTT GCTGCTGTTA TGAATTGTAA AGTAAATACC TATGGTTTTT GATGATCTTA
34321	GGCAATCCCT GTTAAACTGT CATTCAGTCC CCAAAGGGGT CAAGACCCAC AGGTTGAGAA
34381	CTGCTGATTT AGAGAGAGGA AAGGGAAGGG GGGGTGAAAT GCTGTAATTA TAATTCCAAA
34441	AAAAAATTTT TAAAAATTTC TTAAAGGAAC TGAAGAAAAG AGCTGAACAT TCTAAGCTTA
34501	AGGGGGGAAA GGTTCTGGAA TGTTACATTT TTCTGGTTTC CTTAGTCTCA GCAACAGGCT
34561	CCCAGCCTTC TGTTTGGACA GTGGTTTACA GGCATGTGAG CTCAGGGAAC ACTCTTCCAA
34621	GTGAATCAGA CTTCAGGAGA AGACATTCAG TTCAGGGCCC TGGGGAAAGT AAGGACAGAA
34681	CTCCATTCCT GAGAATTACC AGGTTTGCTC AGAAGATAAA ACTGGTGAGC CCAATGGCTG
34741	TGTGCACAAC CCTGACCTCA GTGTCTAGGA TAGCTGGACT CTAGCTGCTA GAAGATAGTC
34801	AGAGGGCCAT CCTTTCCCTG AGGCTAATCT GTGAATCAAG TAAACTACAG TCAGGAAGGG
34861	AGCTGGAGAT GGGGGCCCAG CAAACAGGTC CCCCTTAAAG CCCAGCACAT AGGTGGGGAA
34921	CCCAACCTCC CATTTTGTCT TCACCCCACC ACCAGGCCTT TACCAAGGCC CGAGGTTGCC
34981	ACTATTTTCA GCTTGCCAGG CTCTTTGCAG TTTTAGGGGG ATGAGGAGGA GATGCTCTGA
35041	GGTGCTGGGA GGCACATGGC GGGTGCTATT TATGGCTTGG GCTGAACTCC GATGTCCTAG
35101	AAAGAGTGTT TCTGACACTT TCTGCCTTCT GGGAATCAGG AGACTCATGA CAAACACTGC
35161	CTGGCAGTGT TTCTTTCTTG TTCACAGCAA GAAGTGTGCA GTCCATGGCA CGAAAGAGGC
35221	CTGAGCAGGG CAAGATGGAC ACGATGACAT CACTGAAGGA GCTTCCCAGG GGCTGTCTTG
35281	ACTGCTTCAT TAACTCATTC ATGCAGTTTA TTCAGCAGCT ATGCCTGTCA GACCCCATTC
35341	TGTCTGCACA AGACACATGG CAACAAAGGA GACTTACTAT TCCCATCTTC ATGGGTTTTA
35401	TGTTCTGGCA AGAGGAAGAT AGTAATAATT TTTAAAAAGT AACCAGTCTT GAGAGCATGA
35461	TAAATATGGT TGATAACAAT ATGCTATATT TTAAAAGTTG TGAGATAGTA TACTTTAAGT
35521	GTTCTCAAAA CAAAATGATG AATATGGGTG ATATAACATG TTAATTGGTT TAATTTAGCC
35581	ATGCCTTTGT GAACATACTG TATCGTGTAT CATAATTGTG CATGACTTTA TTTATGAGCT
35641	AAATAAATGA ATGGAAAAAA AAGTAACCAG TCTTGATGCT TACCTGCCAT CCTGGAAGGA
35701	AATGGAAATA GGATCTGCCG CCGCAGCATT GCCCTATGCT CTTATTTCTT CTCTTGAAGA
35761	GGTAGGGGTG TGTGTGTGTG TGTGTGTGTG TGTGTGTGTG TGTTACTAGA GACTGAGCTA
35821	CCGGCCTCAC ACATTCTAGG CAAATGCTCT ACTTTATATT AAACACTTTA TAAAACATTA
35881	AGCCTTTCAG GGTCAGCAAG GTAGCTCAGA GAGTCCGGGC ATTTGCTACC AAGCCTGACA
35941	ACCTGAGTTC GATTGATGAT CCCCCAGACT CACGTGATAG GAGGAAGCTG ACACCTGTGG
36001	GTTGTCCTCT GACTATAGGC ATGCACACAC ATCCCATGAA TAAATATTTA TACATTTTCA
36061	AATCATACTT ATTTTACAAT GATTTTTATT TGTTTGCCTG TCTTTCTGTC TGTGTAGAGA
36121	CAAGGTTTCA TGCAGCTCAG GTTGGCCTCA AACTCACTCT GTGGCAAGGA TGCCTTAACT
36181	TCAGGTCTTC CAGGTCCAGG TAACAAAATG TTCAGGAGGA ACCTGGTACC TCATCATAAC
36241	CGGTTCTAGA TGGTCTTCCC AGGGCTGCTG TAAGAAAGTG CTACACGACG AGTTATTTCA
36301	AACATTCTCA CAGTTCTGGG GATTAGAAGT TTGAAACTAA GGTGCTGAAG AGATTAGTTC
36361	CTTCTGGAAG CTCAGAAGAG CCATCTGGTC CATACTTTTC TCCAGGTTTC TCTTAGTTTT
36421	TGGCAATCCT TGGAATCCCT TGGTTTGTAG ATGCAGCTTC CAAAGCTCAA GATCTCTCTC
36481	CAATGCTGTG TGGCATTTCC CCGTGTTTAT GAGTGTCTAA ATGGCTTTTA AAAACATTTT
36541	TGAGATGTGA AATTCTGGCT GACCCAGAAT ATATAAACCA GGCTGACCTT TGTCTCCCAG
36601	AGATCTCCCT GCCTCTGCTT CCCAAACCTT TTGATTAAAG GTGTGTGTCA AGTGCCCAGA
36661	CCAAATGCCC TTCTTGTAAG GACAACGGTC ATATTGGATT TAGTGTCTAA GTGAGTCCCC
36721	TATGAACTCA TCTCGAACTC AGTTTGCATA GAACACTGTA CCATGCAAAA TAAATGACAC
36781	AGAGACTGAT ATTGGGGTTC ACACTTCAAG CTGAAGGTCA GAAAAGCAAA GCATTGGGCC
36841	ACTAGCTCTT ACCACTACCT CAGGCTGAAC GGGCTGATCC TGCTGCCTCT CCTCAGCATG
36901	GCTGGAGAAT ATCTTCATAT CCTCATTGTG GCTGGAAAAT GAATGCCTGA TATGGAGAAC
36961	TTGCTCCTGT TTTATATAAC TCCCTAATGC TGGGATTAAA GATGTGTGAT CCCAGGTGCT
37021	GAGATCATCT TTGTGTGAGC TGTTTCTCTT TAGGACTGGA TCAATTTTGT GTAGATCTGG
37081	ATGGCTTTGG GCTCACTGAG ATCTATCTAC CTCTTAATCC CTGGTCCTAG GATTAAAGGT
37141	ATGTACCACC ACATCCTAGC TTCTGGCTGC TGGGATTAAA GGTGTATGCC TGGCTTCGAT
37201	GGCTTGTGGC TGACTTTGCT TTCTGAATCC GCAGGCAAGC TTAAAAAAAT CATAAATAAT
37261	ATATCACCAT AGACCACACT TCCAAATAGG CTTCCATTTA GAGGCGCCAG TGGGTGATAA
37321	TGTAGGCGGT TTTACTCAGT TTTGTGCAGA TGGCTGGCGT CCTGTCTGGT GAGTTCAGAT
37381	TTTTTTTTTT TTTTTTTTTA AGTTCAGAAT CTTACCCAGC TCAGCTTTTC AGGCTGCATT
37441	CAGTGTCCGG CTTTTTTCTC ACCGTCTTGA CTTCCTGTCC TGCATCCCAT TTCTCAGCCT
37501	GGACCCTGCC AGTCTATCAG ATAGATAACA TAAACAAAAT TGTACTGGAT TAATGGGAGC
37561	TGTTTGGACA TTTCCTACTT TTGCCTTTTC ACCAATGATT TGCATACTTA AGCCTGCAAC
37621	TACAGCCCCG ATGCAGTAAG CTCAGTCTCT GGCAAGCAAA GGTCTCTCTG GGGTCTTGTT
37681	TAAGAACCAG CTCAGGCTGC TGGCTCTGTT GGCAGTGGAG GTATTTCCTA TAATGGGATG
37741	ATGGGATGGG TTATTCACAC ACATCTCAGT TACTGGGCTA CATGGATCCA AATCAGCCAC
37801	CCAAGGGTTT GCAGTCACAT GTGAGTCACT TAGCACAGAG AAAGAAGCCT GGAGGAGGAG
37861	GGGTCCTCCC AGCTTCAGGA GGGTTTTCCA GGATATAGGC TTCTAGTCTC GTTTTGGATC
37921	AATTTATCAG TTTTGGATTG GGTCTAATAA CTCTTTCCTG AGCCTGGACT GGGCTCAAAG
37981	GCATGAGTAT GTGAGGGGAA TTTACTAGAA TTCACCTGTA GTTTCTGTAT CATTCCTAGA
38041	GAAGGGGAAG TAGAGACACT GGTGATGGGA AATAAAAACA AAACAAAACC TAAATATTGG
38101	GAGCACAGAG GTCCTTGTTC CACAGCTCTT GATAGAAGTC AGGAATGTTA TGTATGTACA
38161	ATTGCCCTTG AAAAGGAAAG GATGTATGAC CTGTTTTTCT GTCCCGAAGG CTGGGAACTG
38221	GGGATGATTA ACAGCCTGTT GATCTGCATT ATCTGAAGGG CTAGGCCATA TCAAGCTCCC
38281	ACAGCTAGCA CTGAAGGAGA ATAGGGCCTT ACAAAGGGAA TTCCCTCTTT GGATCGAACC
38341	TAGGAACATC TTCTGTTTTA CCGCTCTCTC CTTGTTTCAT CTGCAAAGGG AGGAGCTTGG
38401	TAGTGATGTT GAGGCAGGCA CCACTTGTAT TTTTCTAAGC CACAGAGACT GTTTCCCTAC
38461	CTTACAAACA TCCCTGTGCA TCACTGCAGC TCTGTCTCTT ATGGCAGTGT CTCAGTTAGG
38521	GCTTCTATTG CTGCGACTAA ACACCATGAC CAAAAAAGCT CACACTTCCA TACTCCTGTT
38581	CATTATTGAA GAATGTCAGG ACTGGAGCGC AAACAGGGCA GGGTCCTGGA GGCAGGAGCT
38641	GATGCAGAGG TCATGGAGGA AGGCTGCTTA CTGGCTTGCT CTCCATGGCT TGCTCAGCCT
38701	GCTTTCTTAT AGAACCCAGG ACCACCTGCC CAGGGATGAC ACCACCTACA ATGGGCTGGG
38761	CGCTAATATG AGGGATCAAA GAGATGGAGT TGTGGGAGGG ACAGAGGGGG AGAGCAATGA
38821	AAGAGATAAT CTTGATAGAG GGAGCCGTTA TGGGGTTAGG GAGAAACCTG GTGCTAGAGA
38881	AATTCCCAGG AATCCACAAG GAAGACCCCA GCTAAGACTC CTAGCAATAA TGAAGAGGAT
38941	GTCTGAACGG GTCTTCCCCT TTAATCAGAT TAGTGACTAC CCTAATTGTC ATCACAGAAC
39001	CTACATCCAG TAACTGATGG AAGCAGATGC AGTGATCCAC AGCCAAGCAC TGGGCTGAGC
39061	TTCGGGAGTT CAGTTGAAGA GAGAAGGGAT CATGTGAGCA AGGGGGTGGG GGAAGTCAAG
39121	ATCATGATGG GGAAAACCAC AGAGACAGCT GACCCGAGCT AGTGGGAGCT CATGGACTAT
39181	GAAACGCCAG ACGTTGTAGA CTCCCTAAGG AAGGCCTTAC CCCCTCTGAA GAGTGGATGG
39241	GGGGTGGGAA GTGGGGACGC TGGGGGACAG GAGAAAGGGA GGGAGGGGGA ACTGGGTTGG
39301	TTTGTAAAAT GAAAAAATAG ATTTTTTTTA AATAAAAAAA GAAAGTGCTT TACATCTGGA
39361	TTTCATGGAG GCATTTTCTT AACTGAAGCT CCTTCCTCTC TGGCGACTCT AGTTTGTGTC
39421	AAGTTAACAC AGAACCAGCC AGTACAGGCA GCAGAAATAC CTTGCAGAAA TATCTTAGTT
39481	CAGGAGTCCA CGGTGGTCTC AGTCACTTCC TCATGTGCCA CCTGAGTTTA ACATTCCCCA
39541	AAACTTGGAA CACAGGCCAC CACATCATGG AGCCCTGGCT TAAAGCTCAA GTTTTATGGT
39601	ATTTTCTTTT ATCACTGTCT ATAATTCCTA AACATGCTAC AATGTTGTGA GCCCTCACCG
39661	TCTCCTAGGT CCATAGTGAC TTCCTGGCAT TAATAGACTG TGCCCCAAGA GCTCTATGGC
39721	CACGACCACC ACCTGCCATT CCCCTCCCCC TCCATGGTCC CAGCCTCACT TCTTCACTTC
39781	CTGGTCCTTC CGAGCCCAAT GTGCAAACCC ACAGAATCTG TCTGCTTATG TAAGTTTCCT
39841	GGTCACTGAG TGGGGTGACT CAGCACCAAG GTGGTGCCCT GCGATTTCCC AGCCCCAGGC
39901	AGCAGAACAA CTGAAATGGA AAACAAGTCC CGTTAATAGG GTCCAGCTGA GAGCCTCCCT
39961	TTCTCAGGGA GTCTGGCAAA TCTACTCCTC GGGGAACTGC CCTGGGCAGT GGAATTCTCC
40021	AGCTCCCTGC TCATTTCCTA GTTCCTCTTC CCTCTTCTCA CCTTTGGCTG AGGATCAGAA
40081	AGGTTCCCAC TGAGGTCTGC TTTGCCCTGG GCCTGCTCTT TTCAGAGTCC CATTTTTGGA
40141	ATGAATTTTT TTTGTCTCCT ACTTTCAAGT TCACATATTG AAGCCATTAT TGCCAAGGTG
40201	ATGGTATCAG AAGGAGGGAC CTTTGGGAGA TGAATGGATG GATTCCAAGA GGTTATGTGG
40261	GCAGAGCACC CATGATGGGG TTGGTGCCTT CATAGGAAGA AGACACAGTA GAAGGGAAAG
40321	AGATGCCGAC TGAAAAACAG GAAGTCTCCT GGAGTAGGCC ACTCAGCCTA TGACACGCCA
40381	GCACTCAGAT CTCGGACTTC CCATCTCCCA AATGGTGATA AACAAATGCT GTTGTCCAGG
40441	CTGCACAGTC TACGGCATTT TGTTGCAAGG GCCTGGACCA ACCAGGCTCA GGCAGGAAGT
40501	GAATCTAGTG TGGGAGGATG TACAGACTGC CACTCAGTCT GGACACAAAC TGTCCTCAGG
40561	GATCACCTGA GCCACATCTA CCTAAGAATG GCTATTCTTT CCATTTGTTA ACATCAAATG
40621	CCAAGCCCCT ACTGTATGTA GGCTCTTGCT AGCAGTGGAT ATGATGCTAT GTGAGATGGG
40681	AGCAATCCTC TCTGCACAGA ACTATACATA GAACTATGCA TAGAAGACCA ACAGGGAGAC
40741	ATCAGATAAC TATTAACTGT GATAGCTCTG TGGGAGACAA ACAGAATGAG GGAATGGACA
40801	ATGACTTTGA GGAAAAACTA TGATTGAAAA TACTCTATCT GGCTGGGCGG TGGTGGCGCA
40861	TGCCTTTAAT CCCAGCACTT GGGAGGCAGA GGCAGGTAGA TCTCTGTGAG TTCGAGACCA
40921	GCCTGGTCTA TAAGAGCTAG TTCCAGGACA GCCTCCAAAG CCACAGAGAA ACCCTGTCTC
40981	AAAAAAAACA AAACAAACAC ACAAAAAAGA AAATATTCTG TGAGGTAAAC AAGCATCTGG
41041	AAGGGTTGGG AGATAATGCA GGCAAAAATG CATTAGACAG CACACAGTAC AACACAGCAA
41101	TCAAACTTAA TATAAACACA GCAAATGTCA TCTTTGGGCT TTGCCCCATT TCCTGATCTG
41161	ACCATAACAG CCTAGTGTCT GGAAAGCACA CTAAAGCCAT TTACGTCACA CAGGAGTTCA
41221	ATGTTGAGTT CAGAGGGAGG GGGTGGAGGG CAGATTAGCG AGGTACAAGT TCTGGTCCCT
41281	TTGATGAAGT GTTGATGTAC CCATCGACAC CACACAAATA TACCATCATG CTCCATGTTA
41341	GGGTCAGTGA AGGATTGCAT ATGTGACGGT GGCCCACTGG GCTGAGAAAG CCCTATTGCT
41401	TAGTGACATC TGTGATAATG ACATGCGAGC CCTATTGCTT AGTGACATCA CTCTTCTCAT
41461	AGTGTGGGAT CCAATGTGTT TCTTGTACAC TTGTGATAAT GACATGCAAA CAAGTCTATT
41521	GTGCGGCCAG TCACACAAAA AATATATTAT GTGCAGTCAG GAACAGTCCA TAGTACTTGA
41581	TTGGGACAGC ACAAGTCTGT GTTGCTGGTT CACACATTAA TCATTACCAC TGTTTTAGTG
41641	TGCTCCTATA TATATATATT TAAAAATTAC TATAAAATGA TACACCGTGC TGAGCAATAG
41701	CACCTCTTAT ACCTTGTGTT TACTGGATGT ACTCAAGCTA TTTTCTCTTG TGCTTGATTT
41761	ATTTGTATTT GTATTTTTGA GAGAACCTCA TCTAGTCCAT GCTGGCTTCA AACTTGTTAT
41821	AAAGCTGAGG ATGGCTTCGA ACTCCTGATC CCCCAGCCTC TGCCTCCCAA ATGATGAGAT
41881	TACAGGCATA TGCTACCAAA CATGACTTTT ATTTATTTTT ATTACTTAGG TGGTATGGGT
41941	GGTTTGAATG AGACTGTCCC CTTTGGCTTA TATATTTGTA GGTGGACCTT TGGAAAGGTT
42001	TAACAGGTAT GACCATAGTG GAGGCAGTGT GTCAGTAGGG GAGGTCTTTG GGGAACCCAA
42061	TACTCAATCA ATTCCAAGTT AGGGCTGTCT GTCTGTCTGT CCCCTGATTG TGTCACAAGG
42121	CAGAAACTCT CAGCTACTGC TCTAGTTCTA TGCCTACCCA CCTGTTGCCA TGGTCCCTGC
42181	CATGATGGTC ATGTACTTCA ACCCTTTGGA TAGGTGGCCC CCAAATTAAA TGGTTTCTTT
42241	TATAAGTTGC CTTGGTCATG GTGTTTTGTC ATGGCGATAA GAAAGTGACT GAGACAGGTT
42301	TGTTGCTGTT GTTACAAGGT TTAGTCCAGG CATCTGGCAC CACCTCTGGC CTGTGCTTGA
42361	TTCAATCATG TTACCTTTAG AAATAGCAGG CTAAAGGACA TATACCTGTG TACGTATATG
42421	TGTACGTATA TATTAGCTGT ATAGTCTAAG TGTGCACCTG ACTCTAATAT CTAGGTTTGT
42481	GTAAGTAGAC TCCACCAAGC TCACTAAGCA ATGGTATCAC AGTTTTCAGA TAGTGTTCAG
42541	CGATGCTTGG CTGAGTGTTA GTTCTTTTTT TAATATTTTA TTTATTTATT ATGTATACAA
42601	CATTCTGCTT CCATGTATCT CTGCACACCA GAAGAGGACA CCAAATCTCA TAACGGATGG
42661	TTTTGAGCCA CCATGTGGTT GCTGGGAATT GAACTCAGGA CCTCTGGAAG AGCAGTCGGT
42721	GCTCTTAACC TCTGAGCCAT CTCTCCAGCC CCTGAGTGTT TTTAAATCAA GGAAAAAAGC
42781	CTGAGGGAAG GGAGCTCAGG CTGAAGGGGA GGAGTCAAGA CAGTCTGACC CCAAGGCATT
42841	GTGGGACGTA AAGAGTTCTG GGACAAGACT GAGGTCTCTT CCTTCTCAGA GACTGTGGGC
42901	TTCAGTTTCC TTGGTAGCCG GAAGCAAAGC TAATCCATGG CTTAAAATAT AATACTCAGT
42961	GTAACCTTGT GTTGTAGAAG TGACTTGCTT GTCTTCTTCC ATAATTCTAA AACATCTTTA
43021	AGAGCAGGAT CCAGGAAGGG AAAAGGAGAG ATTCTCATCT TCTTCAAAAG GCAGCTTTCC
43081	CTAAAGCATT TTCTGATGAA ATTTAAGTTC TAAAACCAGC AGTGGTATAA TCCCATCATG
43141	AATGGGGATC TCTGAGTTTA AGGCCAGCCT GGTCTACAGA GCAAGTTCCA GGACAGCCAC
43201	GGTTACACAA AGAAATCCTG TCTTAAAACA AAACAAAACC CAAAACAAAC ATAAACAAAA
43261	ACTATCCAAA ACCAACCAAC CCCCCCAACT CAGAAAGAAA GAAAGAAAGA AATCAAGAAA
43321	GAACTGCCCA CCGGGTGTTG GTGGTGCAAG CCTTTAATCC CAGCACTCGG GAGGCAGAGG
43381	CAGGCAGATC TCTGTGAGTT TGAGGCCAAC CTGTTCTCCA GAAAGAGTGC CAGGATAGGC
43441	TCCAAAGCTA CACAGAGAAA CCCTGTCTTG AAAAAAGAAA AGAAAGAACT ACCCATGACC
43501	AAACAGTTCC ATGGCCAGGT AGAGAATGAG GACGCTGAAA GTCACACCTT CTCAGAGTCT
43561	CAAACTGCAC ATCTGGCCTC AAAGTCCAGA AATGAGTGCA AGACCATTAA TGACAGTCTT
43621	TGGAAACAAA CCAGACCAAA GAACATTTGG CTCCTGATAC ATATTCTGAG GGTCACATAG
43681	AAAGAAAGAT CTGCCTTTGG CCACCTCCTT TTGAAGTGGG GAATTTTATT TTCTTCTGCA
43741	TGGAAACTTC ATGTAGGTAT TTGAGAATAC ATACAGACAT GCAGGTGCAC ATGCACGGAC
43801	ATGAACACAC ACATACACCC CGGGTAGGCA GGCAAGAAAG TGTGTGGAAT AACACTTGAA
43861	CTTCCCTTCC AGAACAGAAG CCCTCTGAAG TGTGACATTC ATGCTGGCTG CATGGGGTCT
43921	GATCAGTACT AGTGAGTGGA GGTGGAGGGG TAGGAAACAT GGGGATGATA ATAGGTTGTC
43981	AGGAAAGTGG TGCCCCAGGT AGCACAGAGT AGAAATTTGT CCCCCAAAAT CCTTTTGAAC
44041	CCAGTTGATT TGAATGCCGT GCCCCTGCCA CCCAGGCTTC AGAGCTAAGT GACTTATGTC
44101	TTCAGGTCAG TGATGATTAC CACGGTTGCA GTGCTAACAC AGATGCTTTA TCTACCAGGA
44161	CAGAAACAAG AAAGATGCTC CTTCCCAGGC CCCTTAGCAC TCTCTGGGTG GGGAGGATTG
44221	CCCCACCTTC CAAAAATAGA ATACTGTTTT GGTAAACAGC CACTTTGAGC CCATGAGGAT
44281	ATCTTCATTA GCTATGGAGA CAGGTTTTAG TAAGAAAGCA AGATGAGAGG CTAAAAAACC
44341	CTTGGGGAGC AGGAACTGGG AAGACTGTGG TACCTTGTTC CCAGATCCAC CAGAAACCTT
44401	GCCACCAGAC GATGTGTCCA GGCCCCACAT ATTTCACAAA AAGTTGGATC TGATAACAAT
44461	GAGGATGGAA TCCCGGTCTT AAGGTGGGTT TGGGGTGGGA AGAGGCGGGA TAATGGGTGA
44521	GAGGGTCGGT GGGGACAGGT GAGATGGGGT ATGGTGGGGA GAGGTGGAAT GGGGTGGGGT
44581	GGGTTGAGAT GGAGTATGGT ACAGCGGGGA GGGATAGAAT TGTCTTTTCC CTGTACCACA
44641	GAGAAGTTTG ACTGCTACCC TTGGCAATTA ATCAATTATA GAAAATGCAA CTTTGCTTTT
44701	AAAATGTGTC TATTTCCAAA GGCTTCTTCC CCTCCCCTAC CTAGGGAGAA GGAAAGAATG
44761	GATAATGCTA CTGTAGAGGA GGGTAGCATC ACTATAGAGG CCTCAGTATC TGCCCCAGGG
44821	AGCTGGGAGA GAGTTCTATC ACACAAACAC AGCCCGAGTC ACATACTCAA CAAACCCCAC
44881	AAAACAAAAC AACAATAATG AAGATACAAA ATCTCATTAT GTAGCCCAGG CTAGTCCTAG
44941	ATTTCTGTTT TCTTTTTTTG TTTTTCGAGA CAGGGTTTCT CTGTGTAGCT TTGGAGCCTA
45001	TCCTGGCACT TGCTCTGAAG CCCAGGCTGC CCTCACTCAC AGAGATCCGC CTGCCTCTGT
45061	CTCCAGAGTG CTGGGATTAA AGGCGTGCAC CACTAATGCC TGGCTAGTCC TAGATTTTTT
45121	TATCCTCCTG CCTCAGGCTC CCAACTGTTG GGTTTACTTT TGGGAGTCCA TTTTCTTCCA
45181	GCATGGATTC TTTGAATTGA AATTCAGATT ATCAGGTTTC TGTAGCAATC CCACCAGCCC
45241	ATTTTTTTGT CTGACACTGC TTGTTTTGAG ACACAGTCTC CCACTGCTGT AGCCCAGGCT
45301	GCCCTAGATT TTCTATGTAG CCCAGGCTGG CCTTGAACTC CCAGGAGTCC TCTGGCCTCT
45361	CCCTTTTGAT TACTGGAACT AGAAGAAGTC ACTATGCTTG ACTTGGAACT AATATTAGAA
45421	CAAAATATAT TTTTCATTGA GATTCAACTT TGAAATCCTG ATGCTCCTGC CTCACTCAGG
45481	TCATCAGGGT TGGCAGCAAG AGCCTTTATC CACTGAGTCA TATTGGGCCC TGACCTGCTT
45541	TTAAATTTTG CCTTTAGGGC TGGAGATGTA GCTCGGCTGG TTCAGTGCTT GCCTGGTACC
45601	CACGAAGCCC TGGGTTTGAT CTACAACACA GTATAAGCCA GGCCTGATGG CGTATACATG
45661	TAATCCTAAC ACTTGGGGAG CAAGAGGGAG GCCAAAGCCA TCCTCTGCTA CTTGGTGAGC
45721	TTGAGGCCAG CCTGGGATCC TTGAGACCCT GTTTCAAAAC AATAACAACA AACACAGACT
45781	ACTAAAAAAA ATTAATAAGG GCCAGACTGG GTGGTGTATT CCTTTAATCC AAGCAATGAG
45841	GAGGCAGAGG CAGGCAAATG TCTGTGAGTC TGGGGACAGC CTGGTCTACT GAGCAGCAGG
45901	CCAACTAAGG CTACATAGTG AGACTATCTC AAAAAAAGCA AAATAACAAT AAACAGACCA
45961	GTTCCCCATC TCCTATTTTG CCTTTACCTC CTATTCCCTG CTCAGCAGGT TATTTTTTGT
46021	TCCTGCATCT TGGTTCACTG ATCTGTAAAC TTGTCTGAAT AAGTAGGTAC AGGGTTGTTT
46081	TAAAATTAGA TAATATATTC AATGAGAAGG GCTACCAAGT GCTCAACCAA TGTATGCATA
46141	TGTATGTATG TATGTATGTA TGTATGTATT TATTTTTGTT TTGTTTTTCA AGATAAGGTT
46201	TCTCTGTGTA GTTTTAGAGT CTGTCCTAGA ACTTGCTCTG AAGAGCAGGC TGGTCTTGAA
46261	CTCACAAAGA TCCACCTGTC TCTGCCTCCC AAGTGCTGGG ATTAAAGGCA TGTGACACCA
46321	CCCCCAAAGC CAATGTTCTT ATAGGCATCT TTGATTTTTT TTCTCTTTCT TTGAGTGGAG
46381	TCTGACTAAG TAGCCCATAC TAGCTCTGCA TTTACAATCT GAACACATGG ATAAGAGTGG
46441	TGAAAATTAT CAAGATCATG TTATGCTATG CCTCCTGAGT CACCATGCCC TGCTTCAGAC
46501	TTCTTTGTAT TAAAGAACTG TGTAAAAAAA AAAAAAAAGA CATTTGAAGG CACATAATCA
46561	GAGGAATTTG TCAGTGATTT TTCACATACT GTCTTATTTG TGGCCAAGGT AAGCCTAGAG
46621	AGTATTTCTT AAAATTAAAA ATAGTGGGCA GATTTTGGAG GCGATCTGAT ATGAAAATCC
46681	CTTCCCACCC CAGGTAGTCA TGGGCTGACT ATCAAGGATA CATTCTGAGA CATATATCCT
46741	CAAGCAGTTT CTGCCTTACG CAAATATCAT AGGTCATAGC ACACTGAGAC TATGTGGCAG
46801	TCTATGTGTC TATATACACA TGGTGTGGCC TATTGTTCCC ATGGTCACAA AGAACAAAAC
46861	AACTTTTTCA CAAGGCTTTA CCCCTAGAGG AAGAGCTACA GGCAATCAAT GGTTGCTGAG
46921	AGGAGTATCA GTCTTCTCCA GGGACTTAGC CAATCCCAAG AGGTCAGCCA CGCATAGGAA
46981	CGCTTAGCCA CGCTTGTATA GAACATCTCA AACAACAACC ACCTCAGTGT AAAGCAAGCA
47041	CACAAGGAAC TGATGCAACT AAGAGACAAA GGGCCCGGTG TGTGTGGCCC GTAGCTGTCA
47101	TCCCAGCACT TGAGACTAAG GAAGGAAGGT TGAGAATTTG AGGCCAGCAT GGACTCCACA
47161	GAAAGACCGT TTTCTTTCTC AGAAAAAAGA AGCAAAAACC AAGAACAAGG TGTATGGGAA
47221	TGCTACTGTC TTGGCATATT GTTTATAGAA AACTTTTTTA TATATAAAAG GAATGCACTA
47281	CAAAAATTAT AAACTACTGT AATATTAACT GCATAGATCT ATAACATGGT CATTTATTAT
47341	TGAGTATGAT TATCTATCTA CCCACGCTGC AGGTTTAGAC AGTTGCACTA CAGTAGATCT
47401	GTTTGCAGTA GCATCATTAT TAGACATTTT GGACAAAGCC AAGTGGTAAT GGCACATGCC
47461	TTTAATCCCA GCACTTGGGA AGCAGAGGTA GGCGGATCTC TGTGAGTCAG AGACCAGCCT
47521	GGTCTACAAA GAACTAGTTC CAGGAGAGTC TCCAAGGCCA CAGAGAAACC CTGTCTCGAA
47581	AAACCAAAAG AAAAAAAGAA AACAAAAAAC TAAAAAATAA ATAAATTTGG GGCAATATCT
47641	TGTCCTATGA TGTTACTGGG TAATGGGATT TCCTCCTCTT GTATTATTTT TTCTTTGGGG
47701	GTTTTACTTA TTATTTACTT GAGACAGAGT CTCATTTATG ACAGGCTGGC CTCAAACAGG
47761	AAATGAAGCC AAGGAAGACC TTGAAGACCT AATCCTTCTG TTTCTTCCTC CTATATGGTG
47821	AGTTAAAGGC ATACAGTACC ATGCCCAGTC TATTCACTGC CCAGGGCTTC ATGCATGCTA
47881	GCAAAGCACC AACTGAGCTG CATCCCCACC CCTCCTCCTG GCTTCCATCT CCTTATGTAG
47941	CTAGAAATGA GCCTGTCTGT CTCAAATACT GGGATTATGG GTGTGTGCCA CCACACCTGG
48001	CTTCCTATTA TAGCCTTGTG GGATCACTGT TGTTTACTGA AGCATTGTGA CACACTGCAG
48061	ATTGCTGGAA CAGCGTCTGC CATCATCATG ACACAACTTC AGAGAAAGAG AGAGTTCCCA
48121	ACCAGCCACA CACTTAACTC AATGCCTGTA GCCCTTATTC TGTTAAGACG ATTTCCTGCC
48181	ATCTTACTCA AAGACCCTCT TTAACTCGGT AGGAACATCT GTTACACTGA AAGTCCTGCC
48241	TGTTGCTCCA CTGACCTCCT TCACAAATTA TTATATTTTG GAGCCAATTC TGAACCCAGG
48301	TTTTCTGAGT GACACATTTT AGTATTTTTT TTTTCTTTCT ATTTTCTTTC ATGGAAAGTC
48361	TCTTGTTACT GTTCACATGA CCAAGGATCA CTGCATCATC TTCCAAGGCC AATTTTGGAT
48421	GTTTCAGCAA GGGAGACTGA AGATCCTGAG TCTCAGTGTT GATCTCCTTT AGAATGTCCT
48481	CTGGAGAAGG TAGTGACAAC ACTGCAAGGA TAATAGGTGA ATAAAGGGAA GCCAGAGTGT
48541	CCTCTGGGAT GTGCGGCACT TACATGAAGG ATTCATTTAT AAATTTTAAG TTATGGAGTA
48601	TAATAATAAG ACTAAATATG TAGTGTCGTA ATTTTATAAC TATACATATG TATATAGTAA
48661	ATATAAATTT ATATGTAATG TATTTATAGT AAGTGTACAT AGAATTGAAC ATATGTTACA
48721	TAAATGGCAG AAAGGAATGA TTCTCAATTG CTTTTTTTCT AATTATAATT TCTATTGCTC
48781	TTTGTGGATT TCACACCATG CATTCTGATC CCACTTATCT CCTTGTCTCC TTGCATTTGC
48841	CCTCTGCCCT TGCAACCTCA CCCCCAAATC AAAGCCAAAT TTAAAAAAAA AACCAAAATC
48901	CAAACAAAAC AGAGACAAAA CAAAAATAAA AGCAACAACA AAAAAAGGAG AATCTTGTCA
48961	TGGTAGCTGT AGTGTGGCCT GTTGAATCAC ACAGTATACC CTTTAGTCCA TTCATCTTTT
49021	CTTCCAAGTG TTCATTGATA CAAGTCACGG TCTGGCTCGA GGATTCTGGT TTCTGCTATA
49081	TTACTAATAA TGGGCTCTCA CTGGGGCTCC CCTTGGATAT CCTATTGTCC TGTGTTATGG
49141	AGAGCCTGCT GTTTTGGATA TGTAGGTTTG TCCCCTTCAC ATGCTATAAC AATTCATAAA
49201	TTCAGTGAAT GTTGGGGTGG GCCAACTCAT AGCCCTGGTT CTGGGCTTGG GTGGTATTAT
49261	TAAACCCACT GATGGAGAAT AAGACCACTA CCATAATTTA AAAGCCAAAT TGAAGCAAGT
49321	TTTAATTCAA TACTGCCCAG GTGGACAGGC TCTGGCTAGG TCCATCTCTG AGTTTCCAGG
49381	AGGTGGCCCT GACTCACGGT TTACAGTGGC TTGAGTATTT TCCATAAGGT CCAATCAGGG
49441	GCAAGCATAC ATCCTGATGT ACCTCCAGTC TATATCCAAT CGGGGGCAAG TGTACATCTT
49501	GATGTATTTC CTGCCTGTGA ACCTACTGCC CACATGTGAT CAAGCACATC CGGTGCAGTT
49561	GGGTCAAACA GACTTGTTTA GGGCAATGAA AAACACATGG CTTTTTATCT CCCATAAACA
49621	ATAGCCTCCA GCGGTTCAGG GACTATTTGT CCTTGGGCAA GGAATTTACA GATCCTATAG
49681	GTGAGTCAGG GTCAGCATCC TGCTCTCATG CCCTCAGGGC TGGCTCACTT GTTACCTCCC
49741	CGACCCTCTC TCAACAGGGT CAGCTCTGAG GTGCTGCCCA GGTGGGGTGC AGGGCCTACT
49801	CTTCCGCATG TTGCAGCTGG TCAGGGTTAG TTCTCTCATA TGCCACAGGT GGCAATGGGT
49861	GAAGGGGGAG GGCATGTTTC CCTCATCAAC GCCATTACAT GGGGGGATGG GGTCAGCTCT
49921	CATGCCCTTA GGGTTGGCTC ACCTGCATCC TTGACCATAG GGTCAGCTCT AGTATGCTGC
49981	TCAAGTGAGG CGCACACCTA

SEQ ID NO: 4 (LoxP sequence from bacteriaphage P1)

1	ATAACTTCGT ATAGCATACA TTATACGAAG TTAT

SEQ ID NO: 5 (FRT sequence from the 2i.tm plasmid of the baker′s yeast Saccharomyces

cerevisiae)

1	GAAGTTCCTA TTCtctagaa aGTATAGGAA CTTC

SEQ ID NO: 6 (attB sequence from E. coli)

1	cCTGCTTt t TtatAc tAA CTTGa

SEQ ID NO: 7 (Recognition site for the CHO-23/24 meganuclease, 35,699 basepairs

downstream of CHO DHFR)

1	TAAGGCCTCA TATGAAAATA TA

SEQ ID NO: 8 (Recognition site for the CHO-51/52 meganuclease, 15,898 basepairs

downstream of CHO DHFR)

1	ATAGATGTCT TGCATACTCT AG

SEQ ID NO: 9 (CHO-23/24 meganuclease)

1	MAPKKKRKVH MNTKYNKEFL LYLAGFVDGD GSIKAQIFPN QCYKFKHQLR LRFQVTQKTQ
61	RRWFLDKLVD EIGVGYVTDR GSVSDYMLSQ IKPLHNFLTQ LQPFLKLKQK QANLVLKIIE
121	QLPSAKESPD KFLEVCTWVD QIAALNDSKT RKTTSETVRA VLDSLPGSVG GLSPSQASSA
181	ASSASSSPGS GISEALRAGA GSGTGYNKEF LLYLAGFVDG DGSIIAQIKP GQSYKFKHTL
241	QLVFQVTQKT QRRWFLDKLV DEIGVGYVID RGSASDYRLS EIKPLHNFLT QLQPFLKLKQ
301	KQANLVLKII EQLPSAKESP DKFLEVCTWV DQIAALNDSK TRKTTSETVR AVLDSLSEKK
361	KSSP

SEQ ID NO: 10 (CHO-51/52 meganuclease)

1	MAPKKKRKVH MNTKYNKEFL LYLAGFVDGD GSIIAQIPPN QSCKFKHQLR LTFQVTQKTQ
61	RRWFLDKLVD EIGVGYVRDR GSVSDYILSE IKPLHNFLTQ LQPFLKLKQK QANLVLKIIE
121	QLPSAKESPD KFLEVCTWVD QIAALNDSKT RKTTSETVRA VLDSLPGSVG GLSPSQASSA
181	ASSASSSPGS GISEALRAGA GSGTGYNKEF LLYLAGFVDG DGSIYAGIAP NQSCKFKHQL
241	RLWFVVSQKT QRRWFLDKLV DEIGVGYVID NGSVSHYRLS EIKPLHNFLT QLQPFLKLKQ
301	KQANLVLKII EQLPSAKESP DKFLEVCTWV DQIAALNDSK TRKTTSETVR AVLDSLSEKK
361	KSSP

SEQ ID NO: 11 (CHO-51/52 donor plasmid with EcoRI site)

1	TCGCGCGTTT CGGTGATGAC GGTGAAAACC TCTGACACAT GCAGCTCCCG GAGACGGTCA
61	CAGCTTGTCT GTAAGCGGAT GCCGGGAGCA GACAAGCCCG TCAGGGCGCG TCAGCGGGTG
121	TTGGCGGGTG TCGGGGCTGG CTTAACTATG CGGCATCAGA GCAGATTGTA CTGAGAGTGC
181	ACCATATGCG GTGTGAAATA CCGCACAGAT GCGTAAGGAG AAAATACCGC ATCAGGCGCC
241	ATTCGCCATT CAGGCTGCGC AACTGTTGGG AAGGGCGATC GGTGCGGGCC TCTTCGCTAT
301	TACGCCAGCT GGCGAAAGGG GGATGTGCTG CAAGGCGATT AAGTTGGGTA ACGCCAGGGT
361	TTTCCCAGTC ACGACGTTGT AAAACGACGG CCAGTGAATT CGAGCTCGGT ACCCAGAAAC
421	CTTTCAACCA GCTTTTGAGC TAATGATAGA GAGAAGCTCA AGGAATTGGA GCAATGCTTG
481	ACTAGGGATG TCAGAGGGAG GCTATCCAGA GGAGCTTACA ACTGAGGTAA ACTTAAAAGT
541	TAGGGAGTTT GTCAACTTCA ACCCACAGAA TAGAGCAGAG CCAGGAGGAG CTGAGGCTTC
601	TGAGTGTTAT GGTGGAAGCA TCACCCCAAC CCTTGACATC CATATGCCTG AAGAGTCTGG
661	AATGTTATGG TGGAAGTTCC ACCCAAGCCT CCCTTCCCGG TCGCCCTCCA AACCCTGCTA
721	CATCTCAGAA ATCCCACCAA ATGATGACTC CCTCCCCCAG AGATATTCAA GACCACTCCC
781	ACAGGGTATT TAAACTGCCC CCCAACCCCC AGAAAATAGA TGTGTGGTTT TCCAATCTCT
841	CTTTCCTATC ACGTCTCTGG GGAGCTGGCA GGCCATTTGG GAGCATTGTA TCCATTAAAC
901	GACTTCTCAG TGGAGACTCT GAAAGCCAGA AGAGCCTAGA CAGATAGATG TCTTGCGAAT
961	TCTTGCATAC TCTAGAGACT ACAGATGCCG GCCCAGACTA TTATATCCAG CAAAAGTTTC
1021	AAACACCATA CAAAGTCAAA TTTAAACAGT ATCTATCTAC AAATCCAATA TTACAGAAGG
1081	TGCTAGTAGG AAAACTCCAA ACTAAGATTA ACTATACCTG TGAAGACACA GGAAATAATC
1141	TCACACTGGC AAAAGAAGAA AAACCTCTCT CTCTCTCTCC TCTCTCTCTC TCTCTCTCTC
1201	TCTCTCTCTC TCTCTCTCTC TCTCTCTCTC TCACACACAC ACACACACAC ACACACACAC
1261	ACCAACACCA ATACCATGAA CAACAAAATA ACAGGAATTA ACAATAATTG ATGTGTGTGT
1321	ATGTCCCTGT GTGTGTGTCC TTGTGTGTGT CTGTTTGTGT GTCTGTGTAT ATGTTTGTCA
1381	CCTGAGGGGT GGCTCTTCCT TGGTTTGTGA GGTTTCTACC CAAAAGCTTG GCGTAATCAT
1441	GGTCATAGCT GTTTCCTGTG TGAAATTGTT ATCCGCTCAC AATTCCACAC AACATACGAG
1501	CCGGAAGCAT AAAGTGTAAA GCCTGGGGTG CCTAATGAGT GAGCTAACTC ACATTAATTG
1561	CGTTGCGCTC ACTGCCCGCT TTCCAGTCGG GAAACCTGTC GTGCCAGCTG CATTAATGAA
1621	TCGGCCAACG CGCGGGGAGA GGCGGTTTGC GTATTGGGCG CTCTTCCGCT TCCTCGCTCA
1681	CTGACTCGCT GCGCTCGGTC GTTCGGCTGC GGCGAGCGGT ATCAGCTCAC TCAAAGGCGG
1741	TAATACGGTT ATCCACAGAA TCAGGGGATA ACGCAGGAAA GAACATGTGA GCAAAAGGCC
1801	AGCAAAAGGC CAGGAACCGT AAAAAGGCCG CGTTGCTGGC GTTTTTCCAT AGGCTCCGCC
1861	CCCCTGACGA GCATCACAAA AATCGACGCT CAAGTCAGAG GTGGCGAAAC CCGACAGGAC
1921	TATAAAGATA CCAGGCGTTT CCCCCTGGAA GCTCCCTCGT GCGCTCTCCT GTTCCGACCC
1981	TGCCGCTTAC CGGATACCTG TCCGCCTTTC TCCCTTCGGG AAGCGTGGCG CTTTCTCATA
2041	GCTCACGCTG TAGGTATCTC AGTTCGGTGT AGGTCGTTCG CTCCAAGCTG GGCTGTGTGC
2101	ACGAACCCCC CGTTCAGCCC GACCGCTGCG CCTTATCCGG TAACTATCGT CTTGAGTCCA
2161	ACCCGGTAAG ACACGACTTA TCGCCACTGG CAGCAGCCAC TGGTAACAGG ATTAGCAGAG
2221	CGAGGTATGT AGGCGGTGCT ACAGAGTTCT TGAAGTGGTG GCCTAACTAC GGCTACACTA
2281	GAAGAACAGT ATTTGGTATC TGCGCTCTGC TGAAGCCAGT TACCTTCGGA AAAAGAGTTG
2341	GTAGCTCTTG ATCCGGCAAA CAAACCACCG CTGGTAGCGG TGGTTTTTTT GTTTGCAAGC
2401	AGCAGATTAC GCGCAGAAAA AAAGGATCTC AAGAAGATCC TTTGATCTTT TCTACGGGGT
2461	CTGACGCTCA GTGGAACGAA AACTCACGTT AAGGGATTTT GGTCATGAGA TTATCAAAAA
2521	GGATCTTCAC CTAGATCCTT TTAAATTAAA AATGAAGTTT TAAATCAATC TAAAGTATAT
2581	ATGAGTAAAC TTGGTCTGAC AGTTACCAAT GCTTAATCAG TGAGGCACCT ATCTCAGCGA
2641	TCTGTCTATT TCGTTCATCC ATAGTTGCCT GACTCCCCGT CGTGTAGATA ACTACGATAC
2701	GGGAGGGCTT ACCATCTGGC CCCAGTGCTG CAATGATACC GCGAGACCCA CGCTCACCGG
2761	CTCCAGATTT ATCAGCAATA AACCAGCCAG CCGGAAGGGC CGAGCGCAGA AGTGGTCCTG
2821	CAACTTTATC CGCCTCCATC CAGTCTATTA ATTGTTGCCG GGAAGCTAGA GTAAGTAGTT
2881	CGCCAGTTAA TAGTTTGCGC AACGTTGTTG CCATTGCTAC AGGCATCGTG GTGTCACGCT
2941	CGTCGTTTGG TATGGCTTCA TTCAGCTCCG GTTCCCAACG ATCAAGGCGA GTTACATGAT
3001	CCCCCATGTT GTGCAAAAAA GCGGTTAGCT CCTTCGGTCC TCCGATCGTT GTCAGAAGTA
3061	AGTTGGCCGC AGTGTTATCA CTCATGGTTA TGGCAGCACT GCATAATTCT CTTACTGTCA
3121	TGCCATCCGT AAGATGCTTT TCTGTGACTG GTGAGTACTC AACCAAGTCA TTCTGAGAAT
3181	AGTGTATGCG GCGACCGAGT TGCTCTTGCC CGGCGTCAAT ACGGGATAAT ACCGCGCCAC
3241	ATAGCAGAAC TTTAAAAGTG CTCATCATTG GAAAACGTTC TTCGGGGCGA AAACTCTCAA
3301	GGATCTTACC GCTGTTGAGA TCCAGTTCGA TGTAACCCAC TCGTGCACCC AACTGATCTT
3361	CAGCATCTTT TACTTTCACC AGCGTTTCTG GGTGAGCAAA AACAGGAAGG CAAAATGCCG
3421	CAAAAAAGGG AATAAGGGCG ACACGGAAAT GTTGAATACT CATACTCTTC CTTTTTCAAT
3481	ATTATTGAAG CATTTATCAG GGTTATTGTC TCATGAGCGG ATACATATTT GAATGTATTT
3541	AGAAAAATAA ACAAATAGGG GTTCCGCGCA CATTTCCCCG AAAAGTGCCA CCTGACGTCT
3601	AAGAAACCAT TATTATCATG ACATTAACCT ATAAAAATAG GCGTATCACG AGGCCCTTTC
3661	GTC

SEQ ID NO: 12 (Recognition site for the CHO-13/14 meganuclease, in Intron 2 of CHO

DHFR)
1	TACATGTATG TACAAAATAT AT

SEQ ID NO: 13 (CHO-13/14 meganuclease)

1	MAPKKKRKVH MNTKYNKEFL LYLAGFVDGD GSIFASITPR QCYKFKHELQ LTFVVTQKTQ
61	RRWFLDKLVD EIGVGYVIDQ GSVSHYRLSE IKPLHNFLTQ LQPFLKLKQK QANLVLKIIE
121	QLPSAKESPD KFLEVCTWVD QIAALNDSKT RKTTSETVRA VLDSLPGSVG GLSPSQASSA
181	ASSASSSPGS GISEALRAGA GSGTGYNKEF LLYLAGFVDG DGSIIAQIKP NQSCKFKHQL
241	MLTFTVAQKT QRRWFLDKLV DEIGVGYVID IGSVSEYRLS QIKPLHNFLT QLQPFLKLKQ
301	KQANLVLKII EQLPSAKESP DKFLEVCTWV DQIAALNDSK TRKTTSETVR AVLDSLSEKK
361	KSSP

SEQ ID NO: 14 (Recognition site for the CGS-5/6 meganuclease, in Exon 4 of CHO GS)

1	AAGGCACTCG TGTAAACGGA TA

SEQ ID NO: 15 (CGS-5/6 meganuclease)

1	MAPKKKRKVH MNTKYNKEFL LYLAGFVDGD GSIKAIIRPE QSYKFKHRLR LVFQVTQKTQ
61	RRWFLDKLVD EIGVGYVYDR GSVSDYYLSE IKPLHNFLTQ LQPFLKLKQK QANLVLKIIE
121	QLPSAKESPD KFLEVCTWVD QIAALNDSKT RKTTSETVRA VLDSLPGSVG GLSPSQASSA
181	ASSASSSPGS GISEALRAGA GSGTGYNKEF LLYLAGFVDG DGSIWARIKP GQSYKFKHTL
241	ELVFQVTQKT QRRWILDKLV DEIGVGYVTD AGSASVYRLS EIKPLHNFLT QLQPFLKLKQ
301	KQANLVLKII EQLPSAKESP DKFLEVCTWV DQIAALNDSK TRKTTSETVR AVLDSLSEKK
361	KSSP

SEQ ID NO: 16 (Forward PCR primer for evaluating CHO-23/24 target site)

1	ggagggacat taatctgcat gcagtgatc

SEQ ID NO: 17 (Reverse PCR primer for evaluating CHO-23/24 target site)

1	gtcttggttt gggttgtcta agcaacctc

SEQ ID NO: 18 (Forward PCR primer for evaluating CHO-51/52 target site)

1	CACAGGTGTC CACTCCCAGT TCAATTACAG CTCTTAAGG

SEQ ID NO 19 (Reverse PCR primer for evaluating CHO-51/52 target site)

1	CGATGGCCCA CTACGTGAAC CATCACC

SEQ ID NO: 20 (PCR template for mRNA encoding CHO-23/24)

1	CACAGGTGTC CACTCCCAGT TCAATTACAG CTCTTAAGGC TAGAGTACTT AATACGACTC
61	ACTATAGGCT AGCCTCGAGC CGCCACCATG GCACCGAAGA AGAAGCGCAA GGTGCATATG
121	GCACCGAAGA AGAAGCGCAA GGTGCATATG AACACCAAGT ACAACAAGGA GTTCCTGCTC
181	TACCTGGCGG GCTTCGTCGA CGGGGACGGC TCCATCAAGG CCCAGATCTT TCCGAACCAG
241	TGCTACAAGT TCAAGCATCA GCTGAGGCTC CGTTTCCAGG TCACCCAGAA GACACAGCGC
301	CGTTGGTTCC TCGACAAGCT GGTGGACGAG ATCGGGGTGG GCTACGTGAC TGACCGCGGC
361	AGCGTCTCCG ACTACATGCT GAGCCAGATC AAGCCTCTGC ACAACTTCCT GACCCAGCTC
421	CAGCCCTTCC TGAAGCTCAA GCAGAAGCAG GCCAACCTCG TGCTGAAGAT CATCGAGCAG
481	CTGCCCTCCG CCAAGGAATC CCCGGACAAG TTCCTGGAGG TGTGCACGTG GGTGGACCAG
541	ATCGCGGCCC TCAACGACAG CAAGACCCGC AAGACGACCT CGGAGACGGT GCGGGCGGTC
601	CTGGACTCCC TCCCAGGATC CGTGGGAGGT CTATCGCCAT CTCAGGCATC CAGCGCCGCA
661	TCCTCGGCTT CCTCAAGCCC GGGTTCAGGG ATCTCCGAAG CACTCAGAGC TGGAGCAGGT
721	TCCGGCACTG GATACAACAA GGAATTCCTG CTCTACCTGG CGGGCTTCGT GGACGGGGAC
781	GGCTCCATCA TCGCCCAGAT CAAGCCGGGT CAGTCCTACA AGTTCAAGCA TACCCTGCAG
841	CTCGTTTTCC AGGTCACGCA GAAGACACAG CGCCGTTGGA TCCTCGACAA GCTGGTGGAC
901	GAGATCGGGG TGGGCTATGT GATCGACCGC GGCAGCGCCT CCGACTACCG CCTGAGCGAG
961	ATCAAGCCTC TGCACAACTT CCTGACCCAG CTCCAGCCCT TCCTGAAGCT CAAGCAGAAG
1021	CAGGCCAACC TCGTGCTGAA GATCATCGAG CAGCTGCCCT CCGCCAAGGA ATCCCCGGAC
1081	AAGTTCCTGG AGGTGTGCAC CTGGGTGGAC CAGATCGCCG CTCTGAACGA CTCCAAGACC
1141	CGCAAGACCA CTTCCGAGAC CGTCCGCGCC GTTCTAGACA GTCTCTCCGA GAAGAAGAAG
1201	TCGTCCCCCT AGACAGTCTC TCCGAGAAGA AGAAGTCGTC CCCCTAGCGG CCGCTTCGAG
1261	CAGACATGAT AAGATACATT GATGAGTTTG GACAAACCAC AACTAGAATG CAGTGAAAAA
1321	AATGCTTTAT TTGTGAAATT TGTGATGCTA TTGCTTTATT TGTAACCATT ATAAGCTGCA
1381	ATAAACAAGT TAACAACAAC AATTGCATTC ATTTTATGTT TCAGGTTCAG GGGGAGATGT
1441	GGGAGGTTTT TTAAAGCAAG TAAAACCTCT ACAAATGTGG TAAAATCGAT AAGATCTTGA
1501	TCCGGGCTGG CGTAATAGCG AAGAGGCCCG CACCGATCGC CCTTCCCAAC AGTTGCGCAG
1561	CCTGAATGGC GAATGGACGC GCCCTGTAGC GGCGCATTAA GCGCGGCGGG TGTGGTGGTT
1621	ACGCGCAGCG TGACCGCTAC ACTTGCCAGC GCCCTAGCGC CCGCTCCTTT CGCTTTCTTC
1681	CCTTCCTTTC TCGCCACGTT CGCCGGCTTT CCCCGTCAAG CTCTAAATCG GGGGCTCCCT
1741	TTAGGGTTCC GATTTAGTGC TTTACGGCAC CTCGACCCCA AAAAACTTGA TTAGGGTGAT
1801	GGTTCACGTA GTGGGCCATC G

SEQ ID NO: 21 (PCR template for mRNA encoding CHO-51/52)

1	CACAGGTGTC CACTCCCAGT TCAATTACAG CTCTTAAGGC TAGAGTACTT AATACGACTC
61	ACTATAGGCT AGCCTCGAGC CGCCACCATG GCACCGAAGA AGAAGCGCAA GGTGCATatg
121	gCACCGAAGA AGAAGCGCAA GGTGCATATG AACACCAAGT ACAACAAGGA GTTCCTGCTC
181	TACCTGGCGG GCTTCGTGGA CGGGGACGGC TCCATCATCG CCCAGATCCC GCCGAACCAG
241	TCCTGCAAGT TCAAGCATCA GCTGCGCCTC ACCTTCCAGG TCACGCAGAA GACACAGCGC
301	CGTTGGTTCC TCGACAAGCT GGTGGACGAG ATCGGGGTGG GCTACGTGCG CGACCGCGGC
361	AGCGTCTCCG ACTACATCCT GAGCGAGATC AAGCCTCTGC ACAACTTCCT GACCCAGCTC
421	CAGCCCTTCC TGAAGCTCAA GCAGAAGCAG GCCAACCTCG TGCTGAAGAT CATCGAGCAG
481	CTGCCCTCCG CCAAGGAATC CCCGGACAAG TTCCTGGAGG TGTGCACCTG GGTGGACCAG
541	ATCGCCGCTC TGAACGACTC CAAGACCCGC AAGACCACTT CCGAGACTGT CCGCGCCGTT
601	CTAGACAGTC TCCCAGGATC CGTGGGAGGT CTATCGCCAT CTCAGGCATC CAGCGCCGCA
661	TCCTCGGCTT CCTCAAGCCC GGGTTCAGGG ATCTCCGAAG CACTCAGAGC TGGAGCAGGT
721	TCCGGCACTG GATACAACAA GGAATTCCTG CTCTACCTGG CGGGCTTCGT GGACGGGGAC
781	GGCTCCATCT ACGCCGGGAT CGCGCCGAAC CAGTCCTGCA AGTTCAAGCA TCAGCTGCGC
841	CTCTGGTTCG TGGTCAGCCA GAAGACACAG CGCCGTTGGT TCCTCGACAA GCTGGTGGAC
901	GAGATCGGGG TGGGCTACGT GATTGACAAT GGCAGCGTCT CCCATTACCG CCTGAGCGAG
961	ATCAAGCCTC TGCACAACTT CCTGACCCAG CTCCAGCCCT TCCTGAAGCT CAAGCAGAAG
1021	CAGGCCAACC TCGTGCTGAA GATCATCGAG CAGCTGCCCT CCGCCAAGGA ATCCCCGGAC
1081	AAGTTCCTGG AGGTGTGCAC CTGGGTGGAC CAGATCGCCG CTTTGAACGA CTCCAAGACC
1141	CGCAAGACCA CTTCCGAGAC TGTCCGCGCC GTTCTAGACA GTCTCTCCGA GAAGAAGAAG
1201	TCGTCCCCCT AGACAGTCTC TCCGAGAAGA AGAAGTCGTC CCCCTAGCGG CCGCTTCGAG
1261	CAGACATGAT AAGATACATT GATGAGTTTG GACAAACCAC AACTAGAATG CAGTGAAAAA
1321	AATGCTTTAT TTGTGAAATT TGTGATGCTA TTGCTTTATT TGTAACCATT ATAAGCTGCA
1381	ATAAACAAGT TAACAACAAC AATTGCATTC ATTTTATGTT TCAGGTTCAG GGGGAGATGT
1441	GGGAGGTTTT TTAAAGCAAG TAAAACCTCT ACAAATGTGG TAAAATCGAT AAGATCTTGA
1501	TCCGGGCTGG CGTAATAGCG AAGAGGCCCG CACCGATCGC CCTTCCCAAC AGTTGCGCAG
1561	CCTGAATGGC GAATGGACGC GCCCTGTAGC GGCGCATTAA GCGCGGCGGG TGTGGTGGTT
1621	ACGCGCAGCG TGACCGCTAC ACTTGCCAGC GCCCTAGCGC CCGCTCCTTT CGCTTTCTTC
1681	CCTTCCTTTC TCGCCACGTT CGCCGGCTTT CCCCGTCAAG CTCTAAATCG GGGGCTCCCT
1741	TTAGGGTTCC GATTTAGTGC TTTACGGCAC CTCGACCCCA AAAAACTTGA TTAGGGTGAT
1801	GGTTCACGTA GTGGGCCATC G

SEQ ID NO: 22 (PCR template for mRNA encoding CGS-5/6)

1	CACAGGTGTC CACTCCCAGT TCAATTACAG CTCTTAAGGC TAGAGTACTT AATACGACTC
61	ACTATAGGCT AGCCTCGAGC CGCCACCATG GCACCGAAGA AGAAGCGCAA GGTGCATATG
121	GCACCGAAGA AGAAGCGCAA GGTGCATATG AACACCAAGT ACAACAAGGA GTTCCTGCTC
181	TACCTGGCGG GCTTCGTCGA CGGGGACGGC TCCATCAAGG CCATTATCCG GCCAGAGCAG
241	TCCTACAAGT TCAAGCATCG CCTGCGGCTC GTTTTCCAGG TCACGCAGAA GACACAGCGC
301	CGTTGGTTCC TCGACAAGCT GGTGGACGAG ATCGGGGTGG GCTACGTGTA CGACCGCGGC
361	AGCGTCTCCG ACTACTATCT GAGCGAGATC AAGCCTCTGC ACAACTTCCT GACCCAGCTC
421	CAGCCCTTCC TGAAGCTCAA GCAGAAGCAG GCCAACCTCG TGCTGAAGAT CATCGAGCAG
481	CTGCCCTCCG CCAAGGAATC CCCGGACAAG TTCCTGGAGG TGTGCACGTG GGTGGACCAG
541	ATCGCGGCCC TCAACGACAG CAAGACCCGC AAGACGACCT CGGAGACGGT GCGAGCGGTC
601	CTGGACTCCC TCCCAGGATC CGTGGGAGGT CTATCGCCAT CTCAGGCATC CAGCGCCGCA
661	TCCTCGGCTT CCTCAAGCCC GGGTTCAGGG ATCTCCGAAG CACTCAGAGC TGGAGCAGGT
721	TCCGGCACTG GATACAACAA GGAATTCCTG CTCTACCTGG CGGGCTTCGT GGACGGGGAC
781	GGCTCCATCT GGGCCCGGAT CAAGCCGGGG CAGTCCTACA AGTTCAAGCA TACCCTGGAG
841	CTCGTGTTCC AGGTCACCCA GAAGACACAG CGCCGTTGGA TCCTCGACAA GCTGGTGGAC
901	GAGATCGGGG TGGGCTACGT GACCGACGCC GGCAGCGCCT CCGTCTACCG CCTGAGCGAG
961	ATCAAGCCTC TGCACAACTT CCTGACCCAG CTCCAGCCCT TCCTGAAGCT CAAGCAGAAG
1021	CAGGCCAACC TCGTGCTGAA GATCATCGAG CAGCTGCCCT CCGCCAAGGA ATCCCCGGAC
1081	AAGTTCCTGG AGGTGTGCAC CTGGGTGGAC CAGATCGCCG CTCTGAACGA CTCCAAGACC
1141	CGCAAGACCA CTTCCGAGAC CGTCCGCGCC GTTCTAGACA GTCTCTCCGA GAAGAAGAAG
1201	TCGTCCCCCT AGACAGTCTC TCCGAGAAGA AGAAGTCGTC CCCCTAGCGG CCGCTTCGAG
1261	CAGACATGAT AAGATACATT GATGAGTTTG GACAAACCAC AACTAGAATG CAGTGAAAAA
1321	AATGCTTTAT TTGTGAAATT TGTGATGCTA TTGCTTTATT TGTAACCATT ATAAGCTGCA
1381	ATAAACAAGT TAACAACAAC AATTGCATTC ATTTTATGTT TCAGGTTCAG GGGGAGATGT
1441	GGGAGGTTTT TTAAAGCAAG TAAAACCTCT ACAAATGTGG TAAAATCGAT AAGATCTTGA
1501	TCCGGGCTGG CGTAATAGCG AAGAGGCCCG CACCGATCGC CCTTCCCAAC AGTTGCGCAG
1561	CCTGAATGGC GAATGGACGC GCCCTGTAGC GGCGCATTAA GCGCGGCGGG TGTGGTGGTT
1621	ACGCGCAGCG TGACCGCTAC ACTTGCCAGC GCCCTAGCGC CCGCTCCTTT CGCTTTCTTC
1681	CCTTCCTTTC TCGCCACGTT CGCCGGCTTT CCCCGTCAAG CTCTAAATCG GGGGCTCCCT
1741	TTAGGGTTCC GATTTAGTGC TTTACGGCAC CTCGACCCCA AAAAACTTGA TTAGGGTGAT
1801	GGTTCACGTA GTGGGCCATC G

SEQ ID NO: 23 (Forward PCR primer for evaluating CGS-5/6 target site)

1	tgacagctct ggccttaagt gcctacgaaa ctag

SEQ ID NO: 24 (Reverse PCR primer for evaluating CGS-5/6 target site)

1	gtctttcctc tttgctgtag ccttggtaga actactgcc

SEQ ID NO: 25 (CHO-23/24 Insertion target sequence donor plasmid)

1	TCGCGCGTTT CGGTGATGAC GGTGAAAACC TCTGACACAT GCAGCTCCCG GAGACGGTCA
61	CAGCTTGTCT GTAAGCGGAT GCCGGGAGCA GACAAGCCCG TCAGGGCGCG TCAGCGGGTG
121	TTGGCGGGTG TCGGGGCTGG CTTAACTATG CGGCATCAGA GCAGATTGTA CTGAGAGTGC
181	ACCATATGCG GTGTGAAATA CCGCACAGAT GCGTAAGGAG AAAATACCGC ATCAGGCGCC
241	ATTCGCCATT CAGGCTGCGC AACTGTTGGG AAGGGCGATC GGTGCGGGCC TCTTCGCTAT
301	TACGCCAGCT GGCGAAAGGG GGATGTGCTG CAAGGCGATT AAGTTGGGTA ACGCCAGGGT
361	TTTCCCAGTC ACGACGTTGT AAAACGACGG CCAGTGAATT CCATACCCAG GGGAGCTGTA
421	CTGGGCTGCA GCCCTGCGCC ATTCAGCCAT GCACCAGGCT ACTCCCTCCT CTTCCAGCTT
481	TCTCCTTCTG ATGGCCATAG GATTAGAAGA TAAGGGACTC TAGTGCAGGT CAACTGCTGA
541	CCAGTGTGAA AATGCACAGA CTACATGCTG GTAGATCAGC ACTTCAAACT ACTGTTCACC
601	ATCATCTCTG GAATAAGCAC TACATTTACA GGGTTCAAAC CTCAATGAAT ATAAACAAAC
661	AAAACACACC TCCCTTCCTT CACTGTCTCC CATTTCTTTG GTTCCCATCT CCACATAGAA
721	TTTATAATTA AAATTTCTAA GTATCTTTCC AGAAATACTT CACACATGTT ATAAGCAAAT
781	GTGCTTTTAA AGATACTATT TTAAATTATG AAAATGGTTA TATTAGTTGA GATAAAAGAA
841	TAGAATGGGA AGTTCCAGAA TTTAAGGCCT CATATGGATC CCAGCTGTGG AATGTGTGTC
901	AGTTAGGGTG TGGAAAGTCC CCAGGCTCCC CAGCAGGCAG AAGTATGCAA AGCATGCATC
961	TCAATTAGTC AGCAACCAGG TGTGGAAAGT CCCCAGGCTC CCCAGCAGGC AGAAGTATGC
1021	AAAGCATGCA TCTCAATTAG TCAGCAACCA TAGTCCCGCC CCTAACTCCG CCCATCCCGC
1081	CCCTAACTCC GCCCAGTTCC GCCCATTCTC CGCCCCATGG CTGACTAATT TTTTTTATTT
1141	ATGCAGAGGC CGAGGCCGCC TCGGCCTCTG AGCTATTCCA GAAGTAGTGA GGAGGCTTTT
1201	TTGGAGGCTA CCATGGAGAA GTTACTATTC CGAAGTTCCT ATTCTCTAGA AAGTATAGGA
1261	ACTTCAAGCT TGGCACTGGG TACCGCCAAG TTGACCAGTG CCGTTCCGGT GCTCACCGCG
1321	CGCGACGTCG CCGGAGCGGT CGAGTTCTGG ACCGACCGGC TCGGGTTCTC CCGGGACTTC
1381	GTGGAGGACG ACTTCGCCGG TGTGGTCCGG GACGACGTGA CCCTGTTCAT CAGCGCGGTC
1441	CAGGACCAGG TGGTGCCGGA CAACACCCTG GCCTGGGTGT GGGTGCGCGG CCTGGACGAG
1501	CTGTACGCCG AGTGGTCGGA GGTCGTGTCC ACGAACTTCC GGGACGCCTC CGGGCCGGCC
1561	ATGACCGAGA TCGGCGAGCA GCCGTGGGGG CGGGAGTTCG CCCTGCGCGA CCCGGCCGGC
1621	AACTGCGTGC ACTTCGTGGC CGAGGAGCAG GACTGACACC CGAGCGAAAA CGGTCTGCGC
1681	TGCGGGACGC GCGAATTGAA TTATGGCCCA CACCAGTGGC GCGGCGACTT CCAGTTCAAC
1741	ATCAGCCGCT ACAGTCAACA GCAACTGATG GAAACCAGCC ATCGCCATCT GCTGCACGCG
1801	GAAGAAGGCA CATGGCTGAA TATCGACGGT TTCCATATGG GGATTGGTGG CGACGACTCC
1861	TGGAGCCCGT CAGTATCGGC GGAATTCCAG CTGAGCGCCG GTCGCTACCA TTACCAGTTG
1921	GTCTGGTGTC AAAAATAATA ATAACCGGGC AGGGGGGATC TGCATGGATC TTTGTGAAGG
1981	AACCTTACTT CTGTGGTGTG ACATAATTGG ACAAACTACC TACAGAGATT TAAAGCTCTA
2041	AGGTAAATAT AAAATTTTTA AGTGTATAAT GTGTTAAACT ACTGATTCTA ATTGTTTGTG
2101	TATTTTAGAT TCCAACCTAT GGAACTGATG AATGGGAGCA GTGGTGGAAT GCCTTTAATG
2161	AGGAAAACCT GTTTTGCTCA GAAGAAATGC CATCTAGTGA TGATGAGGCT ACTGCTGACT
2221	CTCAACATTC TACTCCTCCA AAAAAGAAGA GAAAGGTAGA AGACCCCAAG GACTTTCCTT
2281	CAGAATTGCT AAGTTTTTTG AGTCATGCTG TGTTTAGTAA TAGAACTCTT GCTTGCTTTG
2341	CTATTTACAC CACAAAGGAA AAAGCTGCAC TGCTATACAA GAAAATTATG GAAAAATATT
2401	CTGTAACCTT TATAAGTAGG CATAACAGTT ATAATCATAA CATACTGTTT TTTCTTACTC
2461	CACACAGGCA TAGAGTGTCT GCTATTAATA ACTATGCTCA AAAATTGTGT ACCTTTAGCT
2521	TTTTAATTTG TAAAGGGGTT AATAAGGAAT ATTTGATGTA TAGTGCCTTG ACTAGAGATC
2581	ATAATCAGCC ATACCACATT TGTAGAGGTT TTACTTGCTT TAAAAAACCT CCCACACCTC
2641	CCCCTGAACC TGAAACATAA AATGAATGCA ATTGTTGTTG TTAACTTGTT TATTGCAGCT
2701	TATAATGGTT ACAAATAAAG CAATAGCATC ACAAATTTCA CAAATAAAGC ATTTTTTTCA
2761	CTGCATTCTA GTTGTGGTTT GTCCAAACTC ATCAATGTAT CTTATCATGT CTGGATCCCC
2821	AGGAAGCTCC TCTGTGTCCT CATAAACCCT AACCTCCTCT ACTTGAGAGG ACATTCCAAT
2881	CATAGGCTGC CCATCCACCC TACTAGTATA TGAAAATATA AAGCGCTTTC TCTTTTAAGT
2941	CTAGGGTAGG TGTACTAGAT CAGCGCTCAG CTCCATACCA TGAAGCCATC CAGGAGTCAG
3001	ACCTCTCTGA CAGCCCTGCC ATTGTCACAG AGAAGTTTCT GTCACCAGTG CTCATGCTGT
3061	CAGAGGAGCG AAGGAGAAAA GATGTGAGAC CTCCCAAGTC AAAGTCATCT ATGGATAAAA
3121	CCTTAGTTGC ATGGCACACC AGTGTTAGGG AGTCGGGGAA ACACAGCCAT AGCCCAGCTT
3181	CCTCTCTGTT CTTGCTCTTA TTACCACCAG AAAGAGGTTG CTTAGACAAC CCAAACCAAG
3241	ACACAGGGCT CTGTGGGAGG GAATCAGTCC CAGGCTTCTG GCACATGCTA TGTCACCGGA
3301	AAGCCCCAGC CCTACTCCGA ATCCCCACAA GTACAGCAAA TATCAGATTA TAGCATTTAA
3361	AGGGGCACTC TTGCCAAAGA GAAGCACCAT TGGAATAGCC ATGCTTGAGA ACTAAGCTTG
3421	GCGTAATCAT GGTCATAGCT GTTTCCTGTG TGAAATTGTT ATCCGCTCAC AATTCCACAC
3481	AACATACGAG CCGGAAGCAT AAAGTGTAAA GCCTGGGGTG CCTAATGAGT GAGCTAACTC
3541	ACATTAATTG CGTTGCGCTC ACTGCCCGCT TTCCAGTCGG GAAACCTGTC GTGCCAGCTG
3601	CATTAATGAA TCGGCCAACG CGCGGGGAGA GGCGGTTTGC GTATTGGGCG CTCTTCCGCT
3661	TCCTCGCTCA CTGACTCGCT GCGCTCGGTC GTTCGGCTGC GGCGAGCGGT ATCAGCTCAC
3721	TCAAAGGCGG TAATACGGTT ATCCACAGAA TCAGGGGATA ACGCAGGAAA GAACATGTGA
3781	GCAAAAGGCC AGCAAAAGGC CAGGAACCGT AAAAAGGCCG CGTTGCTGGC GTTTTTCCAT
3841	AGGCTCCGCC CCCCTGACGA GCATCACAAA AATCGACGCT CAAGTCAGAG GTGGCGAAAC
3901	CCGACAGGAC TATAAAGATA CCAGGCGTTT CCCCCTGGAA GCTCCCTCGT GCGCTCTCCT
3961	GTTCCGACCC TGCCGCTTAC CGGATACCTG TCCGCCTTTC TCCCTTCGGG AAGCGTGGCG
4021	CTTTCTCATA GCTCACGCTG TAGGTATCTC AGTTCGGTGT AGGTCGTTCG CTCCAAGCTG
4081	GGCTGTGTGC ACGAACCCCC CGTTCAGCCC GACCGCTGCG CCTTATCCGG TAACTATCGT
4141	CTTGAGTCCA ACCCGGTAAG ACACGACTTA TCGCCACTGG CAGCAGCCAC TGGTAACAGG
4201	ATTAGCAGAG CGAGGTATGT AGGCGGTGCT ACAGAGTTCT TGAAGTGGTG GCCTAACTAC
4261	GGCTACACTA GAAGAACAGT ATTTGGTATC TGCGCTCTGC TGAAGCCAGT TACCTTCGGA
4321	AAAAGAGTTG GTAGCTCTTG ATCCGGCAAA CAAACCACCG CTGGTAGCGG TGGTTTTTTT
4381	GTTTGCAAGC AGCAGATTAC GCGCAGAAAA AAAGGATCTC AAGAAGATCC TTTGATCTTT
4441	TCTACGGGGT CTGACGCTCA GTGGAACGAA AACTCACGTT AAGGGATTTT GGTCATGAGA
4501	TTATCAAAAA GGATCTTCAC CTAGATCCTT TTAAATTAAA AATGAAGTTT TAAATCAATC
4561	TAAAGTATAT ATGAGTAAAC TTGGTCTGAC AGTTACCAAT GCTTAATCAG TGAGGCACCT
4621	ATCTCAGCGA TCTGTCTATT TCGTTCATCC ATAGTTGCCT GACTCCCCGT CGTGTAGATA
4681	ACTACGATAC GGGAGGGCTT ACCATCTGGC CCCAGTGCTG CAATGATACC GCGAGACCCA
4741	CGCTCACCGG CTCCAGATTT ATCAGCAATA AACCAGCCAG CCGGAAGGGC CGAGCGCAGA
4801	AGTGGTCCTG CAACTTTATC CGCCTCCATC CAGTCTATTA ATTGTTGCCG GGAAGCTAGA
4861	GTAAGTAGTT CGCCAGTTAA TAGTTTGCGC AACGTTGTTG CCATTGCTAC AGGCATCGTG
4921	GTGTCACGCT CGTCGTTTGG TATGGCTTCA TTCAGCTCCG GTTCCCAACG ATCAAGGCGA
4981	GTTACATGAT CCCCCATGTT GTGCAAAAAA GCGGTTAGCT CCTTCGGTCC TCCGATCGTT
5041	GTCAGAAGTA AGTTGGCCGC AGTGTTATCA CTCATGGTTA TGGCAGCACT GCATAATTCT
5101	CTTACTGTCA TGCCATCCGT AAGATGCTTT TCTGTGACTG GTGAGTACTC AACCAAGTCA
5161	TTCTGAGAAT AGTGTATGCG GCGACCGAGT TGCTCTTGCC CGGCGTCAAT ACGGGATAAT
5221	ACCGCGCCAC ATAGCAGAAC TTTAAAAGTG CTCATCATTG GAAAACGTTC TTCGGGGCGA
5281	AAACTCTCAA GGATCTTACC GCTGTTGAGA TCCAGTTCGA TGTAACCCAC TCGTGCACCC
5341	AACTGATCTT CAGCATCTTT TACTTTCACC AGCGTTTCTG GGTGAGCAAA AACAGGAAGG
5401	CAAAATGCCG CAAAAAAGGG AATAAGGGCG ACACGGAAAT GTTGAATACT CATACTCTTC
5461	CTTTTTCAAT ATTATTGAAG CATTTATCAG GGTTATTGTC TCATGAGCGG ATACATATTT
5521	GAATGTATTT AGAAAAATAA ACAAATAGGG GTTCCGCGCA CATTTCCCCG AAAAGTGCCA
5581	CCTGACGTCT AAGAAACCAT TATTATCATG ACATTAACCT ATAAAAATAG GCGTATCACG
5641	AGGCCCTTTC GTC

SEQ ID NO: 26 (reverse PCR primer in the SV40 early promoter)

1	AGATGCATGC TTTGCATACT TCTGCCTGC

SEQ ID NO: 27 (donor plasmid for inserting GFP into FRT Insertion target sequence)

1	GACGGATCGG GAGATCTCCC GATCCCCTAT GGTGCACTCT CAGTACAATC TGCTCTGATG
61	CCGCATAGTT AAGCCAGTAT CTGCTCCCTG CTTGTGTGTT GGAGGTCGCT GAGTAGTGCG
121	CGAGCAAAAT TTAAGCTACA ACAAGGCAAG GCTTGACCGA CAATTGCATG AAGAATCTGC
181	TTAGGGTTAG GCGTTTTGCG CTGCTTCGCG ATGTACGGGC CAGATATACG CGTTGACATT
241	GATTATTGAC TAGTTATTAA TAGTAATCAA TTACGGGGTC ATTAGTTCAT AGCCCATATA
301	TGGAGTTCCG CGTTACATAA CTTACGGTAA ATGGCCCGCC TGGCTGACCG CCCAACGACC
361	CCCGCCCATT GACGTCAATA ATGACGTATG TTCCCATAGT AACGCCAATA GGGACTTTCC
421	ATTGACGTCA ATGGGTGGAG TATTTACGGT AAACTGCCCA CTTGGCAGTA CATCAAGTGT
481	ATCATATGCC AAGTACGCCC CCTATTGACG TCAATGACGG TAAATGGCCC GCCTGGCATT
541	ATGCCCAGTA CATGACCTTA TGGGACTTTC CTACTTGGCA GTACATCTAC GTATTAGTCA
601	TCGCTATTAC CATGGTGATG CGGTTTTGGC AGTACATCAA TGGGCGTGGA TAGCGGTTTG
661	ACTCACGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA TGGGAGTTTG TTTTGGCACC
721	AAAATCAACG GGACTTTCCA AAATGTCGTA ACAACTCCGC CCCATTGACG CAAATGGGCG
781	GTAGGCGTGT ACGGTGGGAG GTCTATATAA GCAGAGCTCT CTGGCTAACT AGAGAACCCA
841	CTGCTTACTG GCTTATCGAA ATTAATACGA CTCACTATAG GGAGACCCAA GCTGGCTAGC
901	GTTTAAACTT AAGCTTAGCC ACCaTGGTGA GCAAGGGCGA GGAGCTGTTC ACCGGGGTGG
961	TGCCCATCCT GGTCGAGCTG GACGGCGACG TAAACGGCCA CAAGTTCAGC GTGTCCGGCG
1021	AGGGCGAGGG CGATGCCACC TACGGCAAGC TGACCCTGAA GTTCATCTGC ACCACCGGCA
1081	AGCTGCCCGT GCCCTGGCCC ACCCTCGTGA CCACCCTGAC CTACGGAGTG CAGTGCTTCA
1141	GCCGCTACCC CGACCACATG AAGCAGCACG ACTTCTTCAA GTCCGCCATG CCCGAAGGCT
1201	ACGTCCAGGA GCGCACCATC TTCTTCAAGG ACGACGGCAA CTACAAGACC CGCGCCGAGG
1261	TGAAGTTCGA GGGCGACACC CTGGTGAACC GCATCGAGCT GAAGGGCATC GACTTCAAGG
1321	AGGACGGCAA CATCCTGGGG CACAAGCTGG AGTACAACTA CAACAGCCAC AACGTCTATA
1381	TCATGGCCGA CAAGCAGAAG AACGGCATCA AGGTGAACTT CAAGATCCGC CACAACATCG
1441	AGGACGGCAG CGTGCAGCTC GCCGACCACT ACCAGCAGAA CACCCCCATC GGCGACGGCC
1501	CCGTGCTGCT GCCCGACAAC CACTACCTGA GCACCCAGTC CGCCCTGAGC AAAGACCCCA
1561	ACGAGAAGCG CGATCACATG GTCCTGCTGG AGTTCGTGAC CGCCGCCGGG ATCACTCTCG
1621	GCATGGACGA GCTGTACAAG TAAGGATCCA CTAGTCCAGT GTGGTGGAAT TCTGCAGATA
1681	TCCAGCACAG TGGCGGCCGC TCGAGTCTAG AGGGCCCGTT TAAACCCGCT GATCAGCCTC
1741	GACTGTGCCT TCTAGTTGCC AGCCATCTGT TGTTTGCCCC TCCCCCGTGC CTTCCTTGAC
1801	CCTGGAAGGT GCCACTCCCA CTGTCCTTTC CTAATAAAAT GAGGAAATTG CATCGCATTG
1861	TCTGAGTAGG TGTCATTCTA TTCTGGGGGG TGGGGTGGGG CAGGACAGCA AGGGGGAGGA
1921	TTGGGAAGAC AATAGCAGGC ATGCTGGGGA TGCGGTGGGC TCTATGGCTT CTGAGGCGGA
1981	AAGAACCAGC TGGGGCTCTA GGGGGTATCC CCACGCGCCC TGTAGCGGCG CATTAAGCGC
2041	GGCGGGTGTG GTGGTTACGC GCAGCGTGAC CGCTACACTT GCCAGCGCCC TAGCGCCCGC
2101	TCCTTTCGCT TTCTTCCCTT CCTTTCTCGC CACGTTCGCC GGCTTTCCCC GTCAAGCTCT
2161	AAATCGGGGG CTCCCTTTAG GGTTCCGATT TAGTGCTTTA CGGCACCTCG ACCCCAAAAA
2221	ACTTGATTAG GGTGATGGTT CACGTACCTA GAAGTTCCTA TTCCGAAGTT CCTATTCTCT
2281	AGAAAGTATA GGAACTTCCT TGGCCAAAAA GCCTGAACTC ACCGCGACGT CTGTCGAGAA
2341	GTTTCTGATC GAAAAGTTCG ACAGCGTCTC CGACCTGATG CAGCTCTCGG AGGGCGAAGA
2401	ATCTCGTGCT TTCAGCTTCG ATGTAGGAGG GCGTGGATAT GTCCTGCGGG TAAATAGCTG
2461	CGCCGATGGT TTCTACAAAG ATCGTTATGT TTATCGGCAC TTTGCATCGG CCGCGCTCCC
2521	GATTCCGGAA GTGCTTGACA TTGGGGAATT CAGCGAGAGC CTGACCTATT GCATCTCCCG
2581	CCGTGCACAG GGTGTCACGT TGCAAGACCT GCCTGAAACC GAACTGCCCG CTGTTCTGCA
2641	GCCGGTCGCG GAGGCCATGG ATGCGATCGC TGCGGCCGAT CTTAGCCAGA CGAGCGGGTT
2701	CGGCCCATTC GGACCGCAAG GAATCGGTCA ATACACTACA TGGCGTGATT TCATATGCGC
2761	GATTGCTGAT CCCCATGTGT ATCACTGGCA AACTGTGATG GACGACACCG TCAGTGCGTC
2821	CGTCGCGCAG GCTCTCGATG AGCTGATGCT TTGGGCCGAG GACTGCCCCG AAGTCCGGCA
2881	CCTCGTGCAC GCGGATTTCG GCTCCAACAA TGTCCTGACG GACAATGGCC GCATAACAGC
2941	GGTCATTGAC TGGAGCGAGG CGATGTTCGG GGATTCCCAA TACGAGGTCG CCAACATCTT
3001	CTTCTGGAGG CCGTGGTTGG CTTGTATGGA GCAGCAGACG CGCTACTTCG AGCGGAGGCA
3061	TCCGGAGCTT GCAGGATCGC CGCGGCTCCG GGCGTATATG CTCCGCATTG GTCTTGACCA
3121	ACTCTATCAG AGCTTGGTTG ACGGCAATTT CGATGATGCA GCTTGGGCGC AGGGTCGATG
3181	CGACGCAATC GTCCGATCCG GAGCCGGGAC TGTCGGGCGT ACACAAATCG CCCGCAGAAG
3241	CGCGGCCGTC TGGACCGATG GCTGTGTAGA AGTACTCGCC GATAGTGGAA ACCGACGCCC
3301	CAGCACTCGT CCGAGGGCAA AGGAATAGCA CGTACTACGA GATTTCGATT CCACCGCCGC
3361	CTTCTATGAA AGGTTGGGCT TCGGAATCGT TTTCCGGGAC GCCGGCTGGA TGATCCTCCA
3421	GCGCGGGGAT CTCATGCTGG AGTTCTTCGC CCACCCCAAC TTGTTTATTG CAGCTTATAA
3481	TGGTTACAAA TAAAGCAATA GCATCACAAA TTTCACAAAT AAAGCATTTT TTTCACTGCA
3541	TTCTAGTTGT GGTTTGTCCA AACTCATCAA TGTATCTTAT CATGTCTGTA TACCGTCGAC
3601	CTCTAGCTAG AGCTTGGCGT AATCATGGTC ATAGCTGTTT CCTGTGTGAA ATTGTTATCC
3661	GCTCACAATT CCACACAACA TACGAGCCGG AAGCATAAAG TGTAAAGCCT GGGGTGCCTA
3721	ATGAGTGAGC TAACTCACAT TAATTGCGTT GCGCTCACTG CCCGCTTTCC AGTCGGGAAA
3781	CCTGTCGTGC CAGCTGCATT AATGAATCGG CCAACGCGCG GGGAGAGGCG GTTTGCGTAT
3841	TGGGCGCTCT TCCGCTTCCT CGCTCACTGA CTCGCTGCGC TCGGTCGTTC GGCTGCGGCG
3901	AGCGGTATCA GCTCACTCAA AGGCGGTAAT ACGGTTATCC ACAGAATCAG GGGATAACGC
3961	AGGAAAGAAC ATGTGAGCAA AAGGCCAGCA AAAGGCCAGG AACCGTAAAA AGGCCGCGTT
4021	GCTGGCGTTT TTCCATAGGC TCCGCCCCCC TGACGAGCAT CACAAAAATC GACGCTCAAG
4081	TCAGAGGTGG CGAAACCCGA CAGGACTATA AAGATACCAG GCGTTTCCCC CTGGAAGCTC
4141	CCTCGTGCGC TCTCCTGTTC CGACCCTGCC GCTTACCGGA TACCTGTCCG CCTTTCTCCC
4201	TTCGGGAAGC GTGGCGCTTT CTCATAGCTC ACGCTGTAGG TATCTCAGTT CGGTGTAGGT
4261	CGTTCGCTCC AAGCTGGGCT GTGTGCACGA ACCCCCCGTT CAGCCCGACC GCTGCGCCTT
4321	ATCCGGTAAC TATCGTCTTG AGTCCAACCC GGTAAGACAC GACTTATCGC CACTGGCAGC
4381	AGCCACTGGT AACAGGATTA GCAGAGCGAG GTATGTAGGC GGTGCTACAG AGTTCTTGAA
4441	GTGGTGGCCT AACTACGGCT ACACTAGAAG GACAGTATTT GGTATCTGCG CTCTGCTGAA
4501	GCCAGTTACC TTCGGAAAAA GAGTTGGTAG CTCTTGATCC GGCAAACAAA CCACCGCTGG
4561	TAGCGGTGGT TTTTTTGTTT GCAAGCAGCA GATTACGCGC AGAAAAAAAG GATCTCAAGA
4621	AGATCCTTTG ATCTTTTCTA CGGGGTCTGA CGCTCAGTGG AACGAAAACT CACGTTAAGG
4681	GATTTTGGTC ATGAGATTAT CAAAAAGGAT CTTCACCTAG ATCCTTTTAA ATTAAAAATG
4741	AAGTTTTAAA TCAATCTAAA GTATATATGA GTAAACTTGG TCTGACAGTT ACCAATGCTT
4801	AATCAGTGAG GCACCTATCT CAGCGATCTG TCTATTTCGT TCATCCATAG TTGCCTGACT
4861	CCCCGTCGTG TAGATAACTA CGATACGGGA GGGCTTACCA TCTGGCCCCA GTGCTGCAAT
4921	GATACCGCGA GACCCACGCT CACCGGCTCC AGATTTATCA GCAATAAACC AGCCAGCCGG
4981	AAGGGCCGAG CGCAGAAGTG GTCCTGCAAC TTTATCCGCC TCCATCCAGT CTATTAATTG
5041	TTGCCGGGAA GCTAGAGTAA GTAGTTCGCC AGTTAATAGT TTGCGCAACG TTGTTGCCAT
5101	TGCTACAGGC ATCGTGGTGT CACGCTCGTC GTTTGGTATG GCTTCATTCA GCTCCGGTTC
5161	CCAACGATCA AGGCGAGTTA CATGATCCCC CATGTTGTGC AAAAAAGCGG TTAGCTCCTT
5221	CGGTCCTCCG ATCGTTGTCA GAAGTAAGTT GGCCGCAGTG TTATCACTCA TGGTTATGGC
5281	AGCACTGCAT AATTCTCTTA CTGTCATGCC ATCCGTAAGA TGCTTTTCTG TGACTGGTGA
5341	GTACTCAACC AAGTCATTCT GAGAATAGTG TATGCGGCGA CCGAGTTGCT CTTGCCCGGC
5401	GTCAATACGG GATAATACCG CGCCACATAG CAGAACTTTA AAAGTGCTCA TCATTGGAAA
5461	ACGTTCTTCG GGGCGAAAAC TCTCAAGGAT CTTACCGCTG TTGAGATCCA GTTCGATGTA
5521	ACCCACTCGT GCACCCAACT GATCTTCAGC ATCTTTTACT TTCACCAGCG TTTCTGGGTG
5581	AGCAAAAACA GGAAGGCAAA ATGCCGCAAA AAAGGGAATA AGGGCGACAC GGAAATGTTG
5641	AATACTCATA CTCTTCCTTT TTCAATATTA TTGAAGCATT TATCAGGGTT ATTGTCTCAT
5701	GAGCGGATAC ATATTTGAAT GTATTTAGAA AAATAAACAA ATAGGGGTTC CGCGCACATT
5761	TCCCCGAAAA GTGCCACCTG ACGTC

SEQ ID NO: 28 (reverse PCR primer in the hygromycin-resistance gene)

1	CAGAAACTTC TCGACAGACG TCGCGGTGAG

SEQ ID NO: 29 (CHOX-45/46 amino acid sequence)

1	MAPKKKRKVH MNTKYNKEFL LYLAGFVDGD GSICASIRPE QERKFKHRLV LRFEVTQKTQ
61	RRWFLDKLVD EIGVGYVYDS GSVSRYYLSQ IKPLHNFLTQ LQPFLKLKQK QANLVLKIIE
121	QLPSAKESPD KFLEVCTWVD QIAALNDSKT RKTTSETVRA VLDSLPGSVG GLSPSQASSA
181	ASSASSSPGS GISEALRAGA GSGTGYNKEF LLYLAGFVDG DGSIFATICP RQQYKFKHQL
241	RLRFEVDQKT QRRWFLDKLV DEIGVGYVYD LGSVSRYGLS EIKPLHNFLT QLQPFLKLKQ
301	KQANLVLKII EQLPSAKESP DKFLEVCTWV DQIAALNDSK TRKTTSETVR AVLDSLSEKK
361	KSSP

SEQ ID NO: 30 (CHOX-45/46 recognition site sequence)

1	CAGCACGTCT CACCCCACCC CT

SEQ ID NO: 31 (CHOX-45/46 forward screening primer)

1	GGAATCTGAC TGTGGTAAGC CTGTACAC

SEQ ID NO: 32 (CHOX-45/46 reverse screening primer)

1	CAGCACTCAG GAGGTAGAGG CAGG

SEQ ID NO: 33 (artificial splice acceptor)

1	TCTTACTGAC ATCCACTTTG CCTTTCTCTC CACAGG

SEQ ID NO: 34 (SV40 polyadenylation signal)

1	ACTTGTTTAT TGCAGCTTAT AATGGTTACA AATAAAGCAA TAGCATCACA AATTTCACAA
61	ATAAAGCATT TTTTTCACTG CATTCTAGTT GTGGTTTGTC CAAACTCATC AATGTATCTT
121	ATCATGTCTG

SEQ ID NO: 35 (BGH polyadenylation signal)

1	CTGTGCCTTC TAGTTGCCAG CCATCTGTTG TTTGCCCCTC CCCCGTGCCT TCCTTGACCC
61	TGGAAGGTGC CACTCCCACT GTCCTTTCCT AATAAAATGA GGAAATTGCA TCGCATTGTC
121	TGAGTAGGTG TCATTCTATT CTGGGGGGTG GGGTGGGGCA GGACAGCAAG GGGGAGGATT
181	GGGAAGACAA TAGCAGGCAT GCTGGGGATG CGGTGGGCTC TATGG